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Abstract 
Hepatocellular Carcinoma (HCC) is a major healthcare problem, representing the third 
most common cause of cancer-related mortality worldwide. Chronic infections with Hepatitis B 
virus (HBV) and/or Hepatitis C virus (HCV) are the major risk factors for the development of 
HCC. The incidence of HBV -associated HCC is in decline as a result of an effective HBV 
vaccine; however, since an equally effective HCV vaccine has not yet been developed, there are 
130 million HCV infected patients worldwide who are at a high-risk for developing HCC. 
Because reliable parameters and/or tools for the early detection of HCC among high-risk 
individuals are severely lacking, HCC patients are always diagnosed at a late stage where 
surgical solutions or effective treatment are not possible. 
Using urine as a non-invasive sample source, two different approaches (proteomic-based 
and genomic-based approaches) were pursued with the common goal of discovering potential 
biomarker candidates for the early detection of HCC among high-risk chronic HCV infected 
patients. Urine was collected from 106 HCV infected Egyptian patients, 32 of whom had already 
developed HCC and 74 patients who were diagnosed as HCC-free at the time of initial sample 
collection. In addition to these patients, urine samples were also collected from 12 healthy 
control individuals. Total urinary proteins, Trans-renal nucleic acid (Tr-NA) and microRNA 
(miRNA) were isolated from urine using novel methodologies and silicon carbide-loaded spin 
columns. 
In the first, "proteomic-based", approach, liquid chromatography coupled with tandem 
mass spectrometry (LC-MS/MS) was used to identify potential candidates from pooled urine 
samples. This was followed by validating relative expression levels of proteins present in urine 
among all the patients using quantitative real time-PCR (qRT-PCR). This approach revealed that 
significant over-expression of three proteins: DJ-1, Chromatin Assembly Factor-1 (CAF-1) and 
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Heat Shock Protein 60 (HSP60), were characteristic events among HCC-post HCV infected 
patients. As a single-based HCC biomarker, CAF-1 over-expression identified HCC among HCV 
infected patients with a specificity of 90%, sensitivity of 66% and with an overall diagnostic 
accuracy of 78%. Moreover, the CAF-lIHSP60 tandem identified HCC among HCV infected 
patients with a specificity of 92%, sensitivity of 61 % and with an overall diagnostic accuracy of 
77%. 
In the second genomic-based approach, two different approaches were processed. The 
first approach was the miRNA-based approach. The expression levels of miRNAs isolated from 
urine were studied using the Illumina MicroRNA Expression Profiling Assay. This was followed 
by qRT-PCR-based validation of deregulated expression of identified miRNA candidates among 
all the patients. This approach shed the light on the deregulated expression of a number of 
miRNAs, which may have a role in either the development of HCC among HCV infected 
patients (i.e. miR-640, miR-765, miR-200a, miR-521 and miR-520) or may allow for a better 
understanding of the viral-host interaction (miR-152, miR-486, miR-219, miR452, miR-425, 
miR-154 and miR-31). Moreover, the deregulated expression of both miR-618 and miR-650 
appeared to be a common event among HCC-post HCV infected patients. The results of the 
search for putative targets of these two miRNA suggested that miR-618 may be a potent 
oncogene, as it targets the tumor-suppressor gene Low density lipoprotein-related protein 12 
(LPR12), while miR-650 may be a potent tumor-suppressor gene, as it is supposed to down-
regulate the TNF receptor-associated factor-4 (TRAF4) oncogene. The specificity of miR-618 
and miR-650 deregulated expression patterns for the early detection of HCC among HCV 
infected patients was 68% and 58%, respectively, whereas the sensitivity was 64% and 72%, 
respectively. When the deregulated expression of both miRNAs was combined as a tandem 
biomarker, the specificity and the sensitivity were 75% and 58% respectively. 
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In the second, "Trans-renal nucleic acid-based", approach, the urinary apoptotic nucleic 
acid (uaNA) levels of 70ng/mL or more were found to be a good predictor of HCC among 
chronic HCV infected patients. The specificity and the sensitivity of this diagnostic approach 
were 76% and 86%, respectively, with an overall diagnostic value of 81 %. The uaNA levels 
positively correlated to HCC disease progression as monitored by epigenetic changes of a panel 
of eight tumor-suppressor genes (TSGs) using methylation-sensitive PCR. 
Moreover, the pairing of high uaNA levels (:::: 70 ng/mL) and CAF-1 over-expreSSIOn 
produced a highly specific (l 00%) multiple-based HCC biomarker with an acceptable sensitivity 
of 64%, and with a diagnostic accuracy of 82%. In comparison to the previous pairing, the uaNA 
levels (:::: 70 ng/mL) in tandem with HSP60 over-expression was less specific (89%) but highly 
sensitive (72%), resulting in a diagnostic accuracy of 64%. The specificities of miR-650 
deregulated expression in combination with either high uaNA content or HSP 60 over-expression 
were 82% and 79%, respectively, whereas, the sensitivities of these combinations were 64% and 
58%, respectively. The potential biomarkers identified in this study compare favorably with the 
diagnostic accuracy of the a-fetoprotein levels test, which has a specificity of 75%, sensitivity of 
68% and an overall diagnostic accuracy of 70%. 
Here we present an intriguing study which shows the significance of using urine as a non-
invasive sample source for the identification of promising HCC biomarkers. We have also 
introduced new techniques for the isolation of different urinary macromolecules, especially 
miRNA, from urine. Furthermore, we strongly recommend the potential biomarkers indentified 
in this study as focal points of any future research on HCC diagnosis. A larger testing pool will 
determine if their use is practical for mass population screening. This explorative study identified 
potential targets that merit further investigation for the development of diagnostically accurate 
biomarkers isolated from 1-2 mL urine samples that were acquired in a non-invasive manner. 
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Introduction and Literature Review 
The Importance of Cancer Biomarker Development 
Cancer is a major public health problem and its adverse effects are increasingly 
/ 
worldwide. It is the second leading cause of death in the United States, just behind hemt disease 
(Cancer Facts and Figures, 2005). Currently, one in four deaths in the United States is due to 
cancer (Jemal et ai., 2007). Since the enactment of the 1971 National Cancer Act 
(www.cancer.gov/aboutnci/national-cancer-act-19711page1), the burden of cancer has been 
significantly reduced. However, from 1992 to 1998, the overall mortality rate declined only by 
about 1.1 % per year. Despite the recent advancements in molecular medicine, proteomic, 
genomic, and transcriptomic research, mortality rates have not been significantly reduced, for the 
most prevalent cancers (Diamandis, 2004). 
A primary cause of cancer poor survivability is its late detection. Cancer is usually 
detected after being spread or metastasized to distant sites. Since cancer therapies are generally 
more effective for treatment of localized tumors rather than metastasized ones, it is important to 
develop efficient strategies for the early detection of cancer to ensure more effective treatment 
. (Kosary, 1994). For most cancer types, the earlier the cancer was detected, the greater the rate of 
survival (Etzioni et ai., 2003). For example, when colorectal cancer was detected in its earliest 
stages, the survival rate was as high as 95%. On the contrary, if colorectal cancer was detected 
after it has been metastasized; the survival rate was only 7% (Etzioni et ai., 2003). 
Conventionally, cancer screening has been based on the morphologic assessment of relevant 
neoplastic/cancer cells. While morphological-based screening and evaluation of cancer is 
suitable for those cancers at easily accessible sites (e.g., uterine cervix cancer and sigmoid colon 
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cancer), morphologic assessment is unfeasible for cancers at a site that are difficult to access 
such as lung, pancreas, and ovarian cancer (Feng et ai., 2006a). 
The accuracy of any diagnostic test for the detection of a particular disorder, in patients 
without symptoms of this disorder, is considered the main purpose of screening (Arguedas, 
2003). The major objective of any cancer-screening program is to detect a tumor earlier enough 
to guarantee a successful therapeutic outcome (Pepe et ai., 2006). Furthermore, the tools used in 
this screening program must be sufficiently non-invasive and inexpedient to tolerate the mass-
population applicability (Pepe et ai., 2006). Screening tests are not considered as diagnostic tests 
since they detect individuals who may have the disease from the much larger group of people 
who may not have it (Meissner et ai., 2004). Before starting to screen large numbers of healthy 
people without signs or symptoms of cancer, several criteria, recommended by the World Health 
Organization (WHO), are commonly used to assure a net benefit to screeners (Cole and 
Morrison, 1980 & Morrison, 1992); 
~ The disease of interest should be a major health problem. Its significance may be defined 
by several criteria related to disease burden, including morbidity, mortality, and 
premature mortality rates. 
~ There should be a detectable preclinical phase (i.e. a period in the natural history of the 
disease when it is detectable in asymptomatic individuals, thus gaining lead time before 
symptoms develop). 
~ Treatment of the disease in its asymptomatic stage should offer advantages compared 
with the treatment of the same disease after the appearance of its symptoms. 
~ A screening assay should be affordable and provide benefits justifying its cost. 
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~ The assay must be acceptable to the target population and to health care professionals. 
~ Must achieve an acceptable level of accuracy in the population undergoing screening 
(Smith, 1997). 
The importance of screening for pre-invasive lesions is very well demonstrated by 
cervical cancer. Before the use of the routine Pap screening, cervical cancer was the leading 
cause of cancer-related deaths among the U.S. women, with an age adjusted incidence of over 
361100,000 (Dom and Cutler, 1959). After 40 years of cytological screening for the identification 
and treatment of women with pre-invasive cervical neoplasia, the current frequency of cervical 
cancer in the U.S. has noticeably fallen to 8.41100,000 (Surveillance Epidemiology and End 
Results Program, 2006). At present, the most important risk factor for invasive cervical cancer is 
never having had a Pap smear (Sung et ai., 2000 and Miller et ai., 2003). On the contrary, most 
lung, ovarian and pancreatic cancers are generally detected when invasive metastatic disease has 
already developed and therefore is difficult to treat. Not astonishingly, five-year-survival is 
extremely poor for these types of cancers (Surveillance Epidemiology and End Results Program, 
2006). 
A biomarker, according to the National Institute of Health (NIH), is a feature that can be 
. measured and evaluated as an indicator of normal physiological processes, pathogenic effect, or 
pharmaceutical response (Ilyin et ai., 2004). There are a wide range of variations in the 
complexity of biomarkers, ranging from simple indicators such as hair color, blood pressure, or 
cholesterol levels, to more complicated ones, such as transcriptomic profiles (Hedenfalk et ai., 
2001 and Andre et ai., 2006) and protein profiles (Azad et ai., 2006 and Belkowski et ai., 2005). 
In cancer research and detection, a biomarker refers to a substance or process that is indicative of 
the development of cancer. Molecular changes which distinguish cancer cells from normal cells 
3 
Moemen Abdalla HCC Biomarkers 
represent potential cancer biomarkers. Studies of cancer pathogenesis showed that the progress 
of cancer is a multi-stage process with a number of different pathways leading to its malignant 
development. Cancer development always involves the loss of function of genes regulating 
tumor suppression, and/or the gain in function of other genes that facilitate cancer development, 
Deoxyribose Nucleic Acid (DNA) repair and apoptosis. 
As described by the Knudson Two Hit Hypothesis, complete loss of function of a gene 
generally requires changes in both copies of the gene (Knudson, 2001). The first pathway is 
through the attainment of heritable changes in the nuclear and/or mitochondrial DNA primary 
sequence (including genetic mutations or deletions). The second pathway is through the 
acquisition of "epigenetic" changes. Epigenetic changes are heritable changes in gene expression 
that are not related to alterations in the primary nucleotide sequences (Herman and Baylin, 
2003). Genetic or epigenetic changes playa role in most types of cancers and can distinguish 
normal cells from cancer cells. In addition, when such changes occur, gene expression and 
protein production will be altered in both qualitative and quantitative manners. Therefore, 
genomic, transcriptomic and proteomic profiles are useful for the identification and management 
of cancers. Abnormal levels of either over-expressed/suppressed proteins or proteins not 
normally in contact with the immune system in the patients' serum or biological t1uids may be 
useful as a marker for detecting the presence of cancer (Feng et aI., 2006a). 
Initially, tumor signatures were examined in blood, as it was believed that most of the 
tumors that arise from neoplastic epithelial cells can metastasize through both the blood and the 
lymphatic system (Gallucci, 1985). However, recent data indicate that less than 0.01% of the 
circulating tumor cells are capable of initiating metastatic foci (Luzzi et aI., 1998). Circulating 
tumor cells were initially analyzed under the light microscope regarding their potential use as 
tumor markers (Christopherson, 1965). Immuno-magnetic separation techniques, based on tumor 
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types and stages, showed detection rates up to 32% in renal cell carcinoma, and the number of 
circulating tumor cells in peripheral blood tended to be in the range of 1 to nearly 1;000 cells per 
mL (Bilkenroth et ai., 2001). Despite introduction of immunocytologic detection techniques, 
sensitivity and specificity of the methods remained inadequate (Ghossein and Bhattacharya., 
2000). 
Unfortunately, most of the currently used biomarkers have not been useful as independent 
methods for the screening or diagnosis of cancer. However, they still play an important role in 
the diagnostic process and the overall management of the disease. Currently, cancer biomarkers 
are used in patients with established cancers for the purpose of monitoring their response to 
therapy or in surveillance for recurrence of disease (Shau et ai., 2003). Table 1 summarizes most 
of the currently used biomarkers and their clinical/therapeutic applications. Most of the currently 
used biomarkers are considered as single-based biomarkers (i.e. depending on a single parameter 
for the cancer diagnosis) (Srinivas et ai., 2001). However, it would be difficult to sufficiently 
correlate any single-based biomarker to a specific cancer, taking into consideration the 
complexity of the carcinogenesis process (Srinivas et aI., 2001). For example, Prostate-Specific 
Antigen (PSA) is an important tumor marker for prostate cancer. On the contrary, PSA has 
relatively low specificity because its levels can be found elevated in patients with benign 
' conditions (Perrotti, 2001). Furthermore, a-fetoprotein (AFP) levels, a biomarker for 
hepatocellular carcinoma (HCC) in patients with chronic liver disease, were found to be normal 
in many patients with small tumors (Izzo et aI., 1999). 
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Table 1 Common tumor biomarkers and their clinical uses 
Cancer 
Clinical application Cancer type Therapeutic application Reference 
Biomarker 
AFP Liver 
Screening, Diagnosis, 
N/A Johnson, 2001 
Prognosis, Surveillance 
Alpha -fetoproteinl 
human Chorionic Diagnosis, Prognosis, Labdenne and 
Germ cell N/A 
Gonadotropin Surveillance Heikinheimo, 2002 
(AFP/hCG) 
Cancer Antigen 15-3 
(CA 15-3) Breast Anti-MUCI vaccines 
Surveillance Duffy, 2001 
Cancer Antigen 27-29 (experimental) 
(CA 27-29) 
Cancer Antigen 19-9 
Pancreatic Diagnosis, Surveillance N/A Riker and Bartlett, 1999 (CA 19-9) 
Cancer Antigen 125 (CA 
Ovarian 
Screening, Diagnosis, 
N/A Menon and Jacobs, 2000 
125) Surveillance 
Cluster of Differentiation Diagnosis, Prognosis, 
(CD20) Non-Hodgkin lymphoma Surveillance Anti-CD20 antibodies (rituximab) Press et ai, 2001 
Carcinoembryon ic 
Colon Prognosis, Surveillance Anti-CEA vaccines (experimental) Macdonald, 1999 
Antigen (CEA) 
Estrogen 
Estrogen antagonists (tamoxifen)/ 
receptor/Progesterone Breast Prognosis Duffy, 2001 
receptor (ERlPR) aromatase inhibitors (anastrazole) 
Human epidermal 
Anti-Her2/neu antibodies Pegram and Siamon, 
growth factor receptor Breast Prognosis (trastuzumab) 2000 (Her-2/neu) 
PSA Prostate 
Screening, Diagnosis, 
Prognosis, Surveillance 
N/A Smith et ai., 2003 
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Types of Cancer Biomarkers 
As previously mentioned, cancer biomarkers are generally produced due to certain 
molecular changes in cancerous cells. Cancer biomarkers can be divided into six different types, 
based on their function: 
(1) Early detection biomarkers: used for screening patients, at a high-risk for cancer 
development, to discover cancer at an early stage (Bensalah et aI., 2007). 
(2) Diagnostic biomarkers: can determine the presence or absence of cancer, based on 
characteristic events accompanying cancer development. PSA (Van-Gils et aI., 2005), CA125, 
and nuclear matrix protein 22 (NMP22) are examples of such biomarkers currently used in 
clinical practice. Others, such as carbonic anhydrase IX (CAlX), could be useful to determine the 
malignancy of small solid renal masses and hence guiding with therapeutic decisions (Li et ai., 
2006). 
(3) Prognostic biomarkers: used to inspect the outcome of patients, allowing 
individualized management and can predict the development of a disease. They also help in 
understanding the tumor activities, and thus distinguishing aggressive phenotypes through 
. survival probabilities. These markers provide information about the likely clinical course of a 
disease, thus assisting therapeutic assessments (Schnitt, 2001). Classical prognostic markers are 
hormone receptors in breast cancer and PSA in prostate cancer. More recently, low levels of 
CAlX expression were found to be associated with a worse prognosis in patients with localized 
and metastatic renal cell cancer (Leppert et aI., 2007). 
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(4) Predictive biomarkers: predict whether the treatment will be effective or not. They 
can help to identify the best treatment modality and can also monitor the effectiveness of the 
treatment (Bensalah et aI., 2007). 
(5) Therapeutic target biomarkers: identify the molecular targets of novel therapies and 
identify targets affected by therapy. These kinds of biomarkers will benefit patients who will 
follow a certain therapeutic routine (Bensalah et aI., 2007). For example, breast tumors 
expressing estrogen receptors (ERs) are best treated with an anti-estrogen such as tamoxifen or 
an aromatase inhibitor (Andre et aI., 2006). 
(6) Surrogate end point biomarkers: are used to replace a clinical end point assay. 
Surrogate end point biomarkers can reduce time factors and costs for phase 1 and phase 2 clinical 
trials by replacing clinical end points (Bensalah et aI., 2007). An example for such a surrogate 
end point biomarker is the post-therapy PSA changes, to evaluate drugs used in clinical trials or 
in clinical practice. Criteria were proposed to screen for treatment efficiency in prostate cancer 
clinical trials, on the basis of the hypothesis that PSA declines reflect significant cell death in 
response to agents that cause reduction in overall tumor burden (Scher et aI., 1996). 
Phases of Biomarker Development 
Recently, cancer biomarker discovery has been an active and productive area of research, 
due to the availability of the most sophisticated and pioneering techniques. UnfOltunately, the 
transition of these biomarkers from discovery to clinical applications has been slowly 
progressing. Few new biomarkers are being used for the early detection of cancer. A five-step 
approach has been proposed that helps in the transition of the discovered biomarkers to the 
clinical applications (Pepe et aI., 2001). 
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Phase I, "Preclinical Exploratory Studies", is an exploratory study that identifies 
clinically useful biomarkers by comparing tumor to non-tumor tissues. Most of the current 
cancer biomarker researches are focusing on this phase. It identifies characteristics exclusive to 
tumor tissue that might lead to valuable suggestions for clinical assays for detecting cancer. 
Immuno-histochemistry and Western blots have been widely used for this reason. More 
advanced approaches includes gene-expression profiles for thousands of genes-based on 
microarrays (Schummer et at., 1999), protein expression profiles based on mass spectroscopy 
(Merchant and Weinberger, 2000), and levels of circulating antibodies against thousands of 
cancer antigens have been recently used for identifying clinically useful biomarkers. The main 
objective of this phase is to recognize genes or clusters of genes which are differentially 
expressed in tumor versus control tissues. Unfortunately, tissues cannot be used for mass-
population screening because their acquirement is highly invasive. Therefore, serum levels of 
proteins expressed by the genes identified in tumor tissues or antibody levels to these proteins 
should be used for the development of non-invasive clinical assays (Pepe et at., 2006). 
In phase II, "Validation Phase", the biomarker confirmed in phase one will be used to 
develop and validate clinical assays which can measure these biomarkers in specimens that can 
be obtained non-invasively. In order to be considered promising for screening, these clinical 
. assays should discriminate between people with and without cancer. However, since the patients 
who are investigated in this phase have established cancer, it does not determine the usefulness 
of the biomarker for early detection. The primary aim of this phase is to estimate the true positive 
rates (TPR) and false positive rates (FPR) for the clinical biomarker assays and to evaluate their 
ability to distinguish subjects with and without cancer (Pepe et at., 2001). However, many 
biomarkers do not advance beyond this phase due to the difficulties in the development of an 
accurate and effective assay method (Wagner et aI., 2004). 
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Phase III is a Retrospective Longitudinal Repository Study where the capacity of a 
biomarker to detect preclinical diseases is determined by testing the biomarker against tissue 
collected longitudinally from research cohorts. In this phase, repositories of clinical specimens, 
collected and stored from a cohort of apparently healthy subjects, are monitored for the 
development of cancer. Subjects who developed cancer as well as subjects who have not 
developed cancer are identified. If the levels of the biomarker in case subjects only deviate from 
those in control subjects close to the time of clinical diagnosis, the biomarker shows little 
promise for screening. On the other hand, if the levels in case subjects reach levels distinct from 
those in control subjects months or years before clinical symptoms appear, the biomarker's 
potential for early detection is increased. The primary aim from this phase is to evaluate, as a 
function of time before clinical diagnosis, the capacity of the biomarker to detect preclinical 
diseases and to define criteria for a positive screening test in preparation for phase 4 (Pepe et ai., 
2001). 
Phase IV is a Prospective Screening Study where its primary aim is to determine the 
potential characteristics of the biomarker-based screening test in a specific population. It is 
carried out by determining the detection rate and the false referral rate. In this phase 
asymptomatic people are screened, and those who were confirmed to be positive are followed up 
to determine if they have cancers. These studies provide information on the test's specificity and 
disease prevalence (Wagner et ai., 2004). This phase also evaluates the effect of the screening 
methods on the cost and the mortality associated with the cancer. Furthermore, this phase can 
monitor clinically developed tumors but are not detected by conventional screening protocols 
(Pepe et ai., 2001). 
The final phase, "phase V", is conducted on a large-scale population. The major goal 
from this phase is to evaluate the decline in cancer m011ality provided by the proposed screening 
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assay. Furthermore, it evaluates not only the efficiency of the biomarker on cancer detection but 
also the overall impact of screening on the population (Wagner et ai., 2004). Some problems 
may prevent the biomarker from having its full advantage for the screened population, even it 
succeeded in early detecting the cancer. These obstacles include (a) the unavailability of a 
successful treatments for the screen-detected tumor, (b) difficulties in applying the screening 
program in community practice, (c) high-priced or morbidity-associated costs of screening and of 
the diagnostic improvements of subjects who screened false positive for disease, and (d) the 
over-diagnosis of cancers that, in the absence of a screening program, would not be detected and 
would relapse in some cases (Pepe et ai., 2001 and Woods et aI., 1996). 
To discover promising biomarkers, it is necessary to evaluate their performance for 
categorizing subjects into those with and without cancer. The Performance of a biomarker is 
measured using the true positive rate (TPR), which is also called sensitivity, and false positive 
rate (FPR), which equals one minus specificity (Baker et aI., 2006). Sensitivity is the percentage 
of true positives whereas specificity is the percentage of true negatives that are correctly 
identified by the test (Altman and Blend, 1994a). TPR is the probability that a patient with 
cancer has a positive test result, and FPR is the probability that an individual without cancer has 
a positive test result (Baker et aI., 2006). In addition to the specificity and the sensitivity of any 
, diagnostic test, the probability that the diagnostic test will give the correct diagnosis must be 
calculated and represented by predictive values. Positive predictive value is the percentage of 
patients with positive test results who are correctly diagnosed. Moreover, negative predictive 
value is the percentage of patients with negative test results who are correctly diagnosed (Altman 
and Blend, 1994b). It has been suggested that a specific biomarker should have a positive 
predictive value of 100%, a specificity of 99.6%, and a sensitivity of 100% (Jacobs et ai., 1999). 
However, it has not been easy to find a biomarker with a positive predictive value of 100% in all 
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cases. It may also be very difficult for all biomarkers to achieve this high level of precision 
because there will always be some individual variability and idiopathic differences resulting in 
prediction errors (Pastwa et al., 2007). In general, the effort is currently to identify biomarkers 
that will be sensitive, specific, quantitative, and reproducible when compared to a known 
standard. 
Advances and Strategies for Cancer Biomarker Discovery 
Recent advancements in biomarker development using genomIc and proteomic 
technologies have facilitated the discovery of several new cancer biomarkers. The Food and 
Drug Administration (FDA) has approved a number of new urine-based biomarkers such as 
bladder tumor antigen (BTA) and Nuclear Matrix Protein-22, as diagnostic markers for bladder 
cancer (Mungan et al., 2000). However, physicians still depend on invasive techniques including 
biopsy or radiological methods due to the low diagnostic accuracy of the newly discovered 
biomarkers. Recent developments in genomic and proteomic approaches such as microarray and 
mass spectrometry (MS) have provided great expectations for discovering patterns of multiple 
biomarkers (protein/gene profiles "signatures") specific to each particular cancer (Ramaswamy 
et al., 2001). Thus, the ultimate clinical biomarker may more accurately be a pattern of genes 
and/or proteins that provides an indication of the presence of cancer in high risk individuals. 
Advances in molecular biology techniques have assisted the progress of biomarker 
discovery both from traditional sources such as tissues and blood to non-traditional sources such 
as exfoliated cells, stools, and urine. Mutations in the p53 gene have been detected in plasma 
DNA of patients with breast cancer, small-cell lung cancer, and colon cancer (Silva et az', 1999). 
Moreover, the DNA extracted from plasma has been successfully used to identify K-Ras gene 
mutations in patients with pancreatic and colorectal cancers (Anker et az', 1999). Interestingly, 
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mutations of the K-Ras gene have been detected in urine samples of patients with pancreatic and 
colorectal cancer (Botezatu et ai., 2000). Microsatellite instability (MSI) was also detected in 
plasma DNA from patients with head and neck and small-cell lung cancer (Nawroz et ai., 1996 
and Chen et ai., 1996). Schneider et ai. (2000) used fluorescent PCR analysis of DNA from 
urinary exfoliated cells to detect MSI markers associated with bladder cancer, with 80% 
sensitivity. Using stool samples, panel of biomarkers has been found in the paired tumor 
specimens of patients with colorectal cancer (Ahlquist et ai., 2000). A recent study repOlted the 
detection of high concentrations of hypermethylation markers from sputum DNA of individuals 
with squamous-cell lung carcinoma, three years before diagnosis (Palmisano et ai., 2000). 
Concerns still remain about the available tools for biomarker discovery and if these tests 
are suitable to provide the technological support to meet the needs for new biomarker 
development. Until recently, identification of proteins that are deregulated as a consequence of 
the disease and are shed into the body fluids such as serum, urine or saliva was considered a slow 
approach for the discovery of new cancer biomarkers. Unfortunately, due to the complexity of 
the nature of cancer, this approach is very difficult and time-consuming as each candidate 
marker(s) must be screened among thousands of other proteins (Chatterjee and Zetter, 2005). The 
recent progress in genomic and proteomic approaches showed great promise of discovering a 
, variety of new biomarkers that are sensitive and specific. 
Protein-based Cancer Biomarker Approach 
The cancer proteome is very complex due to the variety of information that has been 
gathered from almost all the biological activities that take place in cancer cells (Alaoui-Jamali 
and Xu, 2006). However, only a small percentage of proteins which plays a major role in the 
cellular processes have been well studied (Pastwa et aI., 2007). Therefore, investigating the 
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cancer proteome is the logical starting point for exploring cancer diagnostic biomarkers and 
therapeutic targets (Alaoui-lamali and Xu, 2006). Proteomic cancer biomarkers, as well as other 
cancer biomarkers, should have a number of properties including: (i) sensitivity, selectivity, and 
a strong association with the disease; (ii) should be measurable via non-invasive procedures; (iii) 
should be useful in the majority of the population; and (iv) should have strong diagnostic, 
prognostic, and predictive significance (Arciero et aI., 2003). Protein biomarkers have a great 
advantage over other DNA or RNA-based biomarkers in that each gene may potentially give rise 
to hundreds of protein variants as a result of alternative processing of mRNA (Pastwa et aI., 
2007). The Early Detection Research Network (EDRN) is currently recommending proteomic 
technologies for the discovery and the evaluation of new biomarkers for the early detection of 
cancer (Pastwa et aI., 2007). Several putative cancer biomarkers with potential clinical 
applications have already been reported using the recent proteomic approaches (Table 2). 
Table 2 List of the recent reported putative cancer biomarkers discovered by proteomic 
approach 
Biomarker Cancer type Reference 
Apolipoprotein Al Ovarian, pancreatic Zhang et aI., 2004 and Kozak et aI., 2005 
Haptoglobin a-subunit 
Ovarian, pancreatic, 
Ye et al., 2003 
lung 
Transthyretin fragment Ovarian Kozak et ai., 2005 
Inter-alpha-trypsin inhibitor 
Ovarian, pancreatic Zhang et aI., 2004 
fragment 
Vitamin D-binding protein Prostate, breast Corder et aI., 1993 and Pawlik et aI., 2006 
Serum amyloid A 
Nasopharyngeal, Orchekowski et aI., 2005 and Moshkovskii 
pancreatic, ovarian et ai.,2005 
aI-antitrypsin and a 1-
Pancreatic 
Orchekowski et aI., 2005 and Yu et ai., 
antichymotrypsin 2005 
Osteopontin Ovarian, prostate Khodavirdi et ai., 2006 
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Proteomic Strategies 
HCC Biomarkers 
New strategies have enhanced the expansion and categorization of proteomics into three 
key areas: protein expression profiling, functional proteomics and structural proteomics. Protein 
expression profiling is the most commonly practiced proteomic strategy for the discovery of new 
cancer biomarkers. Protein expression profiling mainly consist of three steps: (i) sample 
preparation, (ii) protein separation, and (iii) protein identification (Gygi et ai., 2000). Each step 
must be handled cautiously to avoid any bias which may lead to unreliable data. This strategy 
aims to isolate, identify, and provide a list of all the differentially expressed proteins as a 
function of different physiological states, e.g., cancer versus normal-state or early-stage cancer 
versus late-stage cancer. Two-dimensional Sodium Dodecyl Sulfate-Polyacrylamide Gel 
Electrophoresis (2D SDS-PAGE), non gel-based technologies such as chromatography in 
combination with mass spectrometry and database search engines are the most widely used tools 
for protein expression profiling (Pastwa et ai., 2007). 
Protein Separation and Identification 
Gel Electrophoresis-based Proteomics 
Many chromatographic and electrophoresis-based technologies are available for protein 
separation. The 2D SDS-PAGE is still the gold-standard and the most widely used method. It 
separates complex protein mixtures into individual and small groups of proteins (O'Farrell, 
1975). In 2D SDS-PAGE, proteins are first separated according to pH (pI) in the first dimension 
and then according to size (molecular weight) in the second dimension. The protein spots are 
visualized by staining the electrophoresis gels with coommassie, silver, or fluorescent dyes. 
Among these fluorescent dyes, SYPRO Ruby is becoming popular due to its high sensitivity (1-2 
ng) (Somiari et ai., 2003). Two-dimensional SDS-PAGE offers the best resolution and coverage 
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amongst all the protein separation methods. It has been successfully used to identify potential 
biomarkers for prostate (Lee et al., 2005a), breast (Somiari et al., 2005), hepatocellular 
carcinoma (Lee et al., 2005b), esophageal (Xiong et al., 2002) and lung cancer (Seike et al., 
2005). However, the assay is slow, labor-intensive, sample-consuming, and does not provide 
quantitative data. Two dimensional gel SDS-PAGE also suffers from low sensitivity, difficulty in 
resolving proteins with extreme masses (e.g., proteins> 400 kDa) or isoelectric points, and the 
inability to resolve proteins with low solubility (Ong and Mann, 2005 & Hanash, 2001). 
Therefore, it is not ideal for the identification of markers for early stage diseases when there may 
only be small differences in protein levels between normal and tumor samples. 
The introduction of differential gel electrophoresis (DIGE) has provided slight 
improvement over the conventional 2D SDS-PAGE. DIGE involves labeling the total protein 
purified from two different samples with two different fluorescent dyes (Cy2, Cy3 or Cy5), then 
mixing the solutions and running them on the same gel. Specialized proteomic software will 
allow comparing these protein mixtures. By using a pooled labeled control with a third dye, the 
software can reliably compare quantitative differences in protein levels across multiple gels 
(Lilley and Friedman, 2004). However, this method still suffers from some of the disadvantages 
seen in 2D SDS-PAGE electrophoresis, especially the limitation in sensitivity and resolution to 
detect low molecular weight proteins (Chakravarti et al., 2005). 
When the conventional 2D SDS-PAGE is used, the proteins of interest are excised from 
the gels and digested prior to mass spectrometric analysis using peptide mass fingerprinting 
(PMF). PMF involves matching essential peptide fragment masses obtained by MS (peptide 
masses) to the theoretical peptide masses generated from a protein database. The principle of 
using PMF for protein identification is that every single protein will have a unique set of peptides 
and thus unique peptide masses. Because varying amounts of information can be accumulated 
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from each fragment spectrum, the data obtained needs to be interpreted carefully. PMF has been 
widely and successfully used in proteome analysis for microorganisms and yeast (Halden et aI., 
2005) and for identification of proteins isolated from diseased tissues (Somiari et aI., 2003). 
Non Gel-based Proteomics 
, The "Bottom-up approach" has been used in analytical protein mass spectrometry. The 
identification of proteins depends on breaking down proteins with a protease (usually trypsin) 
into smaller peptides. Their mass/charge (mlz) ratio can be accurately determined by mass 
spectrometry. This allows reliable identification based on peptide mass fingerprinting or using 
peptide fragmentation spectra in a tandem mass spectrometer (Pang et ai., 2002; Sun et aI., 2005 
and Wang et aI., 2006). Another approach that has been recently used in biomarker discovery 
experiments is the "Top-down approach" in which the native proteins and peptides are delivered 
to the mass spectrometer directly without prior treatment with proteases (Figure 1). Depending 
on the mass accuracy of the mass spectrometer being used, peptides and small proteins (up to 
10-20 kDa) can be recognized (Pisitkun et aI., 2006). 
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Figure 1 Schematic of top-down versus bottom-up approaches for protein identification. The top-down 
approach is normally applied to small proteins andlor peptides without preceding digestion. First stage 
mass analysis of precursor ions (MS 1) in this approach yields the list of mlz that can be used for the 
pattern comparison between control and disease conditions. In contrast, the bottom-up approach requires 
an initial digestion step with proteases to break proteins into peptides, allowing protein identification 
based on peptide mass fingerprinting from MS 1 or on peptide fragmentation spectra from MS2 (Pisitkun 
et al., 2006). 
Exact identification of proteins is more difficult with top-down approaches than with 
bottom-up approaches, since rnIz ratios are often reported but not protein identities. On the other 
hand, top-down approaches have a chief advantage in their ability to recognize native small 
peptides (e.g. proteolytic fragments) that show great potential as excellent markers. This may be 
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of particular value in cancer proteomics where proteases that are secreted by tumors may reflect 
the presence of and/or the degree of aggressiveness of the malignancy (Villanueva et al., 2006). 
Multidimensional Protein Identification Technology (MudPIT) is one of the bottom-up 
approaches. Recently, MudPIT became more widely used as a sensitive method for biomarker 
discovery (Bayer et al., 2006 and Chen et al., 2006). In MudPIT, a complex protein mixture is 
digested with trypsin and then undergoes two-dimensional liquid chromatography, which 
separates the peptides by charge, then by hydrophobicity, allowing adequate separation of 
peptides. The separated peptides will be automatically injected into an electro spray ionization 
(ESI) mass spectroscopy unit that directly identifies peptides, one by one, based on their tandem 
mass spectroscopy spectra. Databases of peptides can then be searched to identify the proteins 
based on the mass spectra of the peptides. This technique has a noticeable sensitivity, reported to 
be in the femtomolar (10- 15) range (Wang et al., 2005). 
Isotope-Coded Affinity Tag (ICAT) is another mass spectrometry-based technology 
which allows quantitative protein profiling of paired protein samples. Protein or peptide mixtures 
from two samples are tagged with unique isotopes, then mixed and separated by high-
performance liquid chromatography and mass spectrometry. Since the isotopic tags have similar 
structures and chemical properties, but differ only with respect to their mass, the paired peptide 
peaks representing different tags can be identified on the mass spectrometer (Feng et al., 2006a). 
The difference between the two peaks represents the quantitative difference of that peptide 
between two samples. A second round of mass spectrometry is utilized to identify differentially 
expressed proteins. Since both tumor and normal samples are mixed and run on the spectrometer 
at the same time, variability between assay runs is minimized. However, this technique does not 
permit high throughput processing of specimens and therefore is not suitable for the profiling of 
clinical samples. Such approaches can be used for the examination of specific fractions of 
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cellular proteins (such as secreted or cell surface proteins) in a limited number of samples to 
support biomarker discovery (Feng et ai., 2006a). 
The Surface-Enhanced Laser Desorption and Ionization Time-of-Flight (SELDI-TOF) is 
the recent affinity-based MS technology which follows the top-down approaches. Proteins «20 
kDa) are selectively absorbed onto a chemically or biologically treated surface. High-speed and 
high-resolution chromatographic separations of proteins are achieved by the use of several 
chromatographic arrays and wash conditions (Merchant and Weinberger, 2000). The SELDI-
TOF method is a powerful clinical proteomics tool that can be used for the recognition of 
patients at risk for the development of cancer, based on the direct analysis of their body fluids 
like serum, plasma, cerebrospinal fluid, and urine (Yang et ai., 2005 and Schwegler et ai., 2005). 
Petricoin et ai. (2002) were the first to present the potential to use a serum proteomic signature 
for diagnosis of patients in clinics. SELDI-TOF-MS combined with a genetic algorithm has been 
utilized for the identification of protein peaks in serum which can distinguish patients with 
ovarian cancer from healthy individuals (Rapkiewicz et ai., 2004). 
Although there are still questions related to the sensitivity and reproducibility of SELDI-
TOF, it is currently one of the proteomic tools that are used to directly analyze clinical samples 
and categorize patients into "normal" and "cancer" groups. In 2005, the EDRN established by 
the National Cancer Institute (NCI) and NIH has approved the SELDI-TOF technology as an 
efficient cancer biomarker discovery tool that holds promise for the screening of body fluids 
(Pas twa et ai., 2007). The identification of reliable biomarkers, with sensitivity and specificity 
better than the currently available standards, remains the main priority for proteomic approaches. 
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Nucleic Acid-Based Cancer Biomarker approach 
Circulating Nucleic Acid and Cancer 
Investigating abnormal circulating nucleic acids is of interest for the early detection and 
clinical management of cancer. Many advantages favor the use of nucleic acid-based biomarkers 
over other approaches, DNA is stable, can be stored at room temperature in an appropriate 
buffer, and can maintain its stability against the harsh conditions to which a clinical specimen is 
often exposed. Furthermore, for DNA samples, only small amounts are needed since they can be 
easily amplified by PCR (Feng et aI., 2006b). Cancer patients have been reported to have higher 
levels of circulating DNA in their blood than normal healthy controls. Circulating DNA in the 
plasma/serum of cancer patients reaches as high as 180-412 ng/mL compared to 10-30 nglmL 
among normal individuals (Steinman, 1975; Leon et aI., 1977 and Shapiro et aI., 1983). 
Approximately, 50-80% of these circulating DNAs are being derived from tumor cells (Goessl et 
al., 2002). In 1977, Leon et aI. demonstrated that patients with pancreatic cancer have high levels 
of circulating nucleic acids and that the plasma DNA levels decreased after chemotherapy (Leon 
et aI., 1977). 
In a healthy person, it is believed that circulating nucleic acids result from apoptosis of 
lymphocytes and other nucleated cells. The possibility that apoptosis is the primary source of 
circulating nucleic acids has been supported by the fact that normal plasma DNA on 
electrophoresis exhibits band sizes equivalent to 150-200 bps (Hasselmann et aI. , 2001). In 
cancer, circulating nucleic acids have been thought to be as a result of apoptosis, based on the 
fact that circulating DNA often exhibits a ladder-like electrophoretic pattern (e.g. as seen in 
pancreatic and lung cancers) which is similar to that shown by apoptotic cells (Fournie et aI., 
1995). During apoptosis, DNA is cleaved and chromatin condensed, and fragmented into small 
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pieces of varying size which are wrapped by membranes, forming apoptotic bodies (Wyllie et ai., 
1980). Apoptotic bodies usually contain either DNA or RNA, but not both (Halicka et ai., 2000). 
Apoptotic bodies are recognized, engulfed and digested by macrophages. These small apoptotic 
bodies are most likely to escape the macrophage engulfment, and thereby appear in the 
bloodstream (Lichtenstein et ai., 2001). 
One of the hypotheses for the origin of circulating nucleic acids in cancer is based on 
micrometastases of tumor origin which are shed into circulation (Stroun et ai., 2000). However, 
Chen et ai., (1999) had reported that the high amounts of DNA, isolated from the plasma of 
cancer patients, did not correspond to the number of cancer cells present in the circulation. High 
amounts of circulating DNA was also thought to originate from the necrosis of 
advanced/metastatic tumors. This hypothesis was then proved to be controversial as the amount 
of circulating DNA was decreased by almost 90% after radiotherapy which is supposed to induce 
cell death/necrosis (Leon et ai., 1977 and Nawroz et aI., 1996). The spontaneous and active 
release of DNA by proliferating cancer cells is another possibility that cannot be ignored. This 
hypothesis was supported by the release of DNA from activated lymphocytes in vitro (Anker et 
ai., 1975). 
Many logical hypotheses have been discussed regarding the presence and stability of 
circulating nucleic acids in different bodily fluids. In healthy individuals, plasma DNase I and II 
degrade DNA and therefore minimal levels of plasma DNA should be detected. However, low 
activities of DNase I and II were noticed in many malignant diseases. The low DNase activity 
was based on the fact that, in tumor tissues, high levels of DNase inhibitors have been detected. 
This explains the reason for the observed elevated levels of DNA in the circulation of cancer 
patients (Cooper et ai., 1950). 
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Another hypothesis which supports the stability of DNA in the circulation is the 
formation of nucleosome structures. Nucleosomes are repeating units which package the DNA 
into chromosomes inside the cell nucleus and control gene expression. They are made up of 
DNA and a set of proteins called histones. These histones are made up of five proteins: H2A, 
H2B, H3 and H4, whereas, HI is the linker DNA between two any nucleosomes. 
Oligonucleosomes, that results from apoptosis and contain the histone HI, are insoluble at the 
physiological ionic strength of normal plasma. It has been reported that serum amyloid P 
component (SAP), present in plasma, effectively binds to nucleosomes. SAP is known to 
substitute for histone HI, and hence protects DNA from nuclease digestion and makes 
oligonucleosomes soluble in plasma (Butler et ai., 1990). 
RNA represents another form of the nucleic acid which has been detected in the 
circulation. RNA is known by its high sensitivity towards the ubiquitous RNases present in the 
circulation. However, the endogenous and exogenous circulating RNA were found to be stable in 
the circulation (i.e. not degraded). This might be due to that the RNA is protected by being 
contained in the apoptotic bodies. Another possibility is that the RNA might be bound to 
proteins/phospholipids. The previously mentioned two possibilities may protect RNA from 
degradation by the ribonucleases in the circulation (Kopreski et ai., 1999). 
Recent Advances in Circulating Nucleic Acid and Cancer Biomarker 
Circulating nucleic acid-based biomarkers identification depends on the detection of 
genetic or epigenetic mutations in either the genomic or the mitochondrial DNA. Activated 
oncogenes, inactivated tumor-suppressor genes, chromosomal reanangements and abenant gene 
methylation are some of the commonly observed genetic alterations in cancer (Swarup and 
Rajeswari, 2007). The oncogenes N-ras (in myelodysplastic syndrome (MDS) and myelogenous 
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leukemia) and K-ras (in pancreatic and colorectal cancer) were the first two genes whose 
mutations have been recommended to be used as an early tumor marker (Sorenson et ai., 1994; 
Vasioukhin et ai., 1994 and Hibi et ai., 1998). The mutations in the tumor-suppressor gene p53 
have also been used to detect cancer recurrence or distant metastasis. However, p53 alterations 
are difficult to detect because of its widespread mutations along the gene (Shao et ai., 2001). 
Mitochondrial DNA may also be of interest for the identification of cancer biomarkers, as it is 
preferentially modified by many carcinogens and is less efficiently repaired. The accumulation of 
such unrepaired mutations results in multiple genetic alterations that make them a perfect 
biomarker (Kagan and Srivastava, 2005). 
Circulating Methylated DNA and Cancer Biomarkers 
Currently there is a great interest in evaluating the potential of epigenetic changes for the 
early detection of cancer, cancer staging, and response to therapy (lnazawa et ai., 2004 & Jones 
and Baylin, 2002). Normally in the human genome, DNA methylation occurs at cytosine 
residues within the symmetric dinucleotide, CpG. The human genome contains roughly 29,000 
CpG islands (Venter et ai., 2001), mainly distributed within the promoter and the first exon 
regions of protein coding genes. Most of the CpG islands are normally free of methylation and 
are associated with transcriptionally active genes, predominantly so-called 'housekeeping' genes 
and tumor-suppressor genes. However certain CpG islands are normally methylated, including 
those associated with oncogenes (Paulsen and Ferguson-Smith, 2001). These methylation 
patterns are copied and stably transmitted to the daughter cells after DNA synthesis. 
The methylation status of promoter CpG islands presents valuable information about the 
transcriptional activity of certain genes. There is an inverse relationship between the intensity of 
promoter methylation of any gene and its transcriptional activity. This inverse relationship was 
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proven by an experiment which showed that the binding of transcription factors, required for the 
transcriptional process, was prevented by the methylation of specific DNA sequences. Therefore, 
in most genes, methylation of CpG islands in the promoter region is associated with "gene 
silencing"; i.e., the gene can no longer be expressed (Figure 2) (Laird, 2003). 
A / CpG island 
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Figure 2 Methylation of specific CpG islands DNA sequences. Unmethylated cytosines are found at high 
densities in CpG islands, usually present in the promoter and first exon regions of housekeeping genes. 
(A) The full hypomethylation state of a promoter CpG island (open circles) is associated with 
transcriptional activity, whereas (B) hypermethylation (closed circles) causes transcriptional silencing 
(Worm and Guldberg, 2002). 
Cancer cells display significant changes in their DNA methylation pattems, which can 
generally be observed as global hypomethylation of the genome accompanied by the 
hypermethylation of several specific genes (Robertson, 2001). Silencing of genes by CpG island 
hypermethylation has been reported in all cancers and many precursor lesions. CpG island 
hypermethylation plays a major role in carcinogenesis and has been reported to occur early 
during oncogenesis (Herman and Baylin, 2003). Among high-risk patients, the presence of 
cancer-associated hypermethylated genes is highly indicative for an increased risk of cancer 
development (Laird, 2003). 
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Carcinogenesis IS a multistep process which has been described in terms of cancer 
progression. When the changes in the methylation of multiple promoters in invasive tumors, pre-
invasive lesions and normal tissues were studied, the timing of the methylation events varied 
greatly. Furthermore, the number of epigenetic changes (CpG hypermethylation) increases as the 
histological changes worsen (Figure 3) (Herman, 2004). Thus, abnormally methylated CpG 
islands are of interest as biomarkers for identification of individuals with, or at risk for, cancer 
(Verma et ai., 2004). Furthermore, the timing of these events is crucial for the development of 
early cancer detection biomarkers (Herman, 2004). 
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Figure 3 A demonstration for the epigenetic progressIOn of histological changes that occur in the 
development of cancer. The number of genes with aberrant methylation increases as the lesion becomes 
more invasive (Herman, 2004). 
Most of the tumor-suppressor genes, which were studied for their aben'ant methylation in 
various cancer types, were found to be commonly methylated targets. These genes were found to 
be involved in cell-cycle control and apoptosis: p14, pIS, p16, Rb, Death-associated protein 
kinase (DAPK); DNA repair: 06-methylguanine-DNA-methyltransferase (MGM1), human mutL 
homologue (hMLR1); adhesion and metastasis: CDRI (Cadherin 1), CDR13 (Cadherin 13), 
biotransformation: Glutathione S-transferase pi (GSTP 1) and signal transduction: Retinoic acid 
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receptor beta (RARfJ) , Adenomatous Polyposis of the Colon (APC). A list of hypermethylated 
genes along with their contribution in carcinogenesis is summarized in Table 3. For example, the 
hypermethylation of GSTP 1 is probably the most common epigenetic alteration, and it accurately 
discriminates benign from malignant prostate lesions (Henri que and Jeronimo 2004). A similar 
frequency of aberrant methylation status in prostate cancer was shown for the RARfJ gene. The 
hypermethylation of the RARfJ gene correlates with a more advanced pathological stage and 
allows the discrimination between neoplastic and non-neoplastic tissue (Jer6nimo et aI., 2004). 
Recurrent colorectal cancer has been correlated with the presence of a hypermethylated p16 
promoter in the circulation of high risk patients (Nakayama et aI., 2003). 
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Table 3 List of hypermethylated genes and their contribution in carcinogenesis 
Gene Function 
Consequences of silencing and 
Joss of heterozygosity 
hMLHl DNA mismatch repair 
genome instability, frameshift 
mutations 
Pl61NK4a Cyclin-dependent kinase loss of cell cycle control 
inhibitor, cell cycle regulation 
Pl4ARF 
MDM2 inhibitor, cell cycle 
loss of cell cycle control 
regulation 
PlSINK4b Cyclin dependent kinase loss of cell cycle control 
inhibitor, cell cycle regulation 
MGMT 
repair of alkylated DNA guanine mutations, chemosensitivity to 
residues alkylating drugs 
biotransformation of 
GSTPl higher incidence of mutations 
electrophilic substances 
Rare 
retinoic acid receptor, cell cycle 
loss of cell cycle control 
and growth control 
RASSFlA Ras effector homologue Unknown 
Rb Cell cycle inhibitor loss of cell cycle control 
CDHl cell adhesion Metastases 
CDHJ3 cell adhesion Metastases 
Hypermethylated in cancer 1 
transcription factor Unknown (HICl) 
APC inhibitor of beta catenin Loss of cellular growth control 
DAPK Apoptosis resistance to apoptosis 
Insulin-like growth factor binding 
growth factor signaling resistance to apoptosis 
protein 3 (lGFBP 3) 
Estrogen receptor alpha (ESRl) estrogen receptor, signal aberrant growth and 
transduction differentiation 
Checkpoint with forkhead and 
Mitotic stress checkpoint gene chromosome instability 
ring finger domains (CHFR) 
Heat shock 70kDa protein 2 
heat shock protein Unknown (HSPA2) 
Suppressor of cytokine signaling 2 
suppressor of cytokine signaling enhanced growth (SOCS2) 
Ataxia telangiectasia mutated 
DNA damage response enhanced DNA damage (ATM) 
Fragile histidine triad gene (FHIT) cell cycle control and apoptosis Unknown 
Laminin-5 cell-basal membrane interaction Unknown 
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Analyzing a panel of four hypermethylated genes, GSTP 1, RARfJ, Tazarotene-induced 
gene-1 (TIG1) and APC, prostate cancer was detected with 100% specificity. The combination of 
this panel with histological tests resulted in a specificity of 97% in detecting prostate 
adenocarcinoma, in comparison with a specificity of 64% when only the histological test was 
used (Tokumaru et al. 2004). Moreover, the hypermethylation of MGMT, p16, Human Ras 
association domain family 1 (RASSF1A), DAPK and RARfJ have been identified in the serum of 
patients with lung cancer. The previously mentioned methylation pattern appeared to be 
moderately a good lung cancer biomarker with a sensitivity of 50.9% in comparison to a 
sensitivity of 11.3% by serum protein tumor markers (Fujiwara et al. 2005). In another study, the 
hypermethylation of p16 and MGMT in patients with squamous cell lung carcinoma was 
detected, three years prior to disease diagnosis, in sputum samples (Palmisano et al. 2000). Kim 
et al. (2004) reported the hypermethylation of p16, RASSF1A, FHIT, H-cadherin and RARfJ 
promoter genes in 68% in all the studied non-small cell lung cancer (NSCLC) patients. The 
analysis of methylation of this panel of genes in bronchial lavage-obtained DNA may be a 
promising biomarker for the early detection of NSCLC. 
Studying the aberrant methylation of eight TSGs (CDH1, APC, RASSF1A, MGMT, p16, 
GSTP 1, RARfJ2, and ARF) allowed the identification of 68% of lung cancer cases in patients' 
, bronchoalveolar lavage fluid (Topaloglu et al. 2004). Three or more hypermethylated genes from 
a panel of five studied genes (CDH13, HSPA2, MLH1, RASSF1A, SOCS2) were detected in the 
vaginal secretions from endometrial cancers whereas 91% of the controls showed no 
hypermethylation of any of the studied genes or fewer than three genes (Fiegl et al. 2004). 
Furthermore, the aberrant methylation of three genes DAPK1, RARfJ, and Twist transcription 
factor 1 (TWIST1) successfully detected cervical neoplasia in urine exfoliated cell samples with 
95% specificity (Feng et al. 2005a). Frequent hypermethylation of RARfJ, p16, p14, RASSF1A, 
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DAPK and GSTP 1 was observed in breast cancer tissues and in 82% of the matched samples of 
nipple aspirate fluid DNA (Krassenstein et al. 2004). Hypermethylation could be detected in the 
early stages of breast cancer, but no hypermethylation was observed in normal and benign breast 
tissue (Krassenstein et al. 2004). 
Profiling aberrant DNA methylation is a promising population screening tool for the early 
and specific cancer detection. This screening tool is beneficial, especially, when non-invasive 
biological samples (blood, body fluids, semen, saliva, urine, stool) containing tumor DNA from 
patients without clinically detectable diseases are utilized. Additional studies, in the field of 
population screening for cancer, are focusing on the identification of more specific methylation 
markers. Table 4 lists a number of hypermethylated genes that have been used as cancer 
biomarkers with their incidence of occurrence in specific types of cancers. 
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Table 4 Hypermethylated genes used as cancer biomarkers 
Examples of disease markers 
Examples of 
Type of cancer prognostic References (% methylated cases) 
markers 
Acute myeloid 
P ISlNK4B (>70%) 
pIS'NK4B Shimamoto et aI., 200S 
Suppressor of cytokine and Aggerholm et aI., 
leukemia (AML) CDHI 
! signaling 1 (SaCSI) (>SO%) 1999 
MDS P IS'NK4B (>SO%) 
pISJNK4lJ, CDHI, 
Aggerholm et aI., 2006 
HICI andER 
Small heterodimer partner 
B-cell (SHPI) (-100%) Lamin gene 
Non-Hodgkin Deleted in bladder cancer I (LMNA) Agrelo et al., 200S and 
Voso et aI., 2006 
lymphoma (DBCI) (-100%) MGMT 
DAPK(>80%) 
Hodgkin lymphoma Spleen tyrosine kinase (SYK) NIA Ushmorov et aI., 2006 
RASSF IA (>80%) 
MGMT Estecio et aI., 2006 and 
Head and neck cancer DAPK(>70%) 
RARfJ2 (>70%) Hamilton et aI., 2006 
Oesophageal 
APC(>90%) 
Tissue inhibitor APC 
cancer/Barretts Clement et aI., 2006 
metallopeptidase inhibitor 3 TIMP3 
esophagus (TIMP3) (>SO%) 
Gastric cancer CDHI (>SO%) CDHI Graziano et aI., 2004 
Colorectal cancer Somatostatin (SS1) (>80 %) pI6
JNK4A and/or 
Mori et aI., 2006 
p14ARF 
Liver cancer 
PI6JNK4A(>SO%) 
NIA 
Fukai et aI., 200S 
RASSF IA (>80%) Yeo et aI., 200S 
Breast cancer 
RASSFIA (>80%) 
CDHl Shinozaki et al., 200S 
CDHl (>70%) 
Non-small cell lung Protocadherin 20 (PCDH20) FHIT Imoto et aI., 2006 and 
cancer (>SO%) PCDH20 KikuchietaI.,2006 
Bladder cancer 
Runt-related transcription CDH1, FHIT, 
Kim et aI., 200Sa 
factor 3 (R UNX3) (>70%) TIMP3 
GSTPI (>70%) 
Prostate cancer 
APC (>70%) 
GSTPI, APC 
Rosenbaum et aI., 2005 
Prostaglandin-endoperoxide and Bastian et aI., 2005 
synthase 2 (PTGS2) (>70%) 
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MicroRNA-based Cancer Biomarker Approach 
Science has discovered a new branch of genetic programmatic synchronization by which 
cells determine their fate through post-transcriptional regulation of gene expression by 
microRNAs (miRNAs) (Calin and Croce, 2006). MiRNAs are, primarily, transcribed in the 
nucleus by an RNA polymerase II enzyme, producing long nucleotide sequences called primary-
miRNA (pri-miRNA) (Lee et aI., 2004 and Zeng et ai., 2005). Pri-miRNA is characterized by 
being capped at the 5' end and poly-adenylated at its 3' end, similar to the protein-coding 
messenger RNA (mRNA) (Cai et aI., 2004). Once produced, pri-miRNA forms a specific 
hairpin-shaped stem-loop structure. This stem-loop structure is processed by a microprocessor 
complex consisting of an RNase III endonuclease (Drosha) and its cofactor DiGeorge syndrome 
critical region gene 8IPasha (DGCR8IPasha) producing a 60-t070-nt pre-miRNA with a 5' 
phosphate and a 3' 2nt overhang (Han et aI., 2004 and Landthaler et aI., 2004). The pre-miRNAs 
are then transported to the cytoplasm by Exportin-5 (Exp5) (Bohnsack et aI., 2004). Once in the 
cytoplasm, pre-miRNAs are further processed to a short double strand miRNA:miRNA * duplex 
by Dicer, a second RNase III endonuclease (Grishok et aI., 2001). This duplex is then loaded into 
the miRNA-associated multiprotein RNA-induced silencing complex (miRISC) and is unwound 
into a mature miRNA and miRNA * by a helicase (Figure 4). 
Mature miRNAs negatively regulate their targets by either one of two ways, based on the 
degree of complementarity between the miRNAs and their targets. The first regulatory 
mechanism involves the perfect or nearly perfect complementarity of the miRNA to its target 
mRNA sequences, thus inducing an RNA-mediated interference (RNAi) pathway. In this 
pathway, the target mRNA transcript will be cleaved by the ribonuclease activity of the miRISC 
(Hannon, 2002). On the other hand, the second mechanism of gene regulation does not involve 
the cleavage of the mRNA target. As the miRNA sequence is not perfectly matching its target 
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(imperfect complementarity), it binds to a sequence within the 3' Untranslated region (UTR) at 
its mRNA target, which repress the gene expression post-transcriptionally (Pillai et al., 2005 and 
Carmell et al., 2002) (Figure 4). 
Nucleus Cyt oplasm 
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Figure 4 The biogenesis of microRNA (Esquela-Kerscher and Slack, 2006) 
Several recent studies showed that miRNA regulates cell growth and apoptosis (Cheng et 
al. , 2005). Furthermore, clinical and experimental analyses suggested that miRNAs may function 
as a novel class of oncogenes or tumor suppressor genes. The up-regulation in the expression of 
some miRNAs has been reported in some cancer types; thus they may be considered as 
33 
Moemen Abdalla HCC Biomarkers 
oncogenes and hence are called "Oncomirs". Oncomirs usually support tumor development by 
negatively down-regulating tumor suppressor genes and/or genes that control cell differentiation 
or apoptosis (Zhang et al., 2007a). For example, mir-17-92, located at chromosome 13q31, was 
found to be over-expressed in many cancer types including lung cancer and lymphomas. This 
was found, mostly, in their aggressive forms, such as small-cell lung cancer and human B-cell 
lymphomas (Hayashita et al., 2005 and He et al., 2005a). The tumor-suppressor gene, PTEN that 
promotes apoptosis through the P13K-Akt-PKB pathway, was predicted to be targeted by the 
miR-17-92 cluster (Hammond, 2006 and Lewis et al., 2003). The deregulation of c-myc 
(Myelocytomatosis oncogene) expression (which regulates cell proliferation, growth and 
apoptosis-mediated cell death) usually causes human malignancies (Fernandez et al., 2003 & 
Cole and McMahon, 1999). O'Donnell et al., (2005) reported that both miR-17-92 and c-myc 
regulate the expression of the cell cycle transcription factor gene E2F transcription factor 1 
(E2F1). C-myc regulated miR-17-92 modulates E2F1 expression which affects apoptosis-
mediated cell death through the ARE-p53 pathway (Hammond, 2006 and O'Donnell et al., 
2005). 
On the other hand, some miRNAs were found to be down-regulated in cancerous cells 
and are considered as tumor suppressor genes, such as let-7 (Zhang et al., 2007a). Tumor 
suppressor miRNAs usually prevent tumor development by negatively inhibiting oncogenes 
and/or genes that control cell differentiation or apoptosis. Let-7 is located at a chromosomal 
region that is usually deleted in human cancers (Calin et al., 2004a). It has been reported that let-
7 was down-regulated in lung cancers which were significantly associated with short-lived 
postoperative survival, no matter the stages of the disease. Recent studies showed that the ras 
oncogene is a major target for let-7 (i.e. it negatively regulates ras expression by binding at its 3' 
UTR mRNA sequence leading to translational repression). Therefore, lung tumor tissues show 
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significantly down-regulated levels of let-7 and hence significantly increased levels ofras protein 
relative to normal lung tissues, suggesting that let-7 regulation of ras is a mechanism where let-7 
functions as a tumor suppressor gene in lung oncogenesis (Johnson et ai., 2005). 
Real-time qRT-PCR is the gold standard approach for miRNA quantification due to its 
high sensitivity and specificity. MiRNAs are tough molecules to be quantified by PCR, since the 
-21nt mature miRNA is nearly the size of any standard PCR primer and the hairpin structure of 
the miRNA precursor is too stable to denature. Despite these challenges, successful real-time 
PCR assays have been established to amplify and quantify both the precursor and the mature 
miRNAs (Schmittgen et ai., 2004). Successful qRT-PCR was performed on the stable hairpins 
by using gene specific primers for the reverse transcription and a thermostable reverse 
transcriptase. Chen et ai., (2005) had developed a method to quantify the mature miRNAs, where 
a loop primer is used to prime the reverse transcription reaction. 
The purpose of this loop primer is to enhance the secondary structure and the priming of 
small miRNA. Furthermore, it will prevent the binding of the primer to the miRNA precursors 
and/or to the genomic DNA. Moreover, the loop primer will increase the size of the 
complementary DNA (cDNA) which maximizes the PCR amplification. Use of TaqMan probes 
is recommended to sort out individual miRNA isoforms from nearly identical miRNAs (e.g., 
members of the let-7 family) (Chen et aI., 2005 and Jiang et ai., 2005). Use of TaqMan probes 
also improves the sensitivity of the assay by reducing the background from low levels of 
detection. Quantification of miRNAs using real-time qRT-PCR has been used for several 
applications including gene expression profiling and biomarker discovery. 
MicroRNA expression profiles of different tumor types, relative to their normal tissues, 
have recently been shown to provide phenotypic signatures for particular cancer types (Lu et ai., 
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2005 and Volinia et ai., 2006). Table 5 lists recently identified miRNAs and their clinical 
significance. Unique patterns of aberrant miRNA expression may serve as molecular biomarkers 
for tumor diagnosis, prognosis of disease specific outcomes, and prediction of therapeutic 
responses (Waldman and Terzic, 2007). When microRNA profiles from patients with normal 
pancreas, chronic pancreatitis, and pancreatic cancer were evaluated, specific patterns of miRNA 
expression identified pancreatic cancer from normal pancreas in 90% of cases and, separately, 
from chronic pancreatitis in 93% of cases. A group of miRNAs was of prognostic value; i.e. 
identifies patients with pancreatic cancer who survived longer than 24 months, compared with 
those who survived less than 24 months. In addition, aberrant expression of only one specific 
miRNA had predicted an overall poor survival (median, 14.3 months) compared with patients 
whose tumors did not express this miRNA species (median, 26.5 months) (Bloomston et ai., 
2007). 
Despite the study conducted by Bloomston, quantitative and qualitative relationships 
between miRNA biomarkers, patient management, and disease outcomes have not undergone 
meticulous clinical investigations, and the proof linking a biomarker with clinical end points may 
not be available (Wagner et ai., 2007). Relationships demonstrating the clinical usefulness of 
miRNA biomarker should be carried out in randomized clinical trials and consequently validated 
in follow-up trials (Wilson, 2006). In the absence of a well-designed approach to validate the 
clinical value of miRNA as a cancer biomarker, the use of miRNAs as biomarkers might be 
overestimated and lead to mis-diagnosis. Therefore, research on miRNA biomarker panels 
should be shifted from discovery studies into developmental studies to define their diagnostic, 
prognostic and predictive value. 
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Table 5 MicroRNA expression profiles in different human cancers and their clinical significance 
Cancer type MiRNA profiling data Significance Reference 
Chronic A unique signature of 13 genes associated with prognostic MiRNAs as diagnostic 
lymphocytic factors (ZAP70 and IgVH mutation status) and progression markers (the identification of Calin et aI, 
2004b 
leukemia (time from diagnosis to therapy) two categories of patients) 
Lung Molecular signatures that differ with tumor histology; MiRNAs as prognostic and Yanaihara et 
adenocarcinoma miRNA profiles correlated with survival (miR-i55 and let-7) diagnostic markers ai., 2006 
~ 
Breast carcinoma 
MiRNA expression correlates with specific pathological MiRNAs as prognostic Iorio et ai., 
features markers 2005 
A signature that distinguishes endocrine from acinar tumors; 
Endocrine the overexpression of miR-2i is strongly associated with both MiRNAs as diagnostic and Roldo et ai., 
pancreatic tumors a high Ki67 proliferation index and the presence of liver prognostic markers 2006 
metastases 
Hepatocellular MiRNAs as prognostic Murakami et 
carcinoma 
MiRNA expression correlated with differentiation 
markers ai., 2006 
Papillary thyroid 
MiRNA upregulation (for example, miR-221 and miR-222) in 
MiRNAs probably involved in He et ai., 
tumoral cells and normal cells adjacent to tumors, but not in 
carC1l10ma cancer initiation 2005b 
normal thyroids without cancers 
MiRNAs as diagnostic Ciafre et ai. , 
Glioblastoma A specific signature compared with normal tissues 
markers 2005 
MiRNA-expression profiles accurately classify cancers; an 
MiRNAs as diagnostic Lu et ai., 
Human cancers miRNA classifier classes poorly differentiated samples better 
markers 2005 
than a messenger RNA classifier 
Human solid 
Specific miRNAs are involved 
Volinia et ai., 
Common signature for distinct types of solid carcinomas in common molecular 
cancers 2006 
pathways 
-
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Urine: A Source for Cancer Biomarker Discovery 
An enormous increase in the information regarding the genetic and epigenetic alterations, 
leading to the development of cancer, has been revealed (Fearon and Vogel stein, 1990 & Jones 
and Baylin, 2002). These cancer-specific alterations can be detected as cell-bound (Ghossein and 
Bhattacharya, 2000 & Sidransky et aI., 1991) and as cell-free (Anker et aI., 1999) in smears and 
bodily fluids like serum/plasma, sputum/saliva, urine, synovial fluid, ascites, cerebrospinal fluid 
and stool. There has been a great expectation to exploit these cancer signatures, in different 
bodily fluids, as non-invasive or minimally invasive cancer molecular markers (Sidransky, 
2002). One of these bodily fluids is urine that has been used by ancient clinicians to diagnose 
diabetes by tasting it or observing whether it attracts ants. For centuries, the presence of albumin 
in large amounts in urine "foam test" has been used to diagnose renal diseases. Even today, 
shaking urine is used to diagnose glomerular diseases; if froth develops it is evidence for high 
level of proteins. Following this trend, urinary cancer biomarkers have been of great interest in 
the field of diagnostics throughout the 20th and the early 21 st century (Pisitkun et aI., 2006). 
The advantage for using urine as a source for cancer biomarkers is that it can be obtained 
in large quantities without using invasive procedures. In addition, repeated sampling from the 
same individual is simple, which facilitates longitudinal studies. Since urine is considered a 
specific filtrate of blood, the protein components of urine are qualitatively similar to those of 
blood (Oh et aI., 2004). Generally, urine contains highly soluble proteins and peptides of low 
molecular weight «30 kDa) thus facilitating the analysis of these polypeptides without 
additional handling (e.g., tryptic digests) (Theodorescu and Mischak, 2007). Urinary 
polypeptides do not undergo significant proteolysis within several hours of collection. However, 
the activation of proteases and the generation of proteolytic breakdown products take place, in 
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blood, during collection (Omenn et aI., 2005). The stability of urinary proteins was investigated 
by two experiments that showed no significant change when urine was stored up to three days at 
4 DC or up to 6 h at room temperature (Schaub et aI., 2004 and Theodorescu et ai., 2006). 
Moreover, urine can be stored for years at -20 DC without significant alteration of its proteome 
(Weissinger et aI., 2007). This stability is possible because urine is "kept" in the bladder for 
hours , and proteolytic degradation by the endogenous proteases is complete by the time of 
voiding (Zhou et aI., 2006). 
However, there are few disadvantages of using urine as a source for cancer biomarker 
discovery. For example, the wide variation in the protein concentration which is due to 
differences in patients' fluid intake. This problem can be solved by standardization based on 
creatinine (Vestergaard and Leverett. 1958) or peptides normally present in urine (Schiffer et al, 
2006). Another disadvantage is the variation of the pH in different urine samples which affects 
the activity of the proteases. This leads to a great variability in the concentrations of particular 
peptide fragments (Theodorescu and Mischak, 2007). Urinary disease-specific biomarkers are 
also complicated due to the changes in the proteome during the day. This biological variability is 
due to many factors such as exercise, diet, circadian rhythms, anabolic or catabolic processes as 
well as the circulatory levels of various hormones (Kussmann et aI. , 2006). These variations are 
. limited to a small fraction of the urinary proteome, whereas the basal or the house-keeping 
fraction remains unaffected and thus facilitates the analysis (Schiffer et al, 2006). Timing of 
sample collection is critical as there is an obvious difference between early and midstream urine 
samples. Therefore, the standardization of urine collection procedures is of great importance. 
Urinary proteomics presents an attractive approach to cancer biomarker discovery, not 
only for renal/urological malignancies (Rehman et aI., 2004 and Irmak et aI., 2005) but also for 
other systemic malignancies (Tantipaiboonwong et ai., 2005 and Ye et ai., 2006). Two principal 
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approaches are involved in the discovery of new urine biomarkers. The first is concerned with 
studying candidate biomarkers (usually tubular proteins, cytokines, growth factors and 
inflammatory mediators) with suggested pathological links to specific diseases. The second 
involves biomarker discovery studies in which urine is screened for disease-associated proteins 
using an array of technologies, predominantly based on mass spectrometry (Barratt and Topham, 
2007). 
So far, 2D SDS-PAGE is the most extensively used technique for separating and 
visualizing UrInary proteins (Gorg et ai., 2004). Urinary biomarkers can be identified by 
comparing 2D gels from patients and healthy subjects, excising differentially expressed protein 
"spots" from the gel which will be then sequenced for identification. In an early attempt for 
specific urinary proteomic biomarker discovery, Anderson et ai., (1979) reported changes in the 
urinary proteomes using 2D SDS-PAGE in patients with bladder cancer and after induced tubular 
damages. A 2D SDS-PAGE proteomic analysis of tumor tissues from both transitional cell 
carcinomas (TCCs) and squamous cell carcinomas has been done to create a reference database, 
useful in biomarker discovery trials (Celis et ai., 1999). 
Despite the revolution in the proteomic tools, several single biomarkers in urine are 
routinely analyzed in the clinical locale and serve as parameters with inconsistent discriminative 
ability (Ivandic et ai., 2000). This inconsistency is not astonishing since it is impossible that 
complex and frequently heterogeneous diseases could be assessed based on a single variable. For 
most diseases, improved sensitivity and specificity can be achieved by carrying out synchronized 
analysis of a set of markers that form disease-specific patterns. 
Besides the presence of proteins and peptides in urine, circulating nucleic acids have also 
been detected in urine (Botezatu et ai., 2000). The content of DNA in plasma appears to be a sign 
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of the amount of dead cells in the whole body and it also increases during harsh pathological 
processes, including cancers (Fournie et ai., 1993). It has been reported that some plasma 
circulating DNA crosses the kidney barrier and appears in urine which was then called 
"trans renal DNA" (Botezatu et ai., 2000). K-ras mutations were detected in urine of patients with 
pancreatic or colorectal carcinoma (Botezatu et ai., 2000). In addition, Y chromosome-specific 
sequences were also detected in the urine of pregnant woman with a male fetus and in a woman 
who previously received blood from a male donor (Lichtenstein et ai., 2001). 
Many advantages favor the use of urinary ~DNA for cancer biomarker discovery over 
blood and tissues samples. Urine-based tests are absolutely noninvasive. Urine is noninfectious 
for HIV and less infectious for many other pathogens. The concentrations of urinary DNA is 
similar to that in plasma. More urine can be easily collected for analysis. Finally, DNA isolation 
from urine is technically much easier because of its low protein concentration (WOO-fold lower 
than blood) (Botezatu et ai., 2000). 
There are many hypotheses explaining how the circulating DNA can cross the kidney 
barrier to the urine. The molecular-weight cutoff of the glomeruli is about 70 kDa, whereas the 
pore size of the glomerular barrier is about 30 A and, recently, large pores of 110-115 A were 
discovered (Tencer et ai., 1998). The average molecular weight of the cell-free urinary DNA was 
found to be about 90 kDa (150 bp). It was also hypothesized that the SAP protein, which 
substitutes the his tones of the nucleosomes, will decrease the diameter of the nucleosome and be 
able to pass through the kidney barrier. The binding of the cell-free DNA to SAP will also 
protect the DNA from being degraded by the circulating nucleases (Lichtenstein et ai., 2001). An 
alternative mechanism for transrenal DNA clearance is based on the ability of small, lipid-
covered particles to penetrate the glomerular barrier. Apoptotic bodies, which contain DNA or 
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RNA, have a liposome-like structure and their penetration through the kidney barrier is highly 
possible (Lichtenstein et a!., 2001). 
Finally, Urine has been known for centuries to reflect pathological changes. It offers a 
great opportunity for the development of novel, non-invasive assays for the diagnosis, 
monitoring and early detection of cancer. Its impact has yet to reach its full potential, especially 
for clinical applications; however, initial studies have revealed its significant potential for 
clinical diagnosis (Pisitkun et a!. , 2006). It is doubtful that any single urine biomarker will have 
sufficient sensitivity and specificity for clinical use. However, it appears more likely that any 
new biomarker will be in the form of a panel of markers to increase its specificity and sensitivity. 
By taking into consideration that the excretion of urine biomarkers varies with sex, age, 
hypertension and current medications, validation of urine biomarkers for one patient group may 
not be diagnostic in another patient group. For that reason, inclusion and exclusion criteria will 
have to be clearly defined (Barratt and Topham, 2007). 
Hepatocellular carcinoma 
Epidemiology and Aetiology 
Hepatocellular carcinoma is one of the most common malignant tumors and represents 
more than 5% of all cancer types. The estimated annual number of cases, worldwide, exceeds 
600,000 (Parkin et a!., 2005), with a mean annual incidence of around 3-4% (Llovet and 
Beaugrand, 2003). HCC ranks as the sixth most common cancer in the world; the fifth among 
men and eighth among women; and also the second among cancers of the digestive tract after 
stomach cancer (Parkin et a!. , 2005 and Bosch et a!. , 1999). The burden of liver cancer is not 
distributed evenly worldwide (EI-Serag and Rudolph, 2007). Sub-Saharan Africa and Eastem 
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Asia have almost 80% of the HCC cases worldwide. China accounts for more than 50% of the 
HCC world's cases (Parkin, 2002) (Figure 5). The incidence of HCC varies considerably within 
various geographic areas due to the differences in the major causative factors. 
• <4.0 
• <5.8 [J <8.7 
II <17.7 
• <93.4 
Figure 5 Regional variations in the mortality rates of HCC categorized by age-adjusted mortality rates. 
The rates are reported per 100,000 persons (EI-Serag and Rudolph, 2007). 
Approximately, 70%-90% of all HCC detected cases have an established background of 
chronic liver disease and cirrhosis (EI-Serag and Rudolph, 2007). The foremost causes of 
cirrhosis in HCC patients are hepatitis B virus (HBV), hepatitis C virus (HCV), alcoholic liver 
disease and nonalcoholic steatohepatitis (EI-Serag and Rudolph, 2007). Hepatitis A (HAV) and E 
(HEV) viruses do not produce long-term pathological problems. Although hepatitis D virus 
(HDV) always occurs as co-infection with HBV and leads to severe acute or chronic hepatic 
diseases, there is controversy as to whether it increases the carcinogenic potential (Verme et al., 
1991). 
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In countries such as Taiwan, the main cause for the high incidence rate of HCC is due to 
HBV infection. However, due to the mass vaccination programs of neonates and children against 
HBV, the number of HBV-associated HCC cases is now falling (Chang et al., 1997 & Lee and 
ko, 1997). On the other hand, an overall reduction in the mortality caused by HBV is not 
expected on the short term, as an estimated 400 million worldwide remains chronically infected 
with HBV, with a risk of developing HCC. It has also become evident that the number of HCC 
cases is increasing in low to middle-incidence countries such as the USA (EI-Serag et al., 1999) 
France (Benhamiche et al., 1998) the UK (Mant and Vessey, 1995) and most particularly, Japan 
(Okuda, 2000 and Makimoto and Higuchi, 1999). This increasing incidence is due to either 
detection bias, longer survival of patients with chronic liver diseases or the growth of the 
population in older age groups (EI-Serag et al., 1999 & Ince and Wands, 1999). Additionally, the 
rising number of cases in these countries is most likely due to chronic HCV infection (Ince and 
Wands, 1999 and Deuffic et al., 1999). The same reason may also be the cause of the similar 
increase in the Middle East and North Africa. Indeed, the spread of HCV has been referred to as 
the 'new epidemic' in many studies (EI-Serag et al., 1999; Ince and Wands, 1999 and Deuffic et 
al., 1999). 
In Japan, the HCC-related mOltality rate has sharply increased from 10/100,000 in 1975 
to almost 401100,000 in 2000. The rapid increase in the HCC mortality, in Japan, is mainly due 
(-80%) to persistent HCV infection (Y oshizawa, 2002). The hepatitis C epidemic in Japan 
originated from intravenous drug use by the young generation after World War II during the late 
40s and early 50s. As the average time interval between the initial infection with HCV and the 
development of HCC is 30 years (Jeng and Tsai, 1991), the growing incidence of HCC in Japan 
is expected to reach its highest levels around the year 2015 (Yoshizawa, 2002). In Italy, one of 
the main reasons for the increase in the mortality rate of HCC is a large cohOlt of subjects 
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infected with HCY through iatrogenic route during the 50s and 60s when glass syringes were 
commonly used for medical treatment (Stroffolini et ai., 1998). Similarly in Australia, France 
and the United States of America (USA) the HCC mortality is increasing, most probably because 
people infected with HCY have grown old and reach the cancer-bearing age (EI-Serag et ai., 
2000). 
Death rates for HCC in Egypt appear to be increasing over the last decade (Bedwani et 
ai., 1996), which is highly related to HCY infection. In 1993, the HCY seroprevalence was 55% 
among children who had received blood transfusions and 67% among patients receiving renal 
dialysis, whereas the HCY seroprevalence was 10% among sexually transmitted disease patients 
and even lower among children who had never received blood transfusions (Khalifa et ai., 1993). 
These findings indicate that parenteral transmission is currently the major route of HCY spread 
in Egypt. Schistosomiasis is one of the major reasons for the vast increase in the number of HCY 
infected patients. Although schistosomiasis is not associated with HCY infection (Kamel et ai., 
1994) a relationship exists between HCY infection and parenteral treatment with tarter emetic 
injections for schistosomiasis (Angelico et ai., 1997). HCY was transmitted during 
schistosomiasis treatment by either unsanitary medical practice or by acupuncture carried out by 
a particular physician or a practitioner during 1918-1970 (Cohen, 1999). 
Molecular Stages and Pathogenesis of Hepatocarcinogenesis 
Hepatocarcinogenesis is a slow multistep process, controlled by several factors that 
ultimately lead to malignant transformation of the hepatocytes (Thorgeirsson and Grisham, 
2002). HCC always develops as a consequence of long-term inflammation due to chronic 
hepatitis and fibrosis (Thorgeirsson and Grisham, 2002). Hepatocarcinogenesis develops during 
a process that may take more than 30 years after chronic HCY infection is first diagnosed 
45 
Moemen Abdalla HCC Biomarkers 
(Grisham, 2001). HCC mainly develops in hepatocytes that are the primary site of chronic 
hepatitis and cirrhosis (Chu, 2000 and Oka et a!. , 1990). The preliminary hepatocellular 
alterations that come before the appearance of HCC include foci of phenotypically altered 
hepatocytes and, subsequently, dysplastic hepatocytes that form foci and nodules (Grisham, 2001 
and Buendia, 2000). Genomic alterations appear to develop randomly, beginning in preneoplastic 
lesions, and their development increases in dysplastic hepatocytes and HCC. The complex 
heterogeneity of genomic lesions displayed by HCC suggests that it may be produced by both 
genomic and epigenetic alterations that may compromise more than one regulatory pathway 
(Thorgeirsson and Grisham, 2002). Figure 6 shows the chronological sequence of cellular lesions 
caused by HCV infection that leads to development of hepatocellular carcinoma in human. 
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Figure 6 Chronological sequence of cellular lesions occurs due to HCY infection leading to the 
development of hepatocellular carcinoma (modified from Thorgeirsson and Grisham, 2002). 
Molecular Pathways in Human Hepatocarcinogenesis 
At least four pathways that regulate either cell proliferation or cell death (phospho-
retinoblastoma (PRb), p53, transforming growth factor-~ (TGF-~) and ~ -catenin pathways) are 
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affected in HCC (Ozturk, 1999; Moradpour and Wands, 2002 & Moradpour and Blum, 2005). 
Retinoblastoma (RB) is a tumor suppressor gene located within a 200kb segment of chromosome 
13, encoding an 110kDa phosphoprotein (PRb). TGF-~ normally suppresses the enzyme that 
phosphorylates pRB (Laiho et aI., 1990). Unphosphorylated pRB localizes in the nucleus, binds 
tightly to an unidentified "nuclear anchor", preventing cellular growth beyond the Gl phase of 
the cell cycle. pRB normally inhibits cell cycle progression by binding to the transcription factor 
E2Fl. Once TGF-~ is not functioning, RB will be activated by phosphorylation (PRb), (Laiho et 
aI. , 1990). The accumulation of the phosphorylated Rb (PRb) in the cytoplasm will lead to an 
uncontrolled cellular growth. Furthermore, pRB will release activated E2Fl which in turn 
stimulates cell cycle entry. As tumors develop and progress, the Rb gene is inactivated by point 
mutations and loss of heterozygosity (LOH) (Edamoto et aI., 2003) resulting in an elevated E2Fl 
activity. In human HCC, the Rb pathway is disrupted in more than 80% of cases, with repression 
of p16 by promoter methylation being the most frequent alteration (Azechi et aI., 2001). 
The p53 pathway is a major tumor-suppressor pathway that induces cell-cycle arrest in 
response to oncogene activation (Di Micco et aI. , 2006), and protects genome integrity. A G-to-T 
mutation at the third base of codon 249 of the p53 was found in up to 50%-70% in HCC patients 
(Bressac et aI., 1991 and Hsu et aI., 1991). This 'hot-spot' mutation, leading to an arginine to 
serine substitution, is associated with high food contamination with the Aflatoxin B 1 (AFB 1) 
mycotoxin (Aguilar et aI., 1994). In other regions where aflatoxin levels in food are low or 
undetectable, low p53 mutation rates were observed « 4% of HCC) and no specific gene 
mutation pattern can been detected (Ozturk, 1999). 
The p53-related tumor suppressor p73 has also been reported to be deregulated in HCC. 
The deregulation of p73 is not due to a genetic or an epigenetic mutation in its gene (Levrero et 
aI., 2000). The amino-terminal deleted isofornl DNp73, which suppresses p53 (Vossio et aI., 
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2002), was found to accumulate in chronic hepatitis, cilThosis and HCC, leading to a 
chemoresistant HCC phenotype (Muller et aI., 2005). The deregulation in both the pRB and the 
p53 pathways causes genomic instability, which plays an important permissive role in the 
malignant transformation of hepatocytes leading to HCC. 
The upregulation of growth factor expression and the activation of their signaling 
pathway components also play an impOltant role in hepatocarcinogenesis. Insulin-like growth 
factor II (IGFII), TGF-a and ~ were reported to be involved in the development of HCC 
(Moradpour and Wands, 2002). TGF~l is a growth regulatory molecule that triggers apoptosis in 
hepatocytes (Gressner et aI., 1997). Although, TGF~l is transcriptionally up-regulated in tumor 
cells, HCC is resistant to TGF~l. Moreover, TGF~l levels were found to be frequently elevated 
in the sera of HCC patients (Ito et aI., 1991).The Wntl~-catenin pathway is known to be involved 
in cell adhesion and cell proliferation. Cellular levels of ~-catenin are tightly regulated by 
proteasome-dependent degradation. This tight regulation is controlled by the activity of the APC 
gene. Deregulated expression of ~-catenin resulting from the APC defect and consequently the 
Wnt signaling pathway, appear to playa role in more than 50% of HCCs (Ozturk, 1999). 
Several studies of paired HCC and non-tumorous liver samples have revealed relatively 
frequent allelic losses (LOH) on specific sites on chromosomes 1, 2q, 4, 5q, 6q, 8, 9, lOq, Up, 
13q, 14q, 16, 17 and 22q. It was suggested that these sites may contain tumor suppressor genes 
relevant for HCC pathogenesis (Ozturk, 1999; Moradpour and Wands, 2002 & Thorgeirsson and 
Grisham, 2002). Furthermore, recent evidence suggested the possibility of a telomere-based 
chromosomal instability, which occurs during the early stages of hepatocarcinogenesis. On the 
other hand, the telomerase enzyme, a ribonucleoprotein enzyme which prevents the shortening of 
telomeres and hence extends the life span of the cell, was found to be activated at the later stages 
of HCC progression (Farazi et aI., 2003). 
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In addition to the LOH, the aberrant methylation (hypo- or hypermethylation) of the CpG 
islands in the promoter regions of certain genes that control cellular proliferation and cell cycle 
was observed at the sites of chronic hepatitis and cirrhosis (Saito et al.,2001). It has also been 
reported that the expressions of DNA methyltransferases (DNMTI and DNMT3a) are strongly 
up-regulated in HCC in the fraction of livers affected with chronic hepatitis and cirrhosis (Saito 
et ai., 2001). Furthermore, S-adenosylmethionine synthase and glycine N-methyltransferase 
(Grisham, 2001), which augments the hepatocellular pool of methyl groups available for 
methylation reactions, were also found to be up-regulated in many HCCs. 
Myc is a potent oncogene that induces hepatocarcinogenesis and it was shown that HCC 
induced by myc depend on continuous activation of the oncogene (Shachaf et ai., 2004). 
Furthermore, the activation of Myc has been positively correlated with the HCC tumor size and 
prognosis (Wang et ai., 2002). The amplification of the chromosome locus, which might be 
induced by telomere dysfunction, is one of the mechanisms leading to the activation of myc in 
HCC (Wilkens et ai., 2004). 
Hepatitis C Virus: A Potent HCC Risk Factor 
Hepatitis C virus infection is a major cause of chronic hepatitis, liver cirrhosis, and 
hepatocellular carcinoma worldwide (National Institutes of Health, 2002). Neither a vaccine nor 
an effective treatment is available for HCV (Moradpour and Blum, 2004). Pegylated interferon-a 
(PEG-IFN- a), combined with ribavirin, is the current standard therapy (Manns et ai., 2001). Its 
efficiency is ranging between 20-80%, depends on the HCV genotype (Hadziyannis et aI., 2004). 
Unfortunately, many HCV infected patients do not respond to or do not tolerate the IFN-based 
therapy (Fa1ck-Ytter et ai., 2002). Therefore, the number of patients progressing to HCC, as a 
result of HCV infection, is expected to increase for the next 20-30 years (Davis et ai., 2003). The 
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natural history of the disease reveals the elusive nature of the virus in a number of features. First, 
the infection is often detected incidentally at the time of blood donation as the acute infection is 
clinically asymptomatic in most patients. Second, Hey successfully escapes multi-specific host 
immune responses in the majority of patients which establishes persistent infection. Third, a 
significant number of persistently infected individuals remain unaware of the infection for 
decades, until liver fibrosis, cirrhosis and/or hepatocellular carcinoma develop (Chander et aI., 
2002). 
Almost all the patients with HCY -related HCC had cirrhosis at the time of diagnosis 
(Liang and Heller, 2004). Therefore cirrhosis is one of the main risk factor for HCC development 
in HCY infected patients (Laurent-Puig et aI., 2001). The number of cases of HCC in patients 
with chronic hepatitis without cirrhosis had been reported but remains very limited (Grando-
Lemaire et aI., 1999). In a cohort of patients with HCY -related cirrhosis, the risk of HCC 
occurrence over time is high and roughly linear and between 2% and 8% annually (Fattovich et 
aI., 2004). A higher rate has been reported in Japan (4%-8%) than in Western countries (2%-4%) 
suggesting the influence of unknown epidemiological factors (Fattovich et aI. , 2004). A study 
from the US shows a longer time (mean 28 years with a range from 8 to 42) between transfusion-
associated hepatitis and development of HCC (Tong et aI., 1995). Moreover this risk seems to be 
. higher in HCY -related cirrhosis than in alcohol or HBY -related cirrhosis (Fattovich et aI., 2004). 
HCY is endemic in most parts of the world with significant sequential differences in 
various geographical areas. To study these sequential variations, age-specific analysis of 
prevalence has been categorized into three broad patterns of transmission (Wasley and Alter, 
2000). In the first category, most HCY infections are found in individuals aged 30-49 years, 
indicating that the risk of transmission was greatest in the recent past and affected primarily 
young adults. This category predominates in the UK and the USA, where the principal risk factor 
50 
Moemen Abdalla HCC Biomarkers 
for the transmission of HCV is known to be intravenous Injecting Drug Use ODU). In countries 
within the second category, such as Japan, most infections are found in the elderly. In countries 
within the third category, such as Egypt, high rates of infection are observed in all age groups. In 
the two latter categories, contamination of equipment used in vaccination programs and unsafe 
healthcare procedures may be the major route of HCV transmission (Wasley and Alter, 2000). 
Taxonomy of HCV 
HCV has been classified in the Hepacivirus genus within the Flaviviridae family 
(Rosenberg, 2001), which includes the classical flaviviruses such as yellow fever and dengue 
viruses and the animal pestiviruses such as bovine viral diarrhea virus (BVDV). The term HCV 
quasispecies refer to the genetic heterogeneity of the population of HCV genomes coexisting in 
an infected individual. Several epidemiological studies showed that HCV genotypes vary in their 
distribution, which may have clinical significance (Zein, 2000). The WHO estimates that there 
are at least 21.3 million HCV carriers in the Eastern Mediterranean countries, which is close to 
the number of carriers estimated in the Americas (13.1 million) and Europe (8.9 million) 
combined. Indeed, one of the highest prevalence of HCV infection (18.1 %) has been repOlted 
from Egypt (World Health Organization, 1999). Genotypes 1, 2, and 3 are the most frequently 
encountered genotypes worldwide (Bhattacherjee et aI., 1995). However, significant differences 
were noticed when subtype distribution was investigated. Surprisingly, epidemiological studies 
show two main patterns for the distribution of HCV genotypes: genotype 4 is predominant in the 
Arab countries (except for Jordan) (Bdour, 2002), whereas genotype 1 predominates in the non-
Arab countries (Turkey, Israel, and Iran) (Chamberlain et aI., 1997). Although varying 
prevalences of genotype 4 have been reported from the Arab countries, it is noteworthy that 
genotype 4 is quasi-exclusive (91 %) in Egypt which is also a North African country (Ray et ai., 
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2000). Based on only one known study in Jordan, HCV la is the dominant subtype (40%) 
followed by Ib (33.3%) and genotype 4 (26.6%) (Bdour, 2002). 
Hepatitis C Virus Genome and its Hepatocarcinogenic Effect 
HCV is a small enveloped virus with a 9.6 kb positive-strand RNA genome composed of 
a 5' untranslated region (5' UTR), a long open reading frame (ORF) encoding a polyprotein 
precursor of about 3300 amino acids, and a 3' UTR (Figure 7). HCV is a completely 
cytoplasmic-replicating virus which induces oncogenic events without directly being integrated 
into the human genome. Different viral proteins, notably core (Moriya et al., 1998 and Yoshida 
et at., 2002), NS3 (Sakamuro et at., 1995) and NS5A (Gale et at., 1999), have been implicated in 
oncogenic transformation and HCC development. 
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Figure 7 Hepatitis C virus: Genetic organization and polyprotein processing. In addition to the HCV viral 
proteins in the viral life cycle, the viral proteins also interact with many host-cell factors modulating the 
host's cellular activities such as signal transduction pathways, transformation, apoptosis, translational 
regulation and membrane rearrangements (Levrero, 2006). 
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Both 5' UTR and 3' UTR bear highly conserved RNA structures essential for polyprotein 
translation and genome replication. The 5'UTR contains an internal ribosome entry site (IRES) 
that binds the 40S ribosomal subunit and initiates polyprotein translation in a cap-independent 
manner. The 3'UTR consists of a variable 40-nt sequence and an internal poly 
(U)/polypyrimidine tract, followed by a 98-nt sequence that is highly conserved among HCV 
genotypes and contains stable stem-loop structures (Kolykhalov et ai., 1996 and Tanaka et ai., 
1996). The 3'UTR is thought to play an important role in initiating viral genome replication. 
Although there is evidence for its replication in lymphocytes or monocytes, HCV mainly 
replicates within hepatocytes in the liver. Circulating HCV particles bind to receptors on the 
surfaces of hepatocytes and consequently enter the cells (Kabir et ai., 2006 and Brass et ai, 
2006). 
Two HCV receptors have been reported, CD81 and human scavenger receptor class B 1 
(SR-Bl). However, these receptors are found throughout the body. The identification of 
hepatocyte-specific cofactors that determine observed HCV liver tropism is cunently under 
investigation (Brass et ai., 2006). Once inside the hepatocyte, HCV utilizes the intracellular 
machinery necessary to accomplish its own replication. The HCV genome is then translated to a 
single polyprotein which is co-translationally and post-translationally cleaved by both cellular 
and viral proteases producing structural (virion-associated) and nonstructural (NS) proteins 
(Figure 7). Alternatively, a frameshift may occur in the core region to produce an Alternate 
Reading Frame Protein (ARFP) (Lindenbach and Rice, 2003). HCV has a high rate of replication 
with approximately one trillion particles produced daily in an infected individual. Due to lack of 
proofreading by the HCV RNA polymerase, HCV also has an exceptionally high mutation rate, a 
factor that may help the virus to evade the host's immune response (Kabir et ai., 2006). 
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Studying the life cycle of HCV has been an obstacle for many virologists due to the lack 
of an efficient cell culture system supporting HCV replication. The study of the molecular 
genetics of HCV was advanced after the development of an efficient cell culture HCV RNA 
replication system based on the replicon technology (Lohmann et ai., 2001; Blight et aI., 2000 
and Guo et aI., 2001). This replication system helped to better understand the function of 
individual HCV proteins during replication and hepatocarcinogenesis. The life cycle of HCV is 
shown in Figure 8. 
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Figure 8 The life cycle of HeV. The steps of the viral life cycle are depicted schematically. The topology 
of HeV structural and nonstructural proteins at the endoplasmic reticulum (ER) membrane is shown. 
HeV RNA replication occurs in a specific membrane alteration, the membranous web (MW) (Brass et ai. , 
2006). 
Structural Proteins 
Core Protein 
After the translation of the HCV genome, the HCV polypeptide is targeted to the host 
endoplasmic reticulum (ER) membrane. Cleavage of the signal sequence by the host signal 
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peptidase yields the immature form of the core protein (191 a. a.). This signal peptide is further 
processed by a host signal peptide peptidase, thereby yielding the mature core protein 
(McLauchlan et aI. , 2002). Most of the core protein is found in the cytoplasm, where it is bound 
to ER membranes or located at the surface of lipid droplets (Hope and McLauchlan, 2000). A 
small proportion of the core protein may also be found in the nucleus. In addition to its role in 
nucleocapsid formation, the core protein has been reported to interact with numerous cellular 
proteins and to affect host cell functions such as gene transcription, lipid metabolism, apoptosis 
and various signaling pathways. Moreover, it has been associated with the induction of HCC 
(Brass et aI. , 2006 and Yan et aI., 2005). 
The tumor suppressor proteins, p53, p73 and pRb, are considered as main targets for the 
HCV core (Ray et aI., 1997; Lu et aI., 1999; Alisi et aI., 2003 and Cho et aI. , 2001). The 
interaction between core/p73 prevents the p73a-dependant cell growth arrest in a p53-dependent 
manner (Alisi et aI., 2003). Hepatitis C virus core protein also modulates the expression of the 
Cyclin dependent kinase (CDK) inhibitor, p21/Waf, which blocks cell cycle entry and 
progression (Wang et aI., 2000). The mature core protein in the nucleus decreases the amount of 
p21 WAF] by a p53-independent pathway (Varaklioti et aI., 2002 and Yamanaka et al., 2002). This 
kind of regulation leads to cell cycle progression, which contributes to tumor development. 
Hepatitis C virus core protein exerts another anti-apoptotic effect (Ray et aI., 1998 and 
Machida et aI., 2001) by its interactions with the tumor necrosis factor receptor (Zhu et aI., 1998) 
and the lymphotoxin ~ receptor (Matsumoto et aI. , 1997). Additional proteins interact with HCV 
core protein and cause the inhibition of apoptosis such as the heterogeneous nuclear 
ribonucleoprotein K (hnRNPK) (Hsieh et aI. , 1998), the RNA helicase DEAD box DDX3 protein 
(Owsianka and Patel, 1999) and the 14-3-3 protein (Aoki et aI., 2000). 
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It has been reported that the binding of the HCV core to apolipoprotein II (Shi et al., 
2002) will down-regulate the microsomal triglyceride transfer protein (MTP) activity. This will 
lead to the abnormal assembly and secretion of very-low-density lipoprotein (VLDL) 
(Perlemuter et al., 2002) and hence hepatic steatosis. Hepatic steatosis is defined as an excessive 
lipid accumulation within the hepatocyte cytoplasm and has been more recently recognized asa 
significant cause of cirrhosis in the United States (Brunt, 2001). This interaction has been 
supported by the development of hepatic steatosis (Perlemuter et al., 2002) and liver cancer 
(Moriya et ai., 2001 and Lerat et aI., 2002) in transgenic mice expressing HCV core protein. 
Furthermore, HCV core was found to stimulate the c-myc promoter in tissue culture (Ray et aI., 
1995). C-myc encodes an oncoprotein that may trigger apoptosis or promote the development of 
tumors depending on its activator and the consequences under which it is expressed. 
Envelope Glycoproteins 
The envelope glycoproteins E1 and E2 are type I trans-membrane proteins with a highly 
glycosylated N-terminal and a C-terminal hydrophobic anchor. E1 and E2 form non-covalent 
heterodimers which are believed to represent the building blocks for the viral envelope. These 
two HCV envelope glycoproteins are released from the HCV polyprotein by signal peptidase 
cleavages. The trans-membrane domains of these glycoproteins playa major role in E1-E2 
heterodimer assembly and sub-cellular localization which is essential for HCV entry. The N-
terminus of the E2 gene is the most variable region of the entire HCV genome and has been 
called the first hypervariable region (HVRl) (Weiner et aI., 1991 and Hijikata et ai., 1991). A 
second hypervariable region has been identified (HVR2), but it seems to be limited only to 
strains of genotype 1b (Okamoto and Mishiro., 1994). The HVR2 encodes approximately seven 
amino acids and its significance is not well understood. 
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Hepatitis C virus genetic variability within the envelope glycoprotein is the main reason 
for the presence of HCV as quasi-species in the patients' sera (Thimme et ai., 2002). In the liver, 
different viral variants have been isolated from cancerous and non-cancerous regions, suggesting 
that these may contribute to HCV -induced carcinogenesis (Alam et ai., 2002). 
The interactions between the HCV E2 and the CD81 or the low-density lipoprotein 
receptor (LDLR) on the hepatocyte cell surface activate the mitogen-activated protein 
kinase/extracellular signal regulated protein kinase (MAPKlERK) pathway. This interaction 
activates the downstream transcription factor ATF-2 that promotes cell proliferation and cell 
survival (Zhao et aI., 2005). It has also been proven that HCV E2 glycoprotein inhibits protein 
kinase R (PKR), which is an important intermediate in the anti-viral interferon pathway {Crotta 
et aI., 2002). 
p7 
p7 is a 63-amino-acid polypeptide that is incompletely cleaved from E2. It has two trans-
membrane domains connected by a short hydrophilic segment (Carrere-Kremer et aI., 2002). p7 
has recently been reported to form hexamers and to possess ion chatmel activity (Griffin et aI., 
2003). Uptill now, p7 did not show any hepatocarcinogenic effect. 
Nonstructural Proteins 
NS2/3 Autoprotease 
The hepatitis C virus NS2/3 protein is a highly hydrophobic protease responsible for the 
cleavage of the viral polypeptide between non-structural proteins NS2 and NS3. NS2/3 has been 
proposed to function as either a cysteine or metalloprotease despite its lack of sequence 
homology to proteases of known functions. Although NS2/3 cleavage is shown to be required for 
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persistent infection In a chimpanzee, its role in the viral life cycle has not yet been fully 
investigated due to the lack of an in vitro system to study HCV replication. However, several 
studies have begun to clarify possible roles of the cleaved NS2 protein in modulation of host cell 
gene expression and apoptosis (Choo et ai., 1991 and Drazan, 2000) 
NS3/4A 
NS3 is a multifunctional protein, harboring a serine protease domain in the N-terminal 
and NTPaselRNA helicase domain in the C-terminal. On the other hand, NS4A, a 54-amino acid 
polypeptide, targets NS3 to intracellular membranes and acts as a cofactor for the NS3 serine 
protease (Brass et ai., 2006). HCV NS3/4A protease is essential for viral replication in cell 
culture and in chimpanzees, and has been considered as one of the most attractive targets for 
developing novel anti-HCV therapies (Brass et ai., 2006 and Drazan, 2000). The enzymatic 
activity of the NS3 NTPaselRNA helicase activity unwinds the HCV double strand RNA 
intermediates to eliminate RNA secondary structures during viral replication (Brass et ai., 2006 
and Drazan, 2000). The oncogenic effect of the HCV NS3 protein takes place by its binding with 
a specific domain located at the C-telminus of the wild type p53 (amino acids 306-360). This 
interaction results in the repression of the p21 WAF] gene transcription (Ishido and Hotta, 1998) 
leading to the increase in the cellular proliferation. 
NS4B 
NS4B is a relatively hydrophobic membrane protein which plays and important role in 
the modulation of the NS5B "RNA dependent RNA polymerase" activity (RdRp). It has also 
been reported to have a possible role in HCV carcinogenesis, impairment of ER function, and 
regulation of both viral and host translation. NS4B has recently been found to be responsible for 
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the formation of a novel intracellular membrane structure termed the membranous web, which 
appears to be the platform upon which viral replication occurs (Brass et ai., 2006). 
NSSA 
The HCV non-structural 5A protein (NS5A) is a phosphorylated zinc metalloprotein 
known to modulate the IFN response. The phosphorylation of the NS5A plays an important role 
in the regulation of viral replication. NS5A also seems to play a critical role in determining the 
susceptibility of the virus to treatment with interferon (IFN). The sensitivity to IFN correlates 
with mutations within a discrete region of NS5A which is named the IFN sensitivity-determining 
region. Subsequent analysis suggested that the possible mechanism of IFN resistance occurs 
through a direct interaction of NS5A with the IFN-induced protein kinase, PKR. Since PKR is a 
critical factor in the response to IFN, its inactivation by NS5A may be a possible mechanism by 
which HCV evades the host immune response .(Breuhahn et ai., 2004 and Chung et ai., 2001). 
HCV NS5A also binds directly to and activates Phosphoinositide Kinase-3 (PI3K), which 
induces cellular growth through blocking apoptosis. Therefore, this interaction results in 
increased cell survival (Street et ai., 2004) and may also promote chronic infection and 
tumorigenesis. In addition, NS5A binds to and inactivates p53 mediated transcriptional trans-
activation and apoptosis in hepatoma cells by sequestering p53 in the cytoplasm (Lan et ai., 
2002). Although intact NS5A is cytoplasmic and membrane-bound (Brass et ai., 2002), the 
caspase-mediated cleavage leads to NS5A nuclear localization (Ide et ai., 1996). The cleaved 
NS5A functions as a protein kinase A (PKA) regulated transcription factor promoting cellular 
proliferation and the inhibition of p53 (Satoh et ai., 2000). NS5A and p53 co-localize in the 
perinuclear region and the functional consequence of these complex interactions is the inhibition 
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of both transcriptional transactivation by p53 and p53-induced apoptosis (Majumder et aI. , 2001 
and Lan et aI., 2002). 
NSSB 
The key enzyme that promotes synthesis of new HeV RNA genomes is the NS5B RNA 
dependent RNA polymerase (RdRp). As the central component of the HeV replicase, NS5B has 
emerged as a major target for antiviral intervention (Brass et aI., 2006). The rate of nucleotide 
mis-incorporation by the viral RNA polymerase has been calculated to be approximately 10-3 to 
10-4 base substitutions per genome site per year (Ogata et aI., 1991 and Okamoto et aI., 1992). 
Thus, HeV shares with other RNA viruses a high mutation rate, which is often 1,000 to 
1,000,000-fold greater than the mutation rate of DNA viruses (Holland et aI., 1982). As a 
consequence of the low fidelity of the viral replication machinery, HeV is never present in vivo 
as a homogeneous population of identical RNA genomes but rather as a mixture of divergent, 
albeit closely related, genomes exhibiting a distribution that follows the model referred to as 
quasispecies (Martell et aI., 1992). 
Endoplasmic Reticulum and Oxidative Stress 
Endoplasmic reticulum stress is a homeostatic mechanism regulating the cellular 
metabolism and protein synthesis in response to abnormal protein folding and synthesis (Ma and 
Hendershot, 2001). Mild ER stress affects the initiation of protein synthesis and the reduction the 
cell growth, whereas extreme or prolonged ER stress causes apoptosis mediated by activating the 
ER-associated caspase 12 (Kaufman, 1999). It has been hypothesized that persistent ER stress 
induction caused by persistent HeV infection results in an intra- and extracellular accumulation 
of DNA-damaging factors that could make the cell amenable to mutagenesis. Indeed, ER stress 
signaling is intimately linked to changes in the intracellular redox state. Transgenic mice 
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expressing HCV core protein showed an unusual production and accumulation of reactive 
oxygen species (ROS) that correlates with HCC development (Moriya et ai., 1998 and 2001). 
HCV NS5A expression alters intracellular calcium levels inducing oxidative stress and activates 
STAT-3 and Nuclear factor KB (NF-KB) (Waris et ai., 2002). 
It is obvious that HCV encodes one or more proteins that alter the activities of specific 
cellular pathways and the expression of certain cellular genes. These pathways are found to be 
suppressed or activated, often by mutation, deletion or duplication, in the cancerous cells. These 
observations suggest that these changes contribute to hepatocarcinogenesis, which supports viral 
gene expression and replication. Also, it is proposed that alteration in the aforementioned cellular 
genes by HCV promotes chronic HCV infection by blocking the elimination of infected cells 
during immune-mediated attack. Furthermore, these alterations will also promote the preferential 
growth of such cells during liver regeneration following bouts of hepatitis. The accumulation of 
the same mutations in the same pathways will be the selection criteria upon which large number 
of virus-altered cells will continue to grow, and thus this preferential cellular growth supports the 
life cycle of the virus, protects the virus infected hepatocytes from being eliminated, and will 
promote the development of HCC. All these interactions are likely to highlight the intimate 
relationship between chronic HCV infection and the development of liver cancer at the molecular 
levels. 
Special Biomarkers for the Early Detection of HCC 
Alpha-Fetoprotein 
Alpha-fetoprotein, a 70 kDa glycoprotein synthesized in the liver, has a half-life of 5-7 
days (Yao et ai., 2007). Alpha-fetoprotein is the gold standard tumor marker for HCC diagnosis. 
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A serum AFP <10 ng/mL is expected in healthy men and non-pregnant women (Lopez, 2005). 
Transient increases and fluctuations in serum AFP may occur in chronic liver diseases and 
cirrhosis, especially during viral hepatitis infection. Such fluctuations are confusing and the 
patients are generally required to be retested for AFP after two weeks. However, a persistently 
elevated serum AFP levels in highly indicative to the possible presence of a tumor (Di Bisceglie 
et ai., .1988). 
Although most symptomatic HCC are associated with AFP > 1000 nglmL, two-thirds of 
patients with small asymptomatic tumors will have an AFP <200 ng/mL (Di Bisceglie et ai., 
1988 and Dusheiko, 1990). The sensitivity and specificity of AFP for HCC depends mainly on 
the cutoff value upon which a patient is considered as HCC positive. In general, an AFP 2: 400 
nglmL in patients with chronic liver disease in the presence of a radiologically detected mass are 
virtually diagnostic of HCC (Bruix, 2001). A comparison of AFP with several other commonly 
available tumor markers, such as CA 125, ferritin, CA 19-9, ~-2-microglobulin, CEA and CA 
72-4, found AFP to be the most efficient HCC marker (Lopez et ai., 1997). 
AFP Fractions 
Total AFP can be divided into three different glyco-forms, AFP-L1, AFP-L2, and AFP-
. L3. Hepatoma specific-AFP (HS-AFP), AFP-L3, is the major glyco-form of AFP in the sera of 
HCC patients (Cha et ai., 2003). One study had reported a specificity of 100% and sensitivity of 
73% for the AFP-L3 in detecting HCC (Haydon and Hayes, 1996). AFP-L3 can be detected in 
the serum of approximately 35% of the patients with small HCC « 2 cm). Compared to imaging 
techniques, it has been shown to detect HCC 9-12 months earlier (Li et ai. , 2001). 
Interestingly, most studies correlating the prognosis of patients with HCC and AFP-L3 
demonstrated that AFP-L3 is associated with reduced liver function and poorer differentiation 
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(Khien et ai., 2001). Therefore, AFP-L3 seems to be a more reliable marker than the total AFP 
and an excellent prognostic parameter in patients with HCC (Spangenberg et ai., 2006). 
However, there are some limitations to the value of AFP-L3 for HCC screening: first, the assay 
is extremely cumbersome; second, fractionation of AFP is not useful in the patients with low 
AFP « 30 ng/mL); and third, no randomized trial has been carried out comparing total AFP with 
fractionated AFP at the time of diagnosis of HCC (Haydon and Hayes., 1996) 
Isoelectric focusing (IEF) has identified the presence of three apparent major AFP 
disease-specific isoforms: +1 (associated with 'benign liver diseases'), +11 (associated with HCC) 
and +111 (associated with non-seminomatous germ cell tumors, NSGCT) (Johnson etaI., 1997). 
HCC-associated isoforms (band +11) represent a group of glycoproteins whose carbohydrate 
structures are characterized by being monosialylated (msAFP), whereas other isoforms 
associated with benign liver diseases and NSGCT are di- and asialo species, respectively 
(Johnson et ai., 2000). MsAFP was found to be a potentially diagnostic marker for HCC with 
non-diagnostic AFP «500 ng/mL) when it was measured by IEF, Western blot, densitometry, 
and by a novel glycosylation immunosorbent assay (Poon et aI., 2002). 
Des-y-Carboxy Prothrombin 
Normal hepatocytes secrete prothrombin (coagulation factor II) (Stanton et aI., 1991). An 
abnormal form of the protein, des-y-carboxy-prothrombin (DCP), was found in the serum of 
patients with HCC and in patients with Vitamin K-deficiency (Weitz and Liebman, 1993). DCP 
is produced by the tumor cells, which have reduced gamma-carboxylase activity resulting in a 
reduced carboxylation of 10 glutamic-acid residues at the N-terminus (Liebman, 1989). DCP is 
considered one of the most useful HCC biomarkers used for HCC screening (Weitz and 
Liebman, 1993). DCP levels are usually measured by enzyme immunoassays (EIA). A DCP 
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level of 40 mAU/mL is now commonly used as the cutoff value for HCC detection (Ikoma et ai., 
2002 and Shimauchi et ai., 2000). 
In contrast to AFP, DCP is more specific than AFP because any liver disease, especially 
HCV infection, can lead to the elevation of AFP but not DCP. In addition, DCP was found to 
correlate with the stage of HCC as well as the survival of the patients. Therefore, the detection of 
DCP in the serum and tissue of HCC patients is considered an important indicator for the 
prognostic outcome (Okuda et ai., 2001). Few studies had demonstrated an improvement in the 
sensitivity and specificity of HCC diagnosis when AFP and DCP were combined (Shimauchi et 
ai., 2000 and Fujiyama et al., 2002). Overall, AFP, AFP-L3 and DCP levels are currently used 
only to monitor HCC progression and prognostic markers in HCC patients, but they have not 
been used as biomarker for the early detection of HCC in high risk patients. 
a-L-Fucosidase 
Alpha-L-fucosidase (ALF) is a ubiquitously expressed lysosomal enzyme with a 
detectable activity in the sera of healthy subjects. Patients with chronic liver disease and HCC 
have increased ALF activities (Deugnier et ai., 1984). Its sensitivity and specificity, at a cutoff 
value of 870 nmollmL, are 82% and 71 %, respectively (Spangenberg et ai., 2006). The disease 
. specificity of the ALF assay is limited since an elevated ALF serum activity was found in non-
cancerous extrahepatic diseases such as diabetes, pancreatitis, and hypothyroidism (Bukofzer et 
ai., 1989). Alpha-L-fucosidase activity in patients with HCC was found to be significantly higher 
than those with cirrhosis, chronic hepatitis or other tumors and in control individuals. Patients 
with cirrhosis, who have a marked increase in ALF activity during monitoring, should be closely 
monitored for HCC development (Tangkijvanich et ai., 1999). 
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Transforming Growth Factor-pI 
Transforming growth factor-B (TGF-B) is a family of related proteins that regulate 
different cellular processes including cellular growth, differentiation and extracellular matrix 
formation (Blobe et ai., 2000). TGF-B1 is one of TGF-B isoforms (TGF-B 1-5) which control the 
cell cycle (i.e. arrest the cell cycle in the G 1 phase and hence cause inhibition of cell proliferation 
and induction of apoptosis) (Pasche, 2001). In normal liver tissues, TGF-B1 is produced only by 
non-parenchymal cells (Kupffer's cell, fat storing cell and endothelial cell). TGFB1 mRNA and 
its protein were found to be over-expressed in patients with Hee compared with healthy 
individuals and patients with nonmalignant liver diseases (Sacco et ai., 2000). The specificity 
and the sensitivity of TGF-B1 at a cutoff value of 800 pg/mL were reported to be >95% and 
68%, respectively, thus being superior to AFP (Song et ai., 2002). 
The combination of both AFP and TGF-B1 resulted in a sensitivity and specificity of 84% 
and 98%, respectively with a diagnostic accuracy of 90% (Tsai et ai., 1997a). Some features 
might limit the TGF-B1 usefulness as a marker for Hee; TGF-B1 levels might increase in 
cirrhotic patients due to the decrease in its hepatic clearance. Moreover, TGF-B1 expression was 
found to be upregulated in wound healing, angiogenesis, fibrosis and extra-hepatic tumors 
(Shirai et ai., 1994). However, elevated urinary TGF-B1 has been suggested as a complementary 
marker to AFP which can differentiate Hee from cirrhosis and for the detection of Hee with 
low AFP production (Tsai et ai., 1997b). 
Insulin-like Growth Factor-II 
Insulin-like Growth Factor II (IGF-II) is a fetal growth factor which was found to play an 
important role in hepatocarcinogenesis (Scharf et ai., 2001). IGF-II was found to increase the 
expression of the vascular endothelial growth factor (VEGF) in human hepatoma cells, which 
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play an important role in the development of neovascularization of HCC (Cantarini et ai., 2006 
and Wang et ai., 2003). The circulating free IGF-II levels were found to be significantly higher 
in HCC than in chronic hepatitis or liver cirrhosis and were also correlated with the stages of 
HCC. Its presence was 100% in HCC patients with extrahepatic metastasis and 35% in HCC 
patients who were AFP-negative (Yao et ai., 2007). The use of IGF-II and AFP in parallel 
significantly increased the diagnostic accuracy and sensitivity while maintaining a high 
specificity (Tsai et ai., 2005). IGF-II may be used as an independent marker for the diagnosis of 
small HCC tumor or as a complementary marker together with AFP for both the diagnosis of 
small HCC tumor and to discriminate HCC from cirrhosis (Tsai et ai., 2003). 
Glypican-3 
Glypican-3 (GPC3) is a member of the glypican family of glycosyl-phosphatidylinositol-
anchored cell-surface heparan-sulfate proteoglycans. It is normally involved in the regulation of 
cellular proliferation and survival during embryo development, where it functions as a tumor 
suppressor (Pilia et ai., 1996). The serum level of GPC3 has been shown to be significantly 
elevated in patients with HCC when compared to healthy individuals or patients with 
nonmalignant liver diseases (Nakatsura et ai., 2003). In 2003, Capurro et al. developed an 
ELISA assay for the C-terminal fragment of GPC3 which identified this fragment in the sera of 
53% HCC patients. On the other hand, the fragment was undetectable in any of the 53 healthy 
controls whereas it was detected in only one of 20 cirrhotic patients suggesting a high degree of 
specificity (Capurro et ai., 2003). Nakatsura et ai. reported the same finding using a different C-
terminal antibody (Nakatsura et ai., 2003). 
On the contrary, Hippo et ai. (2004) showed that the N-terminal of the GPC3, rather than 
the C-terminal, was the predominant fragment in the sera of HCC patients. The sensitivity and 
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specificity of GPC3 at a cutoff value of 2 ng/ml was 51 % and 90% compared to that of AFP at a 
cutoff value of 20ng/ml which was 55% and 90% (Wright et aI., 2007). Unexpectedly, GPC3 
levels were found to be elevated in patients with malignant melanoma which limited the clinical 
utility if this promising candidate marker (Nakatsura et aI., 2004). 
Human Cervical Cancer Oncogene 
The Human Cervical Cancer Oncogene (HCCR) was first reported by Ko et al. (2003) as 
a novel cervical cancer oncogene. HCCR-1 is a 360 amino acid protein with the features of a 
membrane protein, whereas HCCR-2 is a shorter isoform which lacks the transmembrane domain 
and appears to be localized in the cytoplasm. The precise function of the two isofonns is not yet 
known although it is suggested that HCCR-2 may function as an oncoprotein (Ko et aI., 2004). 
HCCR was found to be elevated in cancerous tissues from breast, kidney, ovary, stomach and 
colon. The same study showed a strong expression of HCCR in hepatocellular carcinoma cells 
but not in the surrounding cirrhotic cells (Yoon et aI., 2004). HCCR may have an advantage over 
AFP in being elevated according to disease progression from liver cirrhosis to carcinoma. It was 
also more frequently elevated in patients with early, small HCC (Yoon et aI., 2004). 
Hepatoma-Specific y-Glutamyl Transferase Isoenzyme 
Gamma-glutamyl transpeptidase (GGT) is a membrane-bound enzyme that catalyzes the 
degradation of glutathione and other y-glutamyl compounds by the hydrolysis of the y-glutamyl 
moiety. It shows a tissue-specific expression which is altered under various physiological and 
pathological conditions (Yao et aI., 2004). GGT expression was found to reach a maximum level 
in embryo liver and then decrease to the lowest level after birth. GGT was found to be re-
expressed during the early stages of HCC development. GGT is divided into three sub-fractions 
according to their electrophoretic mobility. The hepatoma-specific GGT (HS-GGT) bands 
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(including I, II, and II') were found in the sera of HCC patients. HS-GGT has been confirmed as 
a useful specific HCC marker which may improve the specificity and sensitivity of HCC 
diagnosis (Yao et ai., 1998). 
Goigi Protein 73 
. Golgi protein 73 (GP73) is a Golgi-specific membrane protein which was found to be up-
regulated in the hepatocytes of patients with acute hepatitis and cirrhosis. GP73 was found in the 
sera of HBV - and HCV -related HCC (lftikhar et ai., 2004). In a study based on Western blotting, 
GP73 was able to detect HCC in cirrhotic patients with a sensitivity and specificity of 69% and 
86% respectively, compared to 30% specificity and 96% specificity for AFP(Block et ai., 2005). 
Heat Shock Protein 
Heat Shock Protein (HSP), a highly conserved protein, participates in the complex 
formation of many proteins. It plays an important role in the proper folding of proteins and also 
takes part in the protein transport between organelles. Within a cell, HSP is known as a 
molecular chaperone (Yao et ai., 2007); additionally, it is known as an apoptotsis inhibitor. HSP 
was found to be up-regulated during the development of HCC and it was correlated with the 
progression and prognosis of HCC (Yao et ai., 2007). HSP gp96 acts as a putative high density 
lipoprotein-binding protein in the liver and it binds to a range of peptides, thus eliciting peptide-
specific T cell immune responses (Li et ai., 2005). 
The long-lived cirrhotic cells and HCC cells are closely related to the apoptotic inhibitory 
effect due to the over-expression of HSP gp96. HSP gp96 was found to be strongly expressed in 
73% of HCC tissues and weakly expressed in non-cancerous tissues. The up-regulation of the 
HSP gp96 expression was correlated with the size as well as the differentiation of the tumor but 
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not with the number of the tumor cells (Yao et al. , 2007). In addition to HSP gp96, HSP70 and 
HSP27 were also found in a large number of human cancers with an apoptotic inhibitory effect 
(loo et aI., 2005). Expressions of HSP70 and HSP27 might play a vital role in 
hepatocarcinogenesis; in particular, HSP70 was closely related to the pathological parameters 
associated with tumor progression by promoting tumor cell proliferation (Qin and Tang, 2004). 
Recent Development in HCC Biomarker Discovery 
Proteomic Approach 
Since the molecular pathogenesis of HCC is very complex and is difficult to detect the 
disease at its early stages, new biomarkers for the early detection of HCC are urgently needed 
(Santamaria et aI. , 2007). Extensive studies have been carried out to define the mechanism of 
HCC progression as well as to identify new biomarkers that may lead to an early HCC detection 
(Santamaria et ai., 2007). HCC cell lines have been extensively used as an in vitro model for 
studying the differential proteomic outcome. HCC cell lines are highly homo genic when 
compared with HCC tissue where multiple cell subpopulations are involved (Feng et ai., 2006b). 
Furthermore, HCC cell lines allow the determination of the effects of altering the 
expression/activity of a particular protein. Investigating the differentially expressed proteins in 
HCC cell lines had provided valuable information to understand the changes in the different 
cellular pathways which might be involved in the development of tumors (Feng et aI., 2006b). 
Variations in the activity of many metabolic enzymes and proteins involved in calcium 
homeostasis, cytoskeleton construction, oxidative stress as well as the down-regulation of tumor 
suppression factors or the increased expression of anti-apoptotic proteins such as heat shock 
protein 27 (HSP 27) have been reported in HCC cell lines (Lee et ai., 2003a and Yu et aI, 2000). 
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The re-expression of the embryonic enzymes such as a-fetoprotein, glutathione-S-transferase 
(GST), 1t hexokinase B, or aldolase A in HCC has also been identified (Zeindl-Eberhart et aI. , 
1994). Using 2D SDS-PAGE, Fujii et ai. (2005) compared the protein expression profiles of 
primary cultured hepatocytes and HCC cell lines, many proteins were found to be differentially 
expressed in the HCC cell lines. When the protein profiles of AFP-producing and non-AFP-
producing cell lines were studied by different proteomic approaches (Yokoo et aI., 2004), 11 
proteins involved in apoptosis, glucose metabolism and cytoskeletal organization were identified. 
In a comparative study which was done using 2D SDS-PAGE to compare the protein 
profiles among HBV+, HCV+ and HBV- IHCV-HCC, 46 proteins were specific to the 
underlying viral etiology (Kim et ai., 2003). The mechanism by which HCC develops due to 
HCV infection has been studied in different in vitro models using 2D SDS-PAGE. Cytokeratins, 
vimentin, HSP 90, cofilin, and low molecular weight phosphotyrosine protein phosphatase are 
some of the identified cellular proteins found to interact with HCV core protein (Kang et ai., 
2005). HSP 27 and RNA-binding protein have also been reported to interact with NS5A and 
NS5B HCV proteins (Choi et aI., 2004). The interaction of different HCV viral proteins with 
such proteins might provide useful information about the mechanism by which HCV interferes 
with various cellular pathways such as translation, replication, apoptosis, and cell signaling 
. (Santamaria et aI., 2007). Consequently, these interactions can evade the immune response and 
can lead to a series of genetic and epigenetic mutations resulting in the development of HCC. 
In HCV -related HCC, many proteolytic fragments and unexpected species of albumin 
and smoothelin have been identified probably due to posttranslational modification (Yokoyama 
et aI., 2004). Up-regulated apolipoprotein E (APOE), calcium intracellular channell (CICI), and 
hnRNPK have been reported in HCV -related HCC (Blanc et aI., 2005). The expression of a 
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enolase has been positively correlated with tumor size and venous invasion in HCV -related HCC 
(Takashima et aI., 2005). 
Moreover, a number of other proteins have been reported to be differentially expressed 
during the development of HCC regardless of its etiology. These identified proteins have helped 
to better understand the mechanism behind cellular transformation during HCC development 
(SantamarIa et aI., 2007). Nuclear factor KB-associated factor Wnt-1 overexpression has been 
associated with the mechanism of hepatocarcinogenesis in both HCV - and HBV -infected patients 
(Lee et aI., 2006a). Three species of glutamine synthetase were found to be over-expressed and 
accumulated in HCC tissues, and the over-expression might be due to the upregulation of the B 
catenin pathway or inadequate degradation by the proteasome (Kuramitsu et aI., 2006). 
Interestingly, the 14-3-Jg protein, which determines whether the cell undergoes 
proliferation or apoptosis, was found to be over-expressed in HCC tissues (Lee et ai., 2005b). 
Over-expression of the aldose reductase- like protein (ARLP) appears to be a specific marker of 
liver tumors. It has been reported that while the tumor cells were positive for ARLP, the 
surrounding cirrhotic or non-cirrhotic tissues would not show any ARLP expression. ARLP up-
regulation might improve the detoxification capacity of tumor cells and hence increase their 
resistance to chemotherapy (Zeindl-Eberhart et aI., 2004). 
Surprisingly, the proteomic profiles of different regions in one tumor node were found 
not to be identical. For example, when LCM and SELDI-TOF were combined to compare the 
protein profiles between central tumor and peripheral tumor tissues (Melle et aI., 2004), the 
heterogeneity between the two protein expression patterns became evident not only between 
patients but also between different tumor sites of the same patient. It also suggested that different 
micro-environmental factors (e.g., hypoxia, host responses) may play critical roles in the 
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differentiation and progression of HCC tumor cells. In a similar study combining LCM with 
protein microarrays, 32 proteins were reported to be expressed differentially between HCC and 
normal liver tissue. Cyclin Dl and SOCSI were also studied using Western blot and tissue 
microarrays. They were found to be associated with HCC prognosis (Tannapfel et aI., 2003). 
Other proteins such as fatty-acid binding protein, S 100 and cytokeratin 18 have also been related 
to mechanisms correlated to the metastatic capacity of primary liver tumors (Song et aI., 2006). 
The identification of HCC biomarkers in biological fluids is promising and attractive for 
many researchers. The initiation of HCC may be determined by measuring and characterizing the 
circulating and differentially expressed proteins and/or peptides (Santamaria et aI., 2007). An 
altered HCC proteome in the serum has been used in monitoring the prognostic outcome in HCC 
patients (Kawakami et al., 2005). In order to identify disease-associated proteins present in very 
low abundance, the abundant serum proteins must be removed. It has been reported that 22 of the 
most abundant serum proteins, which accounts for > 90% of the total serum proteins, can 
severely interfere with the detection of the low abundant proteins (Anderson and Anderson, 
2002). For example, analysis of serum by 2D SDS-PAGE-MS following immuno-depletion of 
highly abundant serum proteins (albumin and IgG) identified heat shock protein 27 (Feng et aI., 
2005b). Although HSP27 has been associated with other diseases (Feng et al., 2005b), its 
. specificity requires further studies to be used for HCC detection (Martin-Ventura et al., 2004). A 
major drawback of the depletion approach is that some of the highly abundant proteins function 
as carriers or transporters, and therefore, their depletion may result in the loss of potentially 
important biomarkers (Mehta et aI., 2003). This was demonstrated, by Feng et al. (2005b), when 
the AFP was found to be retained in the albuminlIgG-containing depleted fraction. In addition, 
83 proteins were found to be bound to the major six abundant serum proteins, i.e. albumin, IgG, 
IgA, antitrypsin, transferrin and haptoglobin (Feng et al., 2006a). 
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SELDI-TOF-MS technology has been extensively used in serum proteomics studies and 
has provided HCC-specific protein profiles that can be used to detect HCC early with or without 
other markers. A proposed 8.9 kDa protein, identified as a C-terminal fragment of VlO 
vitronectin which may be cleaved by metalloproteases enhanced by HCC development, has been 
reported in a study using SELDI-TOF (Paradis et aI., 2005). SELDI TOF-based studies have 
further identified the complement C3a protein in serum from HCV -related HCC patients (Lee et 
aI., 2006b). There are some strong believes for the involvement of the immune response that 
might be elicited against cancer in humans, and this growing evidence is indicated by the 
identification of auto-antibodies to tumor antigens. To take advantage of this immune response, 
several studies have aimed at the identification of such auto-antibodies in the serum of patients as 
biomarkers for HCC. In these studies, samples were tested with autologous serum and the 
immuno-reactive proteins were further characterized. Auto-antibodies against calreticulin, 
cytokeratin 8, nucleoside diphosphate kinase A, and ATP synthase ~ chain have been identified 
independently of the HBV or HCV status (Le Naour et aI., 2002). Recently, auto-antibodies 
against HSP 70, Glyceraldehyde phosphate dehydrogenase (GAPDH), peroxyredoxin, and Mn 
Superoxide Dismutase (SOD) have been described in the serum of NAlNB HCC patients 
(Takashima et aI., 2006). 
The large number of differentially expressed proteins provided by studies on hepatoma 
cell lines and human samples have definitely extended our comprehension about HCC at the 
molecular level. However, even though some of these proteins are associated with HCC, the 
protein repertoires identified are primarily coincident and hence the overwhelming variability 
among studies hindered the immediate identification of ready-to-use biomarkers. As the liver 
executes multiple functions at the same time, no single laboratory test or battery of tests is 
enough to provide a complete estimate about the hepatic functions in each individual clinical 
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situation. In the last decade significant practical breakthroughs have taken place, especially 
within proteomics, and this holds a great promise to contribute to clinical practice by introducing 
new biomarkers in which diseases will be diagnosed, monitored and treated. 
Genomic Approach 
As previously mentioned, circulating cell-free DNA has been reported to be found in 
higher amounts in the serum/plasma of cancer patients compared to their levels among normal 
individuals (Leon et ai., 1977). Recently, great attention has been drawn to utilize the abnormally 
high levels of the circulating cell-free DNA in cancer patients as a marker for cancer diagnosis or 
prognosis (Gormally et ai., 2007). Recently, levels of cell-free DNA were found to be 
significantly higher in the sera of HCV -associated HCC patients compared to their corresponding 
levels in the sera from HCV patients or from normal individuals (Iizuka et ai., 2006). In the same 
study, it has been reported that cell-free DNA levels were related to the degree of tumor 
differentiation and size but not patients' age, gender or levels of AFP (Iizuka et ai., 2006). At a 
cut-off value of 73 ng/mL, cell-free DNA was successful in discriminating between HCC and 
HCV carriers at a sensitivity of 69% and a specificity of 93%. The predictive accuracy of cell-
free DNA was also found to be superior to that of AFP (Iizuka et ai., 2006). Furthermore, it has 
been reported that circulating cell-free DNA can be a useful predictive biomarker for distance 
metastasis of HCC in HCV patients after curative surgery (Tokuhisa et aI., 2007). In a study of 
87 patients who underwent successful hepatectomy, patients with a high cell-free DNA level had 
a significantly shorter overall survival (OS) time than those with a lower cell-free DNA levels 
(Tokuhisa et aI., 2007). 
Genetic and epigenetic alterations are considered characteristic features in the molecular 
pathogenesis of HCC (Thorgeirsson and Grisham, 2002). Many DNA methylation-dependent 
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epigenetic alterations have been described in hepatocellular carcinoma (Zhu, 2006), most of 
which are involved in cell cycle and cellular proliferation control. Among these altered genes, 
many tumor-suppressor as well as cell cycle controlling genes were found to be aberrantly 
methylated such as these encoding the cyclin-dependant kinase inhibitors, pi5 and pi6 (Herath 
et aI., 2006) and RASSFIA (Dammann et aI., 2001). These methylated genes were identified at 
the time of cancer diagnosis circulating in the blood of HCC patients (Wong et aI., 1999, 2000 
and Yeo et aI., 2005). This observation suggests the possibility that these genes were shed from 
the tumor cells into the blood. Therefore, aberrantly methylated sequences corresponding to 
these genes were thought to be potentially valuable epigenetic biomarkers for early (preclinical) 
diagnosis of hepatocellular carcinoma. Zhang et ai. (2007b) were able to identify 
hypermethylation of p16, pIS, and RASSFIA in 44%, 24%, and 70% of HCC patients, 
respectively. Moreover, methylated sequences corresponding to these genes were also detected in 
serum 1 to 9 years prior to the clinical diagnosis of HCC. The results of this study showed a high 
diagnostic accuracy for the use of sensitive and specific epigenetic biomarkers in serum for 
screening individuals at high risk for development of HCC (Zhang et aI., 2007b). 
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Aim of this Study 
The aim of this study is to identify HCC-specific genomic and proteomic signatures from 
urine samples, acquired in a non-invasive manner, which may potentially be used as cancer 
biomarkers for the diagnosis/screening of high risk (HCV-infected) populations. 
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Materials and Methods 
Urine Collection 
Upon the approval of the Research Ethics Board at Brock University (St. Catharines, ON, 
Canada), urine samples were collected in two phases. In Phase I, urine samples were collected 
from random volunteers for optimizing the purification of total proteins and the isolation of the 
trans-renal nucleic acids using a Silicon Carbide (SiC)-based technology. Whereas in phase II, 
urine samples were collected from 118 Egyptians who were residing at either the Alexandria 
University's General Hospital (Alexandria, Egypt) or the National Institute for Liver Diseases at 
Menoufia University (Shebeen EI-Kome, Egypt). The samples were sorted into three main 
groups, according to the information provided from a questionnaire filled by the general 
practitioner responsible for each patient (Appendix A). Group I contains 32 HCC-post HCV 
positive infection patients, group II contains 74 HCV positive patients, whereas group III 
contains 12 health individuals as the negative control group (Table 6). Based on the information 
obtained from the questionnaire (Appendix B), urine samples collected from patients suffering 
from any other disease (Diabetes mellitus, kidney diseases, etc ... ) or infection (chronic HBV 
infection, HB V IHCV co-infection and Schistosomiasis), or receiving any treatment/supportive 
treatment for either HCC or HCV infection were excluded from this study, to avoid interfering 
with the data interpretation. All the three groups were examined by HCV 5'UTR RT-PCR and 
the results confirmed that the HCC-post HCV and the HCV positive patients share the same 
etiological factor, HCV genotype 4. (Appendix C). 
Urine samples were collected in 50 mL sterile containers. The midstream urine samples 
were collected, as the first flow of urine has been shown to have a higher rate of contamination 
(Franz and Horl, 1999 & Morimoto et aI., 2003). Each 50 mL of urine was collected in the 
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presence of sodium Azide (Bioshop, Burlington, ON, Canada) with a final concentration of 1 
mM, 250 J..lL Protease Inhibitor Cocktail (Product Number P2714, Sigma, St. Louis, MO, USA) 
and EDT A (Bioshop, Burlington, ON, Canada) with a final concentration of 5 mM. The 
previously mentioned preservative cocktail was optimized through our optimization procedures. 
The effect of filtering or centrifuging the urine samples before processing was tested. Urine 
samples were filtered using a sterile Acrodisc® 25 mm syringe filter with 0.45 J..l HT Tuffryn® 
membrane (PALL, Life Sciences, MI, USA). Furthermore, Urine was centrifuged at 1000 xg for 
15 min. 
Table 6 Clinical pathological parameters of the patients involved in this study 
Control group HCC post-HCV group HCV positive group 
Number of patients 12 32 74 
Age (mean ± SD) 28±4 50 ± 8 36 ±18 
HCV infection -Ve +Ve +Ve 
HBV Infection -Ve -Ve -Ve 
Schistosomiasis -Ve -Ve -Ve 
Kidney diseases -Ve -Ve -Ve 
Sex Male (6) Male (26) Male (50) 
Female (6) Female (6) Female (24) 
Purification of Total Urinary Proteins from the HCC-Post HCV Positive, the HCV Positive 
and the Control Groups 
Total proteins were purified from urine using the Urine Protein Concentration Micro Kit 
(Norgen Biotek, Thorold, ON, Canada). The Purification was performed with a modified 
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protocol from the manufacturer's instruction. Briefly, 1mL of urine was adjusted to pH 3.5 using 
the pH binding solution which is composed of one volume of 250 mM NaOH ,(Bioshop, 
Burlington, ON, Canada) and two volumes of an acidic solution containing 250 mM phosphoric 
acid (Caledon Laboratories, Georgetown, ON, Canada) and 250 mM citric acid (Sigma, St. 
Louis, MO, USA). All the SiC-loaded columns (Norgen Biotek, Thorold, ON, Canada) were 
washed twice with 500 /-lL activation/washing solution of a pH 3.5 (Appendix D) by spinning the 
columns at 14,000 rpm for 1 min. 
The samples were loaded to the columns and centrifuged at 10,000 rpm for 2 min. The 
columns were then washed twice with 500 /-lL activation/washing solution by spinning the 
columns at 14,000 rpm for 1 min followed by a dry spin. Total urinary proteins were eluted with 
100 /-lL of elution buffer (10 mM sodium phosphate buffer, pH 12.5; Bioshop, Burlington, ON, 
Canada) for 2 min at 10,000 rpm, and neutralized with 9.3 /-lL neutralizer solution (90 mM acidic 
solution). The eluted proteins were stored at -70°C for further analysis. 
Purification of Total Urinary Proteins from Urine Samples Pooled from the Hee-post 
HeV Positive, the HCV Positive and the Control Groups 
Total proteins were purified from urine using the Urine Protein Concentration Maxi Kit 
(Norgen Biotek, Thorold, ON, Canada). The Purification was performed with a modified 
protocol from the manufacturer's instruction. Briefly, 1 mL of urine sample was transferred to a 
50 mL sterile tube in order to pool urine from each group. The three pooled urine samples were 
adjusted to pH 3.5 with the pH binding solution. Maxi columns (Norgen Biotek, Thorold, ON, 
Canada) were washed twice with 5 mL of the activation/washing solution of pH 3.5 by spinning 
the columns at 1,000 xg for 3 min. The urine was loaded to the column and spun down for 5 min 
at 1,000 xg. After loading the pooled urine samples, the columns were washed twice using 10 
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mL of activation/washing solution by centrifugation for 3 min at 1,000 xg followed by a dry spin 
at 2,000 xg for S min. Total urinary proteins were eluted with 2 mL of the protein elution buffer 
at 1,000 xg for S min. The eluted proteins were neutralized with 140 ilL of neutralizer solution 
and stored at -70°C for further analysis. 
Isolation of Trans-Renal Nucleic Acids from the HCC-post HCV Positive, the HCV Positive 
and the Control Groups 
Trans-renal nucleic acids were isolated from urine using the Urine DNA Isolation Kit 
(Norgen Biotek, Thorold, ON, Canada). The isolation was performed with a modified protocol 
from the manufacturer's instruction. Briefly, the pH of 1 mL of urine was adjusted to 3.S and 
mixed with guanidine hydrochloride (GnHCI) (Bioshop, Burlington, ON, Canada) at a final 
concentration of 0.8 M. The SiC-loaded columns were washed twice with SOO ilL of 
activation/washing solution of pH 3.S by spinning for 2 min at 14,000 rpm. Urine samples 
treated with GnHCI were then loaded to the columns and spun down for 2 min at 10,000 rpm. 
The columns were loaded with 2S0 ilL of 0.8 M GnHCI, spun down for 10 s at 3000 rpm and 
then incubated at 60°C for 1 h. After incubation, the columns were spun down for 1 min at 
10,000 rpm. The flow-through was re-Ioaded to the column and re-spun for an additional 1 min 
at 10,000 rpm followed by a dry spin for 1 min at 14,000 rpm. DNA was eluted in 100 ilL of TE 
buffer (pHIl) and stored at -70°C for further analysis. 
Isolation of total RNA from the HCC-post HCV positive, the HCV positive and the Control 
groups 
Total RNA was isolated from 3 mL of urine using the Urine (Exfoliated cell) RNA 
purification Kit (Norgen Biotek, Thorold, ON, Canada). The isolation was performed with a 
modified protocol from the manufacturer's instruction. Three milliliters of urine were mixed with 
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350 ilL of lysis solution and vortexed for 15 s. The lysate was then transferred to an RNase-free 
microcentrifuge tube and mixed with 200 ilL of 95%-100% ethanol by vOltexing for 10 s. The 
lysate plus ethanol were applied to the column and centrifuged for 1min at 10,000 rpm. After 
loading all the lysate, the column was washed twice with 500 ilL of the provided Wash Solution 
by centrifuging at 10,000 rpm for 1 min followed by a dry spin at 14,000 rpm for 1 min. Total 
RNA was eluted with 50 ilL of elution buffer by centrifuging the columns at 2,000 rpm for 2 min 
and at 14,000 rpm for 1 min. The purified RNA sample was stored at -70°C till further analysis. 
Extraction of Low Molecular Weight Nucleic Acids from Agarose Gels 
Trans-renal nucleic acids were separated on 2% agarose gel. The low molecular weight 
apoptotic DNA/RNA fragment was purified using Norgen's Gel extraction Kit following the 
manufacturer's protocol. 
Restriction Enzyme Digestion and Inactivation 
DpnI and AciI (New England Biolabs) digestion was carried out according to 
manufacturer's instructions. Trans-renal DNA isolated from urine samples was digested using 10 
units of DpnI or AciI in a 20 ilL reaction and incubated overnight reaction at 37°C. The enzyme 
was heat-inactivated at 70 °C for 20 min. 
Analysis of miRNA on Agilent 2100 Bioanalyzer 
The isolated miRNA was analyzed qualitatively and quantitatively using the Agilent 
RNA 6000 Kit using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Mississauga, ON, 
Canada) according to the manufacturer's directions. 
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MicroRNA Whole-Genome Expression Profiling 
The differential miRNA expression profiling was performed using the miRNA expression 
profiling assay panel (Illumina, San Diego, CA, USA) at the Sick-Kids Hospital (Genomic 
Facility, Toronto, ON, Canada). This assay is an adaptation of the proven DASL ® (cDNA-
mediated Annealing, Selection, Extension and Ligation) assay. Hybridization and scanning of 
miRNA expression bead array was performed according to the manufacturer's instructions 
(Illumina, San Diego, CA, USA). 
Standard Procedure for MALDI MSIMS Analysis for Protein Bands 
The proteins contained in gel bands were extracted from the gels usmg a modified 
version of the in-gel trypsin digestion procedure (Shevchenko et al. 1996) and identified by mass 
spectrometric (MS) analysis. Modifications to the procedure were done during the dehydration 
steps. Acetonitrile (ACN) (Fisher Scientific, Ottawa, ON, Canada) 50% in 25 mM ammonium 
bicarbonate was used instead of using acetonitrile alone. The extraction of the peptides was 
performed using one extraction with 5% formic acid (VWR, Mississauga, ON, Canada), 50% 
acetonitrile, instead of the three extractions used in the original method. Trypsin used for this 
procedure was a modified sequencing grade porcine trypsin from Promega (Madison, WI, USA). 
, After extraction, samples were dried by speed vacuuming and resuspended in 10 ilL of 0.3% 
trifluoroacetic acid (TFA) (Sigma-Aldrich, Oakville, ON, Canada). Each of these samples was 
then desalted using a C18 Il Zip Tip (Millipore, Billerica, MA, USA). The samples were then 
eluted and spotted on a Matrix-assisted laser desorption/ionization (MALDI) target using 1 ilL of 
a solution of 10 mg/mL a-cyano-4-hydroxycinnamic acid in 60% acetonitrile, 0.3% TFA. After 
trypsin digestion and peptide extraction, MS analysis was performed on a Q-STAR XL (York 
University, proteomic facility, Toronto, ON, Canada) with an o-MALDI source (MDS 
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Sciex/Applied Biosystems Inc.). MS and MS/MS analyses were performed manually. MS/MS 
data acquired were searched using an in-house licensed version of Mascot (Matrix Science, 
London, UK) NCBI's non-redundant database. 
LC-MS/MS Analysis of Pooled Urine Samples 
Protein samples were digested in-solution using 0.1 Ilg of trypsin in 25 mM ammonium 
bicarbonate solution in a total volume of 50 ilL. After overnight incubation at 37°C, the peptide 
solution was lyophilized by SpeedVac centrifugation and re-suspended in 20 ilL 0.1 % TFA. The 
mass spectrometric experiments were performed at the Sick-Kids Hospital (Proteomic Facility, 
Toronto, ON, Canada) using an online LC-MS/MS setup using an Agilent 1100 Capillary LC 
system (Palo Alto, CA, USA) fitted to an LTQ ion trap mass spectrometer (Thermo Electron, 
San Jose, CA, USA). A C18 pre-column (150 11m i.d. x 5.0 cm length) and a I1LC analytical 
column (75 11m x 10 cm) that also served as a I1ESI emitter were used for the separation of the 
digested proteins. The samples injected were first loaded onto the pre-column to get desalted and 
then eluted into the analytical column to perform further separation. The mass spectrometer was 
operated in data-dependent mode automatically cycling through acquisition of a full-scan mass 
spectrum and six MS/MS spectra recorded sequentially on the six most abundant ions present in 
the initial MS scan. A dynamic exclusion time of 1.5 min was used. For the reverse phase 
chromatography, a 60 min gradient elution from water to acetonitrile, each containing 0.1 % 
TFA, was performed at a flow rate of 0.2-0.3 IlUmin. The LC-MSIMS data obtained (in *.RAW 
format) were converted into mzXML format peak list files. The mzXML data were used to 
search against NCBlm human database with a search engine called GPM XE (www.thegpm.org). 
The search results were analyzed with Scaffold software (www.proteomesoftware.com).MSIMS 
data acquired were searched using an in-house licensed version of Mascot (Matrix Science, 
London, UK) NCBI's non-redundant database, SwissProt and the MDSB databases. 
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Synthetic Oligonucleotides 
All the synthetic oligonucleotides were purchased from Sigma Genosys. Depending on 
the scale of the oligonucleotides, they were all diluted to 50 mM in nuclease-free water (Qiagen, 
Cat. #129115). The diluted stock solutions were aliquoted to avoid repeated freezing and thawing 
and were stored at -70°C for long term storage or at -20 °C for short term use (Table 7). 
Table 7 List of oligonucleotides used in this study 
Name Sequence 
YI (Forward) 5'-TCCACTTTATTCCA GGCCTGTCC-3' 
Yl (Reverse) 5'-TTGAATGGAATGGG AACGAATGG-3' 
Y2 (Forward) 5'-GTCCATTACACTACATTCCC-3' 
Y2 (Reverse) 5'-AATGCAAGCGAAAGGAAAGG-3 ' 
K-ras (Forward) 5'-ACTGAATAT AAACTGTGGTCCATGGAGCT -3' 
K -ras (Reverse) 5 '-TTATCTGTATCAAAGAATGGTTCTGCACCA-3 , 
ASCL (Forward) 5'-GAGGGCGCGATCCTGGCGTC-3' 
ASCL (Reverse) 5 '-CGGTGAGGTCCAAGGCGTCC-3 , 
APC (Forward) 5 '-CTGCAGCTTCATATGATC-3 , 
APC (Reverse) 5'- AAGCCGGGAAGGATCTGTAT -3' 
P16 (Forward) 5'-GAAAGATACCGCGGTCCCTCC-3' 
PI6 (Reverse) 5'-CT AAATGAAAACT ACGAAAG-3' 
PI5 (Forward) 5'-CAGTGAGGACTCCGCGACG-3 ' 
PI5 (Reverse) 5'-ATCTAGGTTCCAGCCCCGAT-3' 
SOCS I (Forward) 5'-GCGCGAGAGCCGCCCCGGA-3 ' 
SOCS 1 (Reverse) 5'-TAATCGGCGTGCGAACGGAA-3' 
RASSFIA (Forward) 5'-ATCCTAGAACCTTGGACCTC-3' 
RASSFIA (Reverse) 5'-TCCGGCAGAGGCTGGACCGT -3' 
E-Cadherin (Forward) 5'-GCTTGCGGAAGTCAGTTCAG-3' 
E-Cadherin (Reverse) 5'-TTCTGTAGGTGGAGTCCCAG-3' 
GSTPI (Forward) 5'-AGTTTCGCCGCCGCAGTC-3' 
GSTPI (Reverse) 5'-GGTCCTTCCCAT AGAGCCCAA-3' 
c-myc (Forward) 5'-GCTGGGGTGGGGGGTAATCC-3' 
c-myc (Reverse) 5'-ATGCGGTGAGCCGAAATTTA-3' 
GAPDH (Forward) 5'-TCAATGACCCCTTCATTG-3' 
GAPDH (Reverse) 5 '-GGGTGGAATCATATTGGA-3 , 
DJ-l (Forward) 5'-TGTAGCCGTGATGTGGTCAT-3' 
DJ -1 (Reverse) 5 '-CCGTCTTTTTCCACACGATT-3 , 
CAF-l (Forward) 5' -GGAGCAGGACAGTTGGAGT -3' 
CAF-l (Reverse) 5' -GACGAATGGCTGAGTACAGA-3' 
HSP60 (Forward) 5' -GCTTGCAAAACTTTCAGATGGA-3' 
HSP60 (Reverse) 5' -CTTTTCATTCACTTCAACATCACTTGT -3' 
5SrRNA (Forward) 5' -GCCAT ACCACCCTGAACG-3' 
5SrRNA (Reverse) 5 '-AGCCTACAGCACCCGGTATT-3 , 
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Table 7contd. List of oligonucleotides used in this study 
Name Sequence 
HCV S'UTR (RT) 5' -GCCUUUCGCGACCCAACACU-3' 
HCV 5'UTR (Forward) 5'-GGGGCGACACTCCACCATGAAT -3' 
HCV 5'UTR (Reverse) 5' -GCCTTTCGCGACCCAACACT -3' 
SL-miR-532 5' -GTCGT ATCCAGTGCAGGGTCCGAGGTA TTCGCACTG 
GATACGACACGGTC-3' 
miR-532 (Forward) 5 '-CATGCCTTGAGTGTAGGA-3 , 
SL-miR-618 5' -GTCGT ATCCAGTGCAGGGTCCGAGGT ATTCGCACTG 
GATACGACACTCAG-3' 
miR-618 (Forward) 5' -AAACTCTACTTGTCCTTCTG-3' 
SL-miR-625 5' -GTCGTATCCAGTGCAGGGTCCGAGGT A TTCGCACTGGATA 
CGACAGGACT -3' 
miR-625 (Forward) 5 '-AGGGGGAAAGTTCTATAG-3 , 
SL-miR-650 5' -GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTG 
GATAC GACGTCCTG-3' 
miR-650 (Forward) 5' -AGGAGGCAGCGCTCTCAG-3' 
SL-miR -516-5p 5' -GTCGTATCCAGTGCAGGGTCCGAGGTA TTCGCACTG 
GAT ACGACAAAGTG-3' 
miR-516-5p (Forward) 5 '-CATCTGGAGGTAAGAAGCAC-3 , 
SL-miRNA (Reverse) 5' -GTGCAGGGTCCGAGGT -3' 
Reverse Transcription 
Three microliters of the isolated RNA from each sample was mixed with 0.5 ~L of 0.5 
~g/~L Oligo (dT)18 Primer (Fermentas), HCV (RT) primer or the stem loop miRNA-specific RT 
primer (Table 7). The reaction was then brought up with RNase-free water to 5 ~L. The mixture 
was first heated to 70°C for 5 min to denature the secondary structure of the RNA and then held 
at 4 0c. During the hold, the RT reaction solution containing 4 ~L 5X First Strand Buffer (250 
mM Tris-HCl [pH 8.3 at RT], 375 mM KCl, 15 mM MgC}z), 2 ~L of 0.1 M Dithiothreitol 
(DTT), 1 ~L of 10 mM Deoxyribose nucleoside triphosphates (dNTPs), 0.5 ~L of Superscript III 
reverse transcriptase (Invitrogen) and 7.5 ~L RNase-free water was added. The cDNA was 
synthesized at 25°C for 5 min, 42°C for 90 min and 70 °C for 15 min, followed by a holding at 4 
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PCR and Real-time PCR 
Polymerase chain reaction (PCR) (Mullis et aI., 1986) was performed according to the 
polymerase manufacturer (BioTherm). All of the PCR primers (Table 7) used in this experiment 
were designed using the Vector NTI 9. 1. 0 (Invitrogen). 
All the PCR reactions were performed using the iCycler PCR machine (Bio-Rad). For a 
20 ilL PCR reaction system, 1 ilL of DNA/cDNA template, 0.12 ilL of each primer (50 mM 
stock), 0.2 ilL of BioTherm Taq DNA polymerase (5 units/ilL), 2 ilL of lOX PCR buffer (750 
mM Tris-HCI [pH 8.8], 200 mM (NH4)2S04, 0.1 % v/v Tween 20), 1 ilL of 10 mM dNTPs and 
15.6 ilL of deoxy water (dH20) were added in a PCR tube and placed in the iCycler. The DNA/ 
cDNA template was denatured at 94°C for 30 s. The heat cycles were carried out at various 
annealing temperatures (5°C lower than the primer melting temperature) for 3D s, at the 
extension temperature of 72°C for 90 s, and at the denaturation temperature of 94°C for 30 s. 
The cycling numbers varied from 30 to 35 cycles. Finally, the reaction was incubated at 72°C for 
5 min and held at 4 0c. 
It should also be noted that all the primers used for the amplification of the different 
tumor-suppressor genes and c-myc were designed to be flanking the DpnI and AciI restriction 
, sites (Appendix E). GAPDH gene was used as an internal control as its primer was designed to 
amplify an amplicon free from both the DpnI and the AciI restriction sites (Appendix E). 
Real-time PCR was used to evaluate the expression levels of either the mRNA of the 
target proteins (DJ-1, CAF-1 and HSP60) or target miRNAs (miR-625, miR-532 and miR-618). 
The reaction mixture of Real-time PCR contained 3 ilL of the protein or miRNA cDNA 
template, 7.5 ilL of 2x SYBR GREEN master mix (Bio-Rad), and 0.12 ilL of each primer (50 
mM stock) in a 15 ilL reaction. The SL-miRNA primers were used as the reverse primers for all 
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the miRNAs. The PCR mixture was heated at 95°C for 15 min to activate the Hot-start 
polymerase. The cycling temperature and time were set at 95 °C for 15 s, at various annealing 
temperatures (5°C lower than the primer melting temperature) for 30 s, and at 72°C for 1 min, 
and repeated for 40 cycles. The temperature returned to the annealing temperature for 1 min, and 
the melt curve survey was carried out with an escalating temperature of 0.5 °c per 10 s. The melt 
curve reaction was performed with 80 rounds. 
Agarose Gels 
Agarose gel electrophoresis was carried out according to the standard procedure 
(Sambrook et al., 1989). The gel was then viewed under ultraviolet (UV) light and the image 
was captured using Alphalmager 2200 (Alpha Innotech). 
Polyacrylamide Gels 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) for protein analysis was prepared 
at an acrylamide concentration (15% w/v) with a 30: 1 ratio of acrylamide to BIS (Sambrook et 
ai. , 1989). The protein samples were prepared prior to separation on SDS-PAGE by boiling in a 
protein loading dye (125 mM Tris-HCI pH 6.8, 10% 2-mercaptoethanol, 10% SDS, 10% glycerol 
and bromophenol blue) for 10 min. The samples were cooled in an ice bath before loading onto 
the SDS-PAGE gel. 
The electrophoretic buffer was Tris-glycine (25 mM Tris, 25 mM glycine (pH 8.3) and 
0.1 % SDS). SDS-PAGE gels were generally run at 15V/cm until the migration front was one 
quarter of the gel length from the bottom. The gel was generally stained with Coomassie Brilliant 
Blue R250 (0.25 g in 45:45: 10 v/v/v methanol: water: glacial acetic acid) for 2 h. The gel was 
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then destained with 45:45: 10 v/v/v methanol: water: glacial acetic acid overnight with changes 
every 3 h. 
Quantitation of Protein Concentration 
The BioRad protein assay, based on the Bradford assay (Bradford, 1976), was used to 
detern:ine the concentrations of the total urinary proteins. In this assay, the standard curve was 
constructed using known amounts of bovine serum albumin (BSA) (NEB, Pickering, ON, 
Canada). The concentrations of protein samples were determined based on this standard curve of 
known protein concentration. The absorbance (Abs) readings were taken at 595 nm. 
DNA Quantification by Gel Densitometry with Norgen's FastRunner DNA Ladders 
The relative concentration of the trans-renal nucleic acids was quantified usmg gel 
densitometry with Norgen's quantitative FastRunner DNA ladders 
(www.norgenbiotek.comlindex.php?id=mdnamain). A standard curve was constructed from 
regression lines for the bands' assigned masses and their corresponding pixel densities (Figure 
9). The amount of FastRunner ladder per volume is specified as 500 ng per 10 J..lL. Ten 
microliters from the ladder was loaded to a 1.2% agarose gel. The agarose gel was prepared 
without the addition of Ethidium Bromide (EtBr). After electrophoresis, the gel was soaked in a 
running buffer containing 2.5 ng/mL EtBr. Gel pictures were taken using the AlphaImagerTM 
2200 from AlphaInnotech and the densitometer analysis was performed using the accompanying 
software, AlphaEaseFC. 
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Figure 9 Standard curve using FastRunner DNA ladder. A) Norgen ' s FastRunner DNA ladder used for 
the quantification of trans-renal nucleic acids (www.norgenbiotek.com/index.php?id=12800). B) The 
standard curve constructed by plotting the indicated mass (ng) for each band from the FastRunner DNA 
ladder against its corresponding pixel density. 
Statistical Analysis 
All Statistical analysis was performed and displayed using Excel (Microsoft Corp., USA) 
GraphPad Prism 5 (GraphPad Software, San Diego, CA). The two-tailed independent student' s t 
test was used to evaluate statistical significance. The significance level was set at p < 0.05. The 
relationship between different variables was analyzed by Pearson's correlation coefficient. 
Sensitivity, specificity, positive and negative predictive values, and diagnostic accuracy 
were calculated according to the following formula (in which a = true-positive cases, b = false-
positive cases, c = false-negative cases, and d = true-negative cases) (Sox et aI. , 1988); 
~ Sensitivity = a/(a + c) 
~ Specificity = d/(b + d) 
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~ Diagnostic accuracy = (a +d)/(a + b + c + d) 
~ Positive predictive value (PPV) = a/(a + b) 
~ Negative predictive value (NPV) = dI( c + d) 
The relative expression of genes of interest was displayed in the form of fold difference. 
The fold difference was calculated using the equation 21\-~Ct (Sample)/ 21\-~Ct {Control), where 
21\-~Ct = 2 1\ (-(avg. (Ct (gene of interest)) - avg. (Ct (5SrRNA)))). 
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Results 
Standard Operating Protocol for the Purification of Total Proteins from Urine 
The initial purification of total urinary proteins was done at the physiological pH of urine 
(pH 6) using different volumes of urine in the absence of any protein preservatives. The highest 
protein yield was obtained from a volume of 3.5 mL of urine passed through a SiC-loaded spin 
column (Figure lOA). No sign of proteolytic degradation was observed when the proteins were 
separated on a 15% SDS-PAGE gel (Figure lOB). 
A B 
Figure 10 Purification of total urinary proteins at physiological pH. A) Histogram for the total protein 
yield purified from different volumes of urine. B) The separation of total urinary proteins on a 15% SDS-
PAGE gel. Out of 50 ~, 15 ~ was loaded on the gel. At the urine's physiological pH (pH6), 3.5 mL of 
urine yielded 78.3 ~g. The experiment was done in triplicate and the data are presented as the average 
protein yield ± standard deviation. 
The effect of urine sample handling, namely centrifugation followed by filtration, on 
protein yield was studied across a range of different pH values (Appendix D) and different 
sample volumes. The highest protein yield was obtained from urine samples adjusted to pH 3.5, 
regardless of which sample handling technique was used (Figure 11 and Figure 13). There was 
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no significant difference in the amount of protein yielded from centrifuged/filtered and non-
centrifuged/unfiltered urine samples. Although the difference in the protein yield was not 
significant, the pattern of urinary proteins on a 15% SDS-PAGE gel showed the disappearance of 
some bands from the centrifuged/filtered unne sample compared to the non-
centrifuged/unfiltered samples (Figure 12 and Figure 14). 
3 3.5 4 4 .5 5 5 .5 6 6 .5 7 
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Figure 11 Quantification of the total unnary protein purified at different pH values in both 
centrifuged/filtered samples (gray bars) and non-centrifuged/unfiltered samples (white bars). The 
experiment was done in triplicate and the data are presented inside each bar as the average protein yield 
(J.Lg) ± standard deviation. 
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Figure 12 The separation of total urinary proteins purified from A) Centrifuged/filtered urine samples 8) 
Non-centrifuged/unfiltered urine samples on a 15% SDS- PAGE. The different pH values are showed at 
each gel. The red rectangle in both gels is showing the effect of centrifugation/filtration on the 
purification of certain protein(s)/band(s). 
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Figure 13 Quantification of the total urinary protein purified at different volumes with a pH of 3.5 in both 
centrifuged/filtered samples (black bars) and non-centrifuged/unfiltered samples (white bars).The 
experiment was done in triplicate and the data are presented inside each bar as the average protein yield 
(flg) ± standard deviation. 
A B 
Figure 14 The separation of total urinary proteins purified from A) Non-centrifuged/unfiltered urine 
samples B) Centrifuged/filtered urine samples on a ] 5% SDS- PAGE. In both cases, total urinary proteins 
were purified at different volumes and a constant pH (pH 3.5). Fifteen microlitre of a 50 flL elution was 
loaded on a 15% SDS-PAGE gel. M: Norgen's ProteoLadder 100. 
To concentrate the proteins purified from urine, the volume of the elution buffer was 
optimized. Total urinary proteins were purified from 3.5 mL of urine at pH 3.5. The urinary 
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proteins were eluted in different elution volumes (Figure 15) and it was determined that the 
purified proteins were highly concentrated when eluted in a 100 flL elution volume. 
A B 
Figure 15.1 Purification of total urinary protein at different elution volumes. A) A histogram showing the 
total urinary protein purified from 3.5 mL of urine at pH 3.5 and eluted in four separate elutions of 50 flL 
each. B) A 15% SDS-PAGE gel showing the proteins eluted in different elution volumes. The experiment 
was done in triplicate and the data are presented inside each bar as the average protein yield (flg) ± 
standard deviation. M: Unstained Protein Molecular Weight Marker (Fermentas, #SM0431). 
A B 
Figure 15.2 Purification of total urinary protein at different elution volumes A) A histogram showing the 
total urinary protein purified from 3.5 mL of urine at pH 3.5, B) Fifteen microliter out of each elution 
volume were separated on a 15% SDS-PAGE gel. The experiment was done in triplicate and the data are 
presented inside each bar as the average protein yield (flg) ± standard deviation. M: Unstained Protein 
Molecular Weight Marker (Fermentas, #SM0431). 
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To determine the appropriate protein preservative that should be added to the urine at the 
time of sample collection, total proteins were purified from urine stored at room temperature for 
two days in the presence of different protein preservatives and distilled water as a control. The 
protein yield was the highest from urine samples preserved with a mixture of a protease inhibitor 
cocktail and sodium azide (Figure 16). 
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Figure 16 Purification of total urinary proteins in the presence and absence of protein preservatives. A) A 
histogram showing the total urinary protein yield purified from urine samples mixed with different protein 
preservatives. B) Separation of total urinary proteins purified at the presence or absence of different 
protein preservatives. A: Protease inhibitor cocktail and sodium azide, B: protease inhibitor cocktail, C: 
Sodium Azide and D: distilled water. M: Norgen's ProteoLadder 100. 
To confirm all of our previous observations, total protein was purified from different 
volumes of urine, collected in the presence of mixture of a protease inhibitor cocktail and sodium 
azide, at pH 3.5. The proteins purified were eluted in a 100 ilL elution volume (Figure 17). 
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A B 
Figure 17 The maximal amount of protein purified from urine samples. A) A histogram showing the total 
urinary protein purified from 3.5 mL of urine at different pH values, B) Fifteen microlitter out of 100 !1L 
were separated on a 15% SDS-PAGE. The highest protein yield was recovered from the urine sample 
adjusted at pH 3.5 and eluted in a 100 )1L elution buffer. The experiment was done in triplicate and the 
data are presented inside each bar as the average protein yield ()1g) ± standard deviation. M: Unstained 
Protein Molecular Weight Marker (Fermentas, #SM0431). 
Total proteins were isolated from both 3.5 mL of urine and from 35 )1L of plasma donated 
by the same volunteer. Both samples were adjusted to a pH 3.5, prior to protein purification. The 
amount of the total proteins purified from plasma was higher than that purified from urine. The 
pattern of the proteins purified from plasma was nearly identical to that purified from urine 
(Figure 18). 
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Figure 18 Purification of total proteins from urine and plasma samples. A) A histogram showing the total 
urinary protein yield purified from urine and plasma samples. B) Separation of total proteins purified 
from urine and plasma samples. Uland B 1: Urine and plasma sample collected from the same volunteer. 
U2 and B2: Urine and plasma sample collected from the same volunteer. M: Norgen's ProteoLadder 100 
Standard Operating Protocol for Isolating Trans-Renal DNA from 
Urine 
DNA was initially isolated from urine exfoliated cells, pelleted from two different 50 mL 
urine samples. A high molecular weight genomic DNA (H), a low molecular weight DNA (L) 
and a DNA ladder-like pattern were observed on a 2% agarose gel (Figure 19). The low 
molecular weight DNA band (-150-200 base pairs) and the DNA ladder-like pattern are 
indicative of an apoptotic pattern of DNA degradation, as previously reported by Su et al. 
(2004). 
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Figure 19 A 2% agarose gel showing the DNA isolated from cells that were pelleted from two different 
50 mL urine samples. The dotted rectangle is showing the apoptotic DNA ladder. Arrow (H) is pointing 
to the high molecular weight genomic DNA, whereas arrow (L) is pointing to the low molecular weight 
apoptotic DNA (l50-200bp). The isolated DNA was eluted in a 100 ilL elution buffer; IO ilL was loaded 
to the 2% agarose gel. M: Norgen's FastRunner DNA ladder. 
In light of the findings of the previous experiment, trans-renal DNA was isolated from 3 
mL of urine from three different samples. Guanidine hydrochloride (0.8 M) was used to either 
lyse the exfoliated cells in solution or on columns (i.e. after sample loading to the SiC-loaded 
spin column) by incubating the columns for 1 h at 60°C. Most trans-renal DNA was isolated 
from the sample that was mixed with 0.8 M GnHCI before sample loading to the columns and 
then incubated with 0.8 M GnHCI for 1 h at 60°C after column binding (Figure 20). 
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Figure 20 Trans-renal DNA isolated from urine at different GnRel treatments. Urine was either 
incubated before sample loading (AI, A2 and A3) or incubated before and after loading to the columns 
(BI, B2 and B3) for lh at 60 °e with 0.8 M GnRel. Arrow (R) pointing to high molecular weight 
genomic DNA, whereas arrow (L) is pointing to the low molecular weight apoptotic DNA. The isolated 
DNA was eluted in 100 IJL elution buffer; 10 IJL was loaded to the 2% agarose gel. M: Norgen's 
FastRunner DNA ladder. 
To investigate the effect of pH adjustment on the DNA yield, trans-renal DNA was 
isolated from 3 mL of urine adjusted to pH 3.5 and then mixed with 0.8M GnHCI, before loading 
the sample to the column. After loading the treated urine samples, 0.8 M GnHCI was also loaded 
to the columns and the samples were incubated at different temperatures in order to determine 
the optimal incubation temperature (Figure 21). The highest amount of trans-renal DNA was 
isolated from urine samples adjusted to pH 3.5 and incubated at 60 0c. 
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Figure 21 Trans-renal DNA isolated from urine samples adjusted to a pH of 3.5, mixed with 0.8 M 
GnHCI before loading to the columns and incubated with 0.8 M GnHCI after loading to the columns at 
different temperatures (A: 60°C, B: 55°C, C: 50°C, D: 45°C and E: room temperature). The isolated 
DNA was eluted in 100 !JL elution buffer; 10 !JL was loaded to the gel. M: Norgen's FastRunner DNA 
ladder. 
To qualitatively analyze the DNA isolated from urine, trans-renal DNA was isolated from 
3 mL of three different urine samples following the abovementioned, optimized protocol (Figure 
22A). The isolated trans-renal DNA was partially digested when subjected to either DNase or 
RNase treatment (Figure 22B) indicating the presence of a RNAIDNA hybrid. The DNase and 
the RNase treatment were done overnight to ensure full digestion. To confirm that the observed 
low molecular weight band is DNA, the band was excised from the gel and the K-ras gene was 
amplified from this band (Figure 22C). Furthermore, trans-renal DNA was isolated from various 
amounts of urine to determine the smallest amount of urine that could be used for the DNA 
isolation. Trans- renal DNA was isolated from 25 ilL, 50 ilL, 100 ilL, 250 ilL, 500 ilL, 750 ilL, 
and 1 mL of urine. The purified DNA was then used as a template for the PCR amplification of 
Y -chromosome-specific sequences. For all the input amounts of urine, the initial PCR of the 154 
bp product was very faint. However, the nested PCR reaction resulted in a much brighter and 
more concentrated 154 bp product in all cases, as well as the 77 bp product. The nested PCR 
worked very well even when DNA was isolated from amounts as small as 25 ilL (Figure 23). 
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Figure 22 Qualitative analysis of trans-renal DNA isolated from 3 mL of urine. A) A 2% agarose gel 
showing the Trans-renal DNA isolated from 3 mL of 3 different urine samples. B) 2% agarose gel for the 
treatment of the trans-renal DNA isolated from samples] and 3 with DNase and RNase. C) A 2% agarose 
gel showing the peR amplification of the K-ras gene (166 bp). DNA isolated from HEK 293 cells was 
used as a positive control for the amplification of the K-ras gene. The isolated DNA was eluted in 100 ~ 
elution buffer; 10 ~ was loaded to the gel. M: Norgen's FastRunner DNA ladder. 
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Figure 23 Isolation and detection of DNA from as little as 25 ilL of urine. Lanes 1 and 1 * correspond to 
DNA isolated from 25 ilL of urine, Lanes 2 and 2* from 50 ilL, Lanes 3 and 3* from 100 ilL, Lanes 4 and 
4* from 250 ilL, Lanes 5 and 5* from 500 ilL, Lanes 6 and 6* from 750 ilL, Lanes 7 and 7* from 1 mL. 
Lane M is Norgen's FastRunner DNA ladder. Lanes 1,2,3,4,5,6 and 7 are the results of the first peR, 
and show the 154 bp peR product. Lanes 1 *,2*,3*, 4* , 5*,6* and 7* are the results of the nested peR 
reaction, and contain the 154 bp product (red rectangle) along with the nested 77 bp product (green 
rectangle). 
Proteomic-Based HCC Biomarker Approach 
Purification of Total Urinary Proteins from HCC-post HCV positive, HCV positive and 
Control groups 
Total proteins were purified from 1 mL urine collected from HCC-post HCV patients, 
HCV positive patients and control healthy individuals. Urinary proteins were purified from all 
the samples in triplicate and qualitatively analyzed on 15% SDS-PAGE gels (Figure 24). The 
concentration of the total urinary proteins, as quantified by Bradford assay, differed significantly 
between the HCC-post HCV positive group, the HCV positive group and the Control group. The 
concentration of total urinary proteins purified from HCC-post HCV positive group, with a mean 
of 1.153 1lg/IlL ± 0.8, was significantly higher than that purified from the control group, with a 
mean of 0.4775 1lg/IlL ± 0.2 (p value = 0.0068) (Figure 25). Moreover, the concentration of total 
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urinary proteins purified from the HCV positive group, with a mean of 0.7738 f..lg/f..lL ± 0.5, was 
also found to be significantly higher than that purified from the control group (p value = 0.0335) 
(Figure 25). 
Additionally, the concentration of the total urinary proteins varied considerably within 
each group (Figure 26). The concentration of total urinary proteins ranged from 0.4 /lgi/lL to 4.6 
/lgi/lL in the HCC-post HCV positive group and from 0.1 /lg//lL to 2.4 /lgi/lL in the HCV 
positive group. These variations were visible when the purified proteins were analyzed on 15% 
SDS-PAGE gels. The protein patterns of some samples in the HCC-post HCV positive group (1, 
9, 18,20, 21, 25, 26, 27 and 30) appeared identical to the patterns of some samples in the HCV 
positive group (11, 12, 23-25, 33-38, 40-43, 48, 52-60 and 74). Furthermore, there was no 
correlation between AFP levels and the concentration of urinary proteins among HCC-post HCV 
positive patients. It should be noted that patients who have AFP levels of 400 ng/mL or more are 
considered HCC positive (Bruix, 2001) 
A B 
M I Control 2Control 3Coo<,"1 4 Control 5Coo<,"1 6CoO<1Ol M 7Control 8Con,rol 9 Cootrol 10Con,roi II Coillrol 12eoo'rol 
Figure 24.1 Total urinary proteins purified from the control group and separated on 15 % SDS-PAGE 
gels. Gel A: samples 1-6 and Gel B: samples 7-]2. M: Unstained Protein Molecular Weight Marker 
(Fermentas, #SM0431). Total urinary proteins were purified from] mL of urine sample with SiC-loaded 
columns using the optimized urinary protein purification protocol. Out of ] 00 ~ elution, 20 ilL were 
loaded from each sample on a ]5% SDS-PAGE gel. The purification of urinary proteins was done in 
triplicate. 
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Figure 24.2 Total urinary proteins purified from the HCC-post HCV positive group and separated on 15 
% SDS-PAGE gels. Gel AI: Samples 1-8, Gel A2: Samples 9-16, Gel A3: samples 17-24 and Gel A4: 
samples 25-32. M: Unstained Protein Molecular Weight Marker (Fermentas, #SM0431). Total urinary 
. proteins were purified from 1 mL of urine sample with SiC-loaded columns using the optimized urinary 
protein purification protocol. Out of I 00 ~ elution, 20 ~ were loaded from each sample on a 15% SDS-
PAGE gel. The purification of urinary proteins was done in triplicate. 
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Figure 24.3.1 Total urinary proteins purified from the HCV positive group and separated on 15 % SDS-
PAGE gels. Gel AI: Samples 1-8, Gel A2: Samples 9-16, Gel A3; samples l7-24, Gel A4: samples: 25-
32, Gel A5: Samples 33-40, Gel A6: Samples 41-48. M: Unstained Protein Molecular Weight Marker 
(Fermentas, #SM0431). Total urinary proteins were purified from 1 mL of urine sample with SiC-loaded 
columns using the optimized urinary protein purification protocol. Out of 100 J1L elution, 20 f.l.L were 
loaded from each sample on a 15% SDS-PAGE gel. The purification of urinary proteins was done in 
triplicate. 
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Figure 24.3.2 Total urinary proteins purified from the HCV positive group and separated on 15 % SDS-
PAGE. Gel A7: samples 49-56, Gel A8: samples 57-64, Gel A9: samples 65-69 and Gel AlO: samples 70-
74. M: Unstained Protein Molecular Weight Marker (Fermentas, #SM0431). Total urinary proteins were 
purified from 1 mL of urine sample with SiC-loaded columns using the optimized urinary protein 
purification protocol. Out of 100 ilL elution, 20 ilL were loaded from each sample on a 15% SDS-PAGE 
gel. The purification of urinary proteins was done in triplicate. 
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Figure 2S A histogram showing the concentration of the total urinary proteins purified from the HCC-
post HCV positive, the HCV positive group and the control group. "'The concentration of the proteins 
purified from the HCC-post HCV positive group was significantly higher than that purified from the 
control group (p = 0.0068). 'The concentration of the proteins purified from the HCV positive group was 
significantly higher than that purified from the control group (p = 0.0335). Means are significantly 
different atp < 0.05. 
107 
Moemen Abdalla HCC Biomarkers 
5 .00 
4.50 
4.00 
3 .50 
"-
3 .00 
'" ~ 2.50 
cj 
c: 2.00 0 
0 
c: 1 .50 'OJ 
e 1.00 0.. 
0 .50 
0 .00 
~ ~ ~ ~ "0 ~ ~ >a co 
8 0 0 8 0 0 0 0 0 u u u 
... 
'" '" 
~ :: 
Samples 
Figure 26.1 The concentration of the urinary proteins (mean ± SO) purified from 12 healthy individuals 
(control group). The maximal protein concentration was 0.8 1lg/IlL ± 0.14, whereas the lowest 
concentration was 0.38 1lg/IlL ± 0.02. 
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Figure 26.2 The concentration of the urinary proteins (mean ± SO) purified from 32 patients in the HCC-
post HCV positive group. The maximal protein concentration was 4.61 1lg/IlL ± 0.13, whereas the lowest 
concentration was 0.38 1lg/IlL ± 0.02. 
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Figure 26.3 The concentration of urinary proteins (mean ± SD) purified from 74 patients in the HCY 
positive group. A: samples 1-32, B: samples 33-64 and C: samples 65-74. The maximal protein 
concentration was 2.43 ~g/~L ± 0.14, whereas the lowest concentration was 0.14 ~g/~L ± 0.04. 
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Partial Sequencing of Protein Bands by MALDI-TOF-MS 
Nine protein bands were excised from different HCC-post HCV positive SDS-PAGE 
samples for protein identification (Figure 27). Partial sequencing using MALDI-TOF-MS 
identified 10 proteins in the excised bands and they are listed in table 8. Albumin was identified 
in band #2 and band #3. Alpha-I-acid glycoprotein (AGP) was identified in band #7 along with 
albumin. Tamm-Horsfall protein (uromodulin) and albumin were identified in band #1. Complex 
forming glycoprotein HC was identified in band #4. Immunoglobulin (Ig) lambda light chain, 
Immunoglobulin Kappa light, Immunoglobulin light chain and Ig G 1 H Nie were identified in 
bands #5, #8 and #9, respectively. 
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Figure 27 The protein bands excised from different samples from the HCC-post HCV positive group. 
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Table 8 A list for the proteins identified from the excised protein bands which were identified 
using MALDI-TOF-MS. 
Band 
Protein identified Peptide sequence Accession number 
# 
TLDEYWR 
DWVSVVTPAR 
Tamm-Horsfall protein TALQPMVSALNIR 
gil340166 
(Uromodulin) VGGTGMFTVR 1 
YFIIQDR 
FSVQMFR 
Serum Albumin DVFLGMFL YEY AR gil28592 
YLYEIAR 
RHPYFY APELLFF AK 
2 Serum Albumin VFDEFKPLVEEPQNLIK gil28592 
FQNALLVR 
RPCFSALEVDETYVPK 
LVNEVTEFAK 
3 Serum Albumin RHPYFY APELLFF AK gil28592 
LDELRDEGK 
HHGPTITAK 
4 
Complex forming 
ETLLQDFR gil223373 
glycoprotein HC 
VV AQGVGIPEDSIFTMADR 
Immunoglobulin lambda AAPSVTLFPPSSEELQANK 
gil33700 
light chain Y AASSYLSLTPEQWK 
5 
Immunoglobulin Kappa FSGSGSGTDFTL TISR 
light TV AAPSVFIFPPSDEQLK 
gil1292863 
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Table 8 A list for the proteins identified from the excised protein bands which were identified 
using MALDI-TOF-MS 
Band 
Protein identified Peptide sequence Accession number 
# 
YWGVASFLQK 
Retinol binding GNDDHWIVDTDYDTYAVQYSCR 
gil230284 6 
protein LLNLDGTCADSYSFVFSR 
QRQEELCLAR 
WFYIASAFR 
Alpha-I-acid 
YVGGQEHF AHLLILR gilI197209 
gl ycoprotein 
EQLGEFYEALDCLR 
7 
YLYEIAR 
Serum Albumin DVFLGMFL YEY AR gil28592 
RHPDYSVVLLLR 
LLIYGASSR 
Immunoglobulin light FSGSGSGTDFTL TISR 
8 gil2894829 
chain TV AAPSVFIFPPSDEQLK 
SGTASVVCLLNNFYPR 
Ig GI H Nie 
EPQVYTLPPSR 
gil22960I 9 
GFYPSDIA VEWESNGEPQDNYK 
LC-MS/MS Shotgun Analysis 
Liquid Chromatography coupled with tandem Mass Spectrometry (LC-MS/MS) analysis 
of the proteins pooled from the control group, HCC-post HCV positive group and the HCV 
positive group resulted in 364 spectra. By analyzing the different spectra generated by the 
HPLC-MS/MS analysis with MASCOT, Xl Tandem on-line search engines and the Scaffold 
proteome software, a total of 24 proteins were identified. Ten proteins were identified from the 
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proteins pooled from the control group, 13 from the HCC-post HCV positive group and 16 from 
the HCV positive group (Table 9). Uromodulin, beta-Actin, Chain A of the second Kunitz 
domain of tissue factor pathway inhibitor and keratin 9 were identified in the 3 groups. Chain A 
of a humanized Fab fragment of anti- tissue-factor in complex with tissue factor and Chain L of 
an antigen-binding fragment from a humanized version of the anti-human Fas antibody Hfe7a 
were only identified among the HCC-post HCV positive group. 
Seven proteins were found to be expressed among the HCV positive group: 
immunoglobulin K light chain, Zinc-a-2-glycoprotein precursor, Ig G 1 H Nie, immunoglobulin "-
light chain VLJ region, Adenylyl cyclase-associated protein 1 (CAP 1) and matrin 3. Four 
proteins were only identified in the control group (keratin 1 & 10, pyruvate kinase 3 and 
Homerin). In addition, six proteins were found to be expressed in both the HCC-post HCV 
positive and the HCV positive groups, but not in the control group. These proteins were: 
Chromatin Assembly factor p150 (CAF-l), DJ-l protein, heat shock 60kDa protein (HSP60), Ig 
heavy chain variable region, Ig J chain and Stathmin 1/0ncoprotein 18. 
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Table 9 A list for all the proteins identified from the LC-MSIMS analysis resulted from the shotgun proteomic analysis of proteins 
pooled from Control group, HCC-post HCV positive group and HCV positive group 
Accessioll Protein name 
"umhers 
ACTB protein gi ll 17167827 
beta-subunit (AA 1-312) gi l28931 
Chain A, Crystal Structure Of A Humanized Fab 
Fragment Of Anti- Tissue-Factor Tn Complex With gi l51247838 
Tissue Factor 
Cbromatin Assembly factor-p150 g/1505J3Z45 
Heat sbock 60kDa protein 1 (cbaperonin) g/1306890 
Immunoglobulin heavy chain variable region gil2 6801 144 
Immunoglobulin kappa light chain VLJ region gi l21669327 
Keratin I gi ll 1935049 
Keratin 9 (epidermolytic palmoplantar keratoderma) gi ll19581148 
PREDICTED: pyruvate kinase 3 isoform 2 gi ll 14657944 
Statbmin l/oncoprotein 18 (Homo sapiens) gil 15680064, 
Uromodulin (uromucoid, Tamm-Horsfall gill 19570699 glycoprotein), isoform CRA_a [Homo sapiens] 
Peptide sequellce 
TTGIYMDSGDGVTHTVPIYEGY ALPHAILR 
SLQDIIAILGMDELSEEDKLTVSR 
THQG LSSPVTKSFNRG ECT 
VDNALQSGNSQESVTEQDSKDSTYS 
VQ~VDNALQSGNSQE 
LKEEAKRAKEEAKKKKEEEKELKEKE 
KPKTPQAPKTLAGSCG 
KPL VllAEDVDGEALSTLVLNR 
TALLDAAGVASLLTTAEVVVTEIPKEEKD 
NSLYLQMNSLRAEDTAFY¥CVTGYCSGG 
NCYGPR 
VDNALQSGNSQESVTEQDSK 
SGGGFSSGSAGIINYQR 
SLNNQFASFIDKVR 
THNLEPYFESF~LR 
GGGGSFGYSVGGGSGGGFSASSLGGGFGG 
GSR 
HGVQELEIELQSQLSK 
FGVEQDVDMVFASFIR 
MAEEKLTHKMEANK 
DSTlQVVENGESSQGR 
TALQPMVSALNIRVG 
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%of 
sequellce 
coverage 
8% 
9% 
22% 
38% 
9% 
41% 
16% 
12% 
21% 
3% 
90/0 
8% 
Protei" Best Peptide Protei" idellt(!icatioll probability 
molecular 
weight idelltijicat;oll 
(Da) probability 
41718.8 95% 88% 90% 90% 
.= 
. 0!UI 
56542.5 95% 88%) 90% 0 
23435.1 95% 0 100% 0 
106843.5 95% o 90% 85% 
6/037.7 95% o 100% 77% 
9392.5 95% 0 90% 100% 
29835.5 95% 0 0 97% 
66050.3 95% 100% 0 0 
62047.8 95% 100% 90% 50% 
57919.5 75.2% 53% 0 0 
17285 91.3% 0 850/0 360/0 
69741.5 95% 88% 100% 100% 
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Screening the HCC-post HCV Positive Group for the Over-Expression of DJ-l, CAF-l and 
HSP60 
DJ-l, CAF-l and HSP60 were chosen as possible protein biomarkers ofHCC because of 
their proposed roles in carcinogenesis. Using qRT-PCR, the expression of DJ-1, CAF-1 and 
HSP60 was evaluated in HCC-post HCY positive patients relative to their expression in healthy, 
control individuals. The expression of the three candidate proteins was nOffi1alized against the 
5SrRNA. The fold difference and the p value of the student t-test for each candidate protein in 
the HCC-post HCY positive patients is listed in Table 10. 
DJ-l, CAF-1 and HSP60 were significantly over-expressed in 30, 28 and 29 HCC-post 
HCY positive patients, respectively (Figure 28). The over-expression of each protein in the 
HCC-post HCY patients, relative to the control group, was determined to be significant when the 
difference in expression was three or more fold with p value of less than 0.05 (Figure 29). All 
three proteins were found to be, simultaneously, significantly over-expressed in 20 patients, 
whereas in another 12 patients only two of the three proteins were being significantly over-
expressed. There was no correlation between the expression of any of the three proteins and the 
levels of AFP in the HCC-post HCY positive patients. Typical quantitative Real-time PCR data 
for the amplification of DJ-1, CAF-l and HSP60 in the control group as well as the HCC post 
HCY positive group are shown in Figures 30 and 31, respectively. 
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Table 10 The/old difference and the p values for the expression o/DJ-J, CAF-J and HSP60 
among HCC-post HCV positive patients. 
DJ-l Chromatin Assembly Factor 1 
Samples showing three or more fold difference are highlighted 
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Figure 28 The fold difference for the expression of the DJ-I, CAF -I and HSP60 in the HCC-post HCV 
positive group relative to the Control group. Fold difference was calculated using the equation 2-l>Ct (protein) 
HCC / 2-W (Protein) Control. DJ-I, CAF -I and HSP60 were found to be significantly over-expressed in 30, 
28, and 29 out of 32 patients, respectively. 
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Figure 29 A Volcano Plot graphs the log2 for the fold difference of A) DJ-l, B) CAF-l and C) HSP60 
expression versus its p value from the (-test among HCC-post HCV positive group. The black line 
indicates a fold-difference in gene expression of 1. The pink lines indicate the desired fold-difference in 
gene expression threshold (3). The blue line indicates the desired threshold for the p value of the t-test (p 
< 0.05). Samples with a significant protein over-expression (dotted oval) were chosen with a fold 
difference of three or more and ap < 0.05. 
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Figure 30 Real-time PCR amplification of DJ-i , CAF-I and HSP60 in the control group. The 5SrRNA 
was used for normalization. A) PCR quantification curve. B) Melt curve. The experiment was carried out 
in duplicate to avoid the reading error of the PCR machine. - 5SrRNA, - DJ-i , CAF-i , - HSP60 
and - (-RT) 5SrRNA. 
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Figure 31 Real-time PCR amplification of DJ-l , CAF-i and HSP60 in the HCC-post HCV positive 
group. The 5SrRNA was used for normalization. A) PCR quantification curve. B) Melt curve. Ai and B 1: 
Samples 1-19. A2 and B2: samples 20-32. The experiment was carried out in duplicate to avoid the 
reading error of the PCR machine. - 5SrRNA, - OJ-I , CAF-I and - HSP60. 
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Screening the HCV Positive Group for the Over-Expression ofDJ-l, CAF-l and HSP60 
Because DJ-l, CAF-l and HSP60 over-expression appeared to be a characteristic event 
among HCC-post HCY positive patients, we hypothesized that aberrantly high levels of these 
proteins in urine could facilitate their use as biomarkers for the early detection of HCC among 
high-risk HCY positive patients. Therefore, we studied the expression of DJ-l, CAF-l and 
HSP60 in HCY positive patients using qRT-PCR. The expression of these proteins was 
compared to their expression in the control group. DJ-l, CAF-l and HSP60 were found to be 
significantly over-expressed (fold difference greater than three and p < 0.05) in 27,27 and 51 of 
74 patients, respectively (Figure 32). Typical quantitative Real-time PCR data for the 
amplification of DJ-l, CAF-l and HSP60 in the HCY positive group as well as in the control 
group are shown in Figure 33. 
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A 
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Figure 32 The fold difference in the expression of A) DJ-l B) CAF-l and C) HSP60 in the HCV positive 
group relative to the control group. DJ-l, CAF-l and HSP60 were significantly over-expressed in 27,27 
and 51 out of 74 HCV positive patients. Fold difference was calculated using the equation 2-ilCt (protein) 
HCV / 2-ilCt (protein) control. OJ-I, CAF-l or HSP60 was considered to be significantly over-expressed ifthe 
fold difference of its expression in HCV positive patients relative to the control group was?:: 3 with a p 
value < 0.05. 
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Figure 33 Real-time PCR amplification of OJ-I, CAF-l and HSP60 in the HCV positive group. The 
5SrRNA was used for normalization. A) PCR quantification curve. B) Melt curve. Al and Bl: samples 1-
23, A2 and B2: samples 24-46, A3 and B3: samples 47-69 and A4 and B4: samples 70-74. The 
experiment was carried out in duplicate to avoid the reading error of the PCR machine. - 5SrRNA, -
OJ-I, CAF-l and - HSP60. 
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Diagnostic Value of DJ-l, CAF-l and HSP60 for the Detection of HCC in High-Risk HCV 
Infected Group 
To validate the diagnostic value of the three candidate proteins for the detection of HCC 
III the high-risk HCY infected group, the medical records of the HCY infected patients, 
specifically AFP levels and the CT scan (Computed tomography scan) results, were updated 2 
years after sample collection. It should be noted that all the patients within the HCY positive 
group were not diagnosed with HCC at the time of sample collection, based on their AFP levels 
and CT scan results. The updated records showed that AFP levels were elevated in 35 HCY 
infected patients, all of whom also tested positive for HCC by CT scans. Only one patient, #7, 
had a normal AFP level, but was diagnosed with HCC by CT scan. As a reminder, patients with 
AFP levels of 400ng/mL or more and confirmed presence of a tumor by CT scan are considered 
truly HCC positive (Bruix, 2001). 
Using the updated medical records, the diagnostic value of the over-expression of the 
three selected proteins for predicting HCC in HCY infected patients was determined (Table 11). 
The specificity and the sensitivity for each selected protein, independently or by combining any 
two proteins, showed either high sensitivity/low specificity or low sensitivity/high specificity in 
detecting HCC among HCY positive patients (Table 12). When the three proteins were used as 
one panel for diagnosing HCC in HCY infected patients, the specificity was significantly 
improved, whereas the sensitivity was significantly reduced. CAF -1, solely or combined with 
HSP60, showed the highest specificity, sensitivity and diagnostic accuracy in identifying HCC 
among high-risk HCY infected patients. 
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Table 11 TheJold difference and the p values for the expression oJDJ-J, CAF-J and HSP60 as 
well as the AFP levels among the HCV positive patients using qRT-PCR (Wi True Positive, _ 
False Positive, iii False N, and 0 True N, 
946 
92 
594 
712 
647 
167 
74 
61 
98 
378 
648 
2021 
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Table llcontd The fold difference and the p values for the expression ofDJ-1, CAF-1 and HSP60 
as well as the AFP levels among the HCY positive patients using qRT-PCR ( WM True Positive, _ 
False Positive, II False Ne and 0 True M 
65HCV 
66HCV 
67HCV 
0.02 
1.82 
0.01 4.18E-05 
125 
AFP levels 
(nglL) 
90 
51 
324 
245 
846 
71 
88 
425 
224 
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Table 12 The specificity and the sensitivity oJDJ-J, CAF-J and/or HSP60 in detecting HCC in 
HCV positive group 
Positive Negative 
Candidate Specificity Sensitivity Predictive Predictive Diagnostic 
Biomarker(s) (%) (%) Value (PPV) Value (NPV) accuracy (%) 
(%) (%) 
DJ-l 82 58 75 67 70 
CAF-l 90 66 85 74 78 
HSP60 42 83 58 73 62 
DJ-lICAF-l 92 36 81 60 65 
DJ-I/HSP60 87 51 78 67 70 
CAF -1/ HSP 60 92 61 88 71 77 
DJ-1/CAF-1/HSP60 95 31 85 61 65 
Genomic-Based HCC biomarker approach 
Isolation of Trans-Renal DNA from Urine Samples Collected from HCC-post HCV 
positive, HCV positive and Control Groups 
Using the optimized urine DNA isolation protocol, trans-renal DNA (Tr-DNA) was 
isolated from a 1 mL urine sample, acquired from HCC-post HCV patients, HCV positive 
patients and the healthy, control group, individuals. For most of the patients in the HCC-post 
HCV group and the HCV positive group, both the high molecular weight DNA (gDNA) and low 
molecular weight DNA (~150-200bp) were visible on a 2% agarose gel (Figure 34). On the 
contrary, the low molecular weight DNA was not observed in DNA samples isolated from the 
control group, except in one sample. When the trans-renal DNA was subjected to either DNase 
or RNase treatment, the low molecular weight DNA showed partial digestion, suggesting that the 
low molecular weight band is a mix of DNA and RNA (DNA/RNA hybrid) (Figure 35). 
According to published reports (Wyllie et al., 1980 and Halicka et al., 2000), these DNA/RNA 
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hybrids were generated as a result of apoptosis and we designated them as urinary apoptotic 
nucleic acids (uaNAs). 
The uaNA levels, as quantified by gel densitometry, differed significantly between the 
HCC-post HCV positive group, the HCV positive group and the Control group (Figure 36). The 
levels ofuaNA in the HCC-post HCV positive group had a mean value of 157.3 nglmL whereas 
a mean value of 98.96 nglmL was found in the HCV positive group. The levels of uaNA in the 
HCC-post HCV positive group and the HCV positive group were significantly higher than in the 
control group, where the mean concentration ofuaNA was 26.75 nglmL (Figure 37). In addition, 
a-feto protein levels, which are used to monitor the progression of cancer among HCC patients, 
positively correlated to the levels of uaNA within the HCC-post HCV group (r2= 0.7739, p= 
0.0001) (Figure 38). This finding led to the hypothesis that uaNA levels are, therefore, also 
closely related to HCC development and progression. Examining the aberrant methylation of 
CpG islands of eight tumor-supressor genes that are closely related to the development and 
progression ofHCC was the initial step in testing this hypothesis. 
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Figure 34A Trans-renal DNA isolated from control group. The arrow (L) is pointing to the apoptotic 
DNA, whereas arrow (H) is pointing to gDNA. Total DNA was isolated from I mL of urine using our 
optimized urinary DNA isolation protocol, 10 ilL out of 100 ilL elution were loaded from each sample. 
M: Norgen's FastRunner DNA ladder. 
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Figure 34B Trans-renal DNA isolated from HCC-post HCV positive group. The arrow (L) is pointing to 
the apoptotic DNA, whereas arrow (H) is pointing to gDNA. Total DNA was isolated from 1 mL of urine 
using our optimized urinary DNA isolation protocol, 10 ilL out of 100 ilL elution were loaded from each 
sample. M: Norgen's FastRunner DNA ladder. 
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Figure 34C Trans-renal DNA isolated from HeV positive group. The arrow (L) is pointing to the 
apoptotic DNA, whereas arrow (H) is pointing to gDNA. Total DNA was isolated from 1 mL of urine 
using our optimized urinary DNA isolation protocol, 10 f..lL out of 100 f..lL elution were loaded from each 
sample in the presence of Norgen's FastRunner DNA ladder. 
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A 
B 
Figure 35 DNase and RNase treatment ofthe isolated trans-renal DNA. A) A 2% agarose gel showing the 
DNA isolated from urine samples collected from HCC-post HCV positive group treated with DNase. B) 
A 2% agarose gel showing the DNA isolated from urine samples collected from HCC-post HCV positive 
group treated with RNase. DNase and RNase treatment were done in 20 JlL reaction and were loaded on a 
2% agarose gel. M: Norgen's FastRunner DNA ladder. 
130 
Moemen Abdalla HCC Biomarkers 
A 
B 
c 
Figure 36 Urinary apoptotic nucleic acids levels (mean ± CI) isolated from A) Control group, B) HCC-
post HCY positive group and C) HCY positive group. Quantification was done based on plotting a 
standard curve using the Norgen's FastRunner DNA ladder. Urinary apoptotic nucleic acids were isolated 
and quantified in triplicate. 
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Figure 37 A Histogram showing the levels of urinary apoptotic nucleic acids (mean ± CI) isolated from 
HCC-post HCY positive group, HCY positive group and control group. *** p = 5.62327E-7, ** P = 
2.76392E-4. 
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Figure 38 Correlation between the urinary apoptotic nucleic acids levels and alpha-fetoprotein levels 
among HCC-post HCY positive group (r2 = 0.7739, p = 0.0001). 
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QRT-PCR Analysis ofthe Liver-Specific miR-122 in Urine 
In order to prove that the observed RNA/DNA hybrid isolated from urine originated from 
liver cancers, we looked for the presence the liver-specific miR-122 (Jopling et ai., 2005) in the 
urine of HCC-post HCY positive patients. MiRNA was isolated from 3mLs of urine using a 
modified protocol (see Materials and Method section) from the miRNA purification Kit 
(Norgenbiotek, Thorold, ON, Canada). The presence ofthe liver-specific miR-122 in the urine of 
HCC post HCY positive patients was analyzed using qRT-PCR. To calculate the expression 
levels of the miR-122 in terms of fold change, the Ct values were normalized against the 5S 
rRNA (~Ct) in both the control group as well the HCC-post HCY positive group. The fold 
change of the miR-122 expression was calculated using the equation 2-~Ct (miR-I22) HCY / 2-~Ct 
(miR-I22) Controls. The liver-specific miR-122 was abundantly found in the urine of all HCC-post 
HCY positive patients. No correlation has been found between the expression levels ofmiR-122 
and the concentration of the urinary apoptotic nucleic acids. Figure 39 shows the relative 
expression levels of miR-122 as a fold difference among HCC-post HCY positive patients 
(HCC/Control). A typical quantitative Real-time PCR amplification results for miR-122 among 
the HCC-post HCY positive group as well as the control group is shown in Figure 40. 
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Figure 39 The relative expression ofmiR-122 as appears in the urine of HCC-post HCY positive patients 
relative to the control. 
A B 
-W~~4+~H4++~hH++--~~~~hH++~HH 
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Figure 40 Real-time PCR amplification of miR-122 and 5SrRNA in the HCC-post HCY positive and 
control groups. The 5SrRNA was also amplified for normalization. A) PCR quantification curve. B) Melt 
curve. The experiment was carried out in duplicate to avoid the reading error of the PCR machine. -
5SrRNA (HCC), - 5SrRNA (Control), - miR-122 (HCC), - miR-122 (Control), 
(HCC). 
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Aberrant Methylation Profiles in the BCC-post BCV Positive Group 
The aberrant methylation of CpG islands located within the promoter regions of eight 
tumor-supressor genes (RASSFIA, APC, ASCL, E-Cadherin, SOCSl, p15, p16 and GSTPl) and 
the proto-oncogene c-myc was studied using methylation sensitive restriction enzyme PCR. 
Trans-renal DNA, isolated from the HCC-post HCV positive group, was digested with Dpnl or 
Aci!, followed by end-point PCR. All the tested genes were amplified before digestion and 
GAPDH was amplified before and after digestion as an internal control for the digestion process. 
In the HCC-post HCV positive group, aberrant methylation ofTSGs as well as the c-myc 
were characteristic events, but with some variations in the methylation pattern (Table 13). The 
mean number of the methylated TSGs was 4.75. Twenty nine patients (91%) showed 
hypermethylation of 4 or more TSGs. Three hypermethylated TSGs were observed in only one 
patient, whereas two patients (6%) showed hypern1ethylation of only one TSG. The most 
frequently methylated TSGs were: RASSFIA (94%), p16 (72%), ASCL and GSTPI (59%), APC 
and SOCS-l (53%). E-Cadherin and p15 were hypermethylated in less than half of the patients 
(40% and 44%, respectively). On the contrary, c-myc was hypomethylated in 26 out of 32 HCC-
post HCV positive patients (81 %). Figure 41 is the representative gels showing the different 
methylation patterns among HCC-post HCV infected patients. The complete digestion patterns 
are shown in appendix F 1. 
The number of hypermethylated TSGs positively correlated to the levels of uaNA in the 
HCC-post HCV positive group (/= 0.7661; p=O.OOOI) (Figure 42). Patients with four or more 
hypermethylated TSGs and a hypomethylated c-myc had the highest uaNA levels, reaching as 
high as 331.42 ngimL. On the contrary, in patients with low uaNA levels, namely below 70 
nglmL, hypermethylation of only two or three TSGs with a normally hypermethylated c-myc 
135 
Moemen Abdalla HCC Biomarkers 
was observed. In addition, there was a positive correlation between the levels of AFP and the 
number ofhypermethylated TSGs (/= 0.7568;p=0.0001) (Figure 43). 
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Figure 41 Representative 1.2% agarose gels showing the methylation profile of eight tumor-suppressor 
genes and the proto-oncogene, c-myc, among the HCC-post HCV infected patients. U=Uncut, C=Cut. 
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Table 13 CpG island methylation profile of eight TSG*/c-myct, urinary apoptotic nucleic acids 
and AFP levels among the HCC-post HCV positive patients 
Case # 
I Hcc 
2HCC 
3HCC 
4HCC 
5HCC 
6HCC 
7HCC 
19Hcc 
20HCC 
21 HCC 
22HCC 
23HCC 
24HCC 
25HCC 
26HCC 
27HCC 
28HCC 
29HCC 
30HCC 
hypermethy1ated 
53 40 53 59 44 72 
c-myc 
• Filled boxes, in case ofTSGs, indicate the presence of hypennethy1ation. 
t Open boxes, in case of c-myc, indicate the presence of hypomethy1ation. 
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#TSG 
5 
4 
5 
3 
5 
4 
4 
5 
5 
4 
5 
3 
4 
2 
3 
6 
5 
2 
94 59 81 
uaNA AFP 
91 1158 
177 1210 
107 220 
93 610 
71 410 
107 500 
112 250 
172 1208 
164 950 
155 1050 
145 790 
171 820 
70 120 
94 320 
45 491 
78 421 
196 1965 
171 1020 
57 179 
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Figure 42 Correlation between the number of hypermethylated TSGs and the urinary apoptotic nucleic 
acids levels among HCC-post HCY positive patients. (r2 = 0.7661 ; p=O.OOO 1). 
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Figure 43 Correlation between the number of hypermethylated TSGs and the AFP levels among HCC-
post HCY positive patients. (r2 = 0.7568; p=O.OOO 1). 
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Methylation Profiles of HeV Positive Patients with High uaNA Levels 
All the patients in the HCC-post HCY positive group and in the HCY positive group were 
sub-grouped into two groups: the high uaNA levels subgroup and the low uaNA levels subgroup. 
The sub-grouping was based on the concentration ofuaNA in the urine ofHCC patients, with the 
cutoff point being 70 ng/mL (basically the amount of uaNA that can be visualized on a 2% 
agarose gel) (Figure 44). It was hypothesized, based on the positive correlation between the . 
number ofhypermethylated TSGs and the levels ofuaNAs among the HCC-post HCY patients, 
that HCY positive patients with uaNA levels greater than or equal to 70 ng/mL were developing 
HCC or had developed HCC but were not yet diagnosed. To test this hypothesis, the aberrant 
methylation profiles of the previously discussed TSGs/c-myc was studied among the HCY 
positive patients with high (:2: 70 ng/mL) uaNA levels. Among the 40 HCY positive patients with 
high uaNA levels, 36 patients showed various aberrant methylation patterns (Table 14). The 
mean number of hypermethylated TSGs was 3.42. Notably, 75% of the patients were 
experiencing hypermethylation of three or more TSGs. Five patients (12.5%) showed 
hypermethylation of two TSGs; one patient (2.5%) showed hypermethylation of only SOCSI. 
Four patients (10%) did not show any aberrant methylation for the tested TSGs. The most 
frequently methylated TSGs were: pl6 (65%), RASSFIA (62.5%), SOCS-1 (55%), and GSTP1 
(50%). The rest of the TSGs were suppressed in less than half of the patients: pI5 (35%), ASCL 
(30%), APC (28%), and E-Cadherin (17.5%). Furthermore, 70% of the HCY positive patients 
with high uaNA levels showed c-myc hypomethylation. Figure 45 is the representative gels 
showing the different methylation patterns among HCY infected patients with high apoptotic NA 
levels. The complete digestion patterns are shown in appendix F2. 
The levels ofuaNA positively correlated with the number ofhypennethylated TSGs (/= 
0.7368; p=O.OOOl) (Figure 46). To validate the positive correlation between the number of the 
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hypennethylated TSGs and the levels of uaNA, CT scan results as well as AFP levels were 
updated for all the HCV positive patients after two years of sample collection. It should be noted 
that all the patients within the HCV positive group exhibited AFP levels below the diagnostic 
HCC cutoff value at the time of initial sample collection (i.e. 400 ng/L) (Bruix, 2001). Two years 
later, AFP levels were found to be elevated in 30 patients with high uaNA levels, who also tested 
positive for HCC by CT scan. One patient (patient #7) showed AFP levels below the HCC 
diagnostic value but had a positive CT scan result. Nine patients had AFP levels below the HCC 
diagnostic cutoff value and had a negative CT scan result. Moreover, all the patients with AFP 
levels above the HCC diagnostic cutoff value and a positive CT scan result had three or more 
hypennethylated TSGs. The AFP levels (updated two years after sample collection) positively 
correlated to the number of hypennethylated TSGs (/=0.6934; p=O.OOOl) (Figure 47). There 
was no correlation between the AFP levels (at the time of sample collection) and neither the 
uaNA levels nor the number of the hypennethylated TSGs. 
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Figure 44 A Histogram showing the sub-grouping of the patients within the HCC-post HCV positive 
group and the HCV positive group (mean ± CI). Sub-grouping was based on the lowest apoptotic DNA 
conc. could be visualized on a 2% agarose gel within the HCC-post HCV positive group. The cutoff point 
was set to be::; 70 ng/m!. (CI: Confidence Interval). 
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Figure 45 Representative 1.2% agarose gels showing the methylation profile of eight tumor-suppressor 
genes and the proto-oncogene, c-myc, among HCV infected patients with high apoptotic NA levels. A 
U=Uncut, C=Cut. 
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Table 14 CpG island methylation profile of eight TSG*/c-myct, urinary apoptotic nucleic acids 
and AFP levels in HCV positive sub-group with high apoptotic NA levels 
%of 
hyper methylated 27.5 17.5 55 50 35 65 
' Filled boxes, in case ofTSGs, indicate the presence ofhypennethylation. 
t Open boxes, in case of c-myc, indicate the presence of hypomethylation. 
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Figure 46 Correlation between the number of hypermethylated TSGs and the urinary apoptotic nucleic 
acids levels in the HCY positive group with high levels of urinary apoptotic nucleic acids. (r2 = 0.7368; P 
= 0.0001). 
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Figure 47 Correlation between the number of hypermethylated TSGs and the AFP levels among HCY 
positive patients with levels of urinary apoptotic nucleic acids. (r2 = 0.6934; p=O.OOO I). 
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Aberrant Methylation Profile among HCV Positive Patients with Low uaNA Levels and 
Control Groups 
To evaluate the possibility of using uaNA levels greater than or equal to 70ng/mL as 
diagnostic method for HCC, the aberrant methylation of the 8 TSGs/c-myc was studied among 
the HCY patients with uaNA levels lower than 70 ng/mL (Table 15). The frequency of the 
hypermethylated TSGs was low, with a mean number of 1.35 genes among HCY positive 
patients with low uaNA levels. Furthermore, c-myc was hypomethylated among 6% of these 
patients. Figure 48 is the representative gels showing the different methylation patterns among 
HCY infected patients with low apoptotic NA levels. The complete digestion patterns are shown 
in appendix F3. There were no aberrant methylation events detected in the control group. Figure 
49 is the representative gels showing the different methylation patterns among the control group. 
The complete digestion patterns are shown in appendix F4. 
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Figure 48 Representative 1.2% agarose gels showing the methylation profile of eight tumor-suppressor 
genes and the proto-oncogene, c-myc, among HCV infected patients with low apoptotic NA levels. A 
U=Uncut, C=Cut. 
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Table 15 CpG island methylation profile of eight TSG*/c-myct, urinary apoptotic nucleic acids 
and AFP levels among HCV positive sub-group with low apoptotic NA levels as a negative 
control for HCC preclinical diagnosis 
APC E-Cadherin SOCS-l 
6 o 18 41 26 
• Filled boxes, in case ofTSGs, indicate the presence ofhypennethylation. 
t Open boxes, in case of c-myc, indicate the presence of hypomethylation. 
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Figure 49 Representative 1.2% agarose gels showing the methylation profile of eight tumor-suppressor 
genes and the proto-oncogene, c-myc, among HCV infected patients with low apoptotic NA levels. A 
U=Uncut, C=Cut. 
Correlation between uaNA Levels and AFP Levels 
Finally, we checked the AFP levels among the HCC-post HCY and HCY positive 
patients. The levels of AFP positively correlated to the uaNA levels within the HCC-post HCY 
group (/= 0.7739, p = 0.0001) (Figure 38), suggesting that the patients with higher degrees of 
HCC development have higher uaNA levels. It is not surprising that the HCC patients had 
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significantly high concentrations of uaNAs because published reports suggested that cancer 
patients generally have more circulating nucleic acids (Leon et aI., 1977 and Shapiro et aI. , 
1983). However, it was interesting to find out that among the HCY positive patients the uaNA 
levels significantly correlated to the AFP levels (;'=0.8228; p=O.OOOI) (Figure 50). On the other 
hand, among control individuals and HCY positive patients with low uaNA levels, such 
correlations were not found. 
400 
350 • 
• 
:g 300 
(J 
~ 250 I~ 200 150 
! 
:; 100 
50 
0 
0 500 1000 1500 2000 2500 
AFPlevels (ng/L) 
Figure 50 Correlation between AFP levels and the urinary apoptotic nucleic acids levels among HCV 
positive patients with high levels of urinary apoptotic nucleic acids. (r2 = 0.8228; p=O.OOO 1). 
Diagnostic value of high uaNA levels for detection of HCC in high-risk HCV infected group 
The diagnostic value of uaNA levels, more than or equal 70 ng/mL, in detecting HCC in 
high-risk HCY infected patients was evaluated according to the AFP levels and the CT scan 
results updated two years after sample collection. Urinary apoptotic nucleic acid levels with a 
cutoff value of more than or equal 70 ng/mL showed a specificity of 76% and a sensitivity of 
86% with an overall diagnostic accuracy of 81 % for early detecting HCC in high-risk HCY 
infected patients. 
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Micro-RNA-Based BCC biomarker approach 
Micro-RNA Microarray Expression Profiles among HCC-post HCV Positive, HCV Positive 
and Control Groups 
Micro-RNA was isolated using the miRNA purification Kit (Norgen Biotek, Thorold, 
ON, Canada) from urine samples pooled from the three groups participating in this project (i.e. 
HCC post HCY positive group, HCY positive group and Control group). The quality and the 
quantity of the isolated miRNA were tested using the Agilent RNA 6000 Kit (Figure 51). The 
RNA concentrations in the HCC post HCY positive group, HCY positive group and the control 
group were 82 ng/j.lL, 148 ng/j.lL and 30 ng/j.lL, respectively. 
Differential expression analysis of miRNA isolated from pooled urine samples was done 
usmg the Illumina MicroRNA Expression Profiling Assay, which includes 470 miRNAs 
described in the miRBase database v9.15 and 265 potential miRNAs identified in a RAKE 
analysis study (Berezikov et. aI., 2006a, 2006b). The signal intensity of each gene in the HCC-
post HCY positive group and the HCY positive group was normalized against its equivalent in 
the control group (Figure 52). After calculating the fold change in the expression of different 
miRNAs in the HCC-post HCY positive group and in the HCY positive group relative to the 
control group, miR-152, miR-486, miR-219, miR452, miR-425, miR-154 and miR-31 were 
significantly up-regulated only among chronic HCY patients. Furthermore, miR-640, miR-765, 
miR-200a, miR-521 and miR-520 were significantly up-regulated only in the HCC-post HCY 
positive group, relative to their expression (or lack thereof) in the control group. MiR-453 and 
miR-61O were expressed relatively weakly in the control group, but their expression was 
markedly increased in the HCC-post HCY positive group. It should also be noted that miR-486 
and miR-219 (up-regulated among the HCY positive group) were found to be down-regulated in 
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the HCC-post HCV positive group. The opposite was true for the expression levels of miR-765, 
miR200a and miR-610, which were significantly up-regulated in the HCC-post HCV group but 
were down-regulated in the HCV positive group (Figure 53A). Moreover, miR-323, miR-449, 
miR-502d, miR-92b, miR-516-5p and miR-650 were found to be commonly down-regulated in 
both the HCC-post HCV positive group and in the HCV positive group relative to the control 
group. Finally, miR-335, miR-618, miR-625, miR-532, miR-7 were found to be commonly up-
regulated in both the HCC-post HCV positive group and in the HCV positive group relative to 
the control group (Figure 53B). Scanning the TargetScan and MiRanda databases (Griffiths-
Jones et aI., 2006) revealed that the commonly up-regulated miRNAs (miR-625, miR-532 and 
miR-618) were likely playing a significant role in the development of HCC among high risk 
HCV positive patients. The methyl-CpG binding domain protein 2 gene (MBD2) is likely to be 
targeted by miR-625. MiR-532 likely targets DNA ligase I (LIG 1), whereas, the putative target 
ofmiR-618 was found to be the low density lipoprotein-related protein 12 (LRPI2). 
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Figure 51 Qualitative analysis of the RNA isolated from urine samples pooled from the HCC-post HCY 
positive group, HCY positive group and Control group using Agilent Bioanalyzer 2100. The dotted 
rectangle is indicating the isolated urinary miRNA. 
150 
Moemen Abdalla 
A 
HCVpooled 
Co n1r01 pooled 
HCCpooled 
B 
HCVpooled 
Co n 1r01 pooled 
HCC pooled 
HCC Biomarkers 
'100.00 
80.00 
60.00 
40.00 
20.00 
0.00 
-20.00 
-40.00 
-&>.00 
~------------ ------------~~----------- -----------~ 'Y 'Y 
·80.00 
·100.00 
miRNAs down-regulated in HCC-post HCV 
positive and HCV-positive patients 
miRNAs up-regulated in HCC-post HCV 
positive and HCV-positive patients 
Figure 52 Heat map of miRNA expression in HCC-post HCY positive, HCY positive and Control group. 
A) MiRNA up-regulated in HCC-post HCY positive and HCY positive group. B) MiRNA de-regulated in 
both HCC-post HCY positive and HCY positive group relative to the control group. The signal intensity 
from each miRNA tested in either the HCC or the HCY groups was normalized against its equivalent in 
the control group. 
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Figure 53 Relative miRNA expression levels (Fold change) among HCC-post HCV positive and HCV 
positive. A) MiRNA up-regulated in HCC-post HCV positive and HCV positive group. B) MiRNA 
deregulated in both HCC-post HCV positive and HCV positive group. The bars indicate the relative 
abundance of each miRNA (ratio of the signal intensities of the differentially expressed miRNA in HCC 
and HCV pooled sample to the signal intensities of the differentially expressed miRNA in the Control 
pooled sample). (Blue bars indicate the miRNAs expressed in HCV positive patients whereas the red bars 
indicate the miRNAs expressed in HCC-post HCV positive group). 
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Validation of miR-625, miR-532, miR-618, miR-516-5p and miR-650 Deregulation among 
HCC-post HCV Positive Patients using qRT-PCR 
Five of the miRNAs, three up-regulated miRNAs (miR-625, miR-532 and miR-618) and 
two down-regulated miRNAs (miR-516-5P and miR-650) whose levels were significantly 
different in the urine pooled from the HCC-post HCY positive group relative to the control 
group, were studied as potential HCC biomarker(s) because their putative targets had a role in 
cancer development. In order to evaluate their potential as biomarkers, the relative expression 
levels of these miRNAs were examined among patients in the HCC-post HCY positive group 
using qRT-PCR. Each gene was normalized against the 5SrRNA for both the HCC-post HCY 
positive and the control group. The relative expression of each miRNA was calculated as a fold 
difference of expression using the equation T~Ct (target miRNA) HCY / T~Ct (target miRNA) Control. 
Differences in the expression levels of miRNAs between the groups were considered significant 
when there was a three or more fold difference in expression and the p value was less than 0.05 
(Figure 54, Table 16). 
MiR-625, miR532 and miR-618 were found to be significantly up-regulated in 56%, 
62.5% and 72% of HCC-post HCY positive patients, respectively (i.e. 18, 20 and 23 of 32 
patients). Moreover, miR-516-5p and miR-650 were found to be significantly down-regulated in 
50% and 72% of HCC post HCY positive patients, respectively (i.e. 16 and 23 of 32 patients). 
Figure 55 shows the relative expression levels of the examined miRNAs, expressed as the fold 
difference in expression level relative to the control, among HCC-post HCY positive patients. 
Typical quantitative Real-time PCR amplification results for miR-625, miR-532, miR-618, miR-
516-5p and miR-650 in the HCC-post HCY positive group and the control group are shown in 
Figures 56, 57, 58, 59, 60 and 61. 
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Figure 54 A Volcano Plot graphs the log2 for the fold difference in A) miR-625, B) miR-532, C) miR-
618 D) miR-516-5p and E) miR-650 expression versus its p value from the t-test among HCC-post HCV 
positive group. The black line indicates a fold change in gene expression of 1. The pink lines indicate the 
desired fold difference in miRNA expression threshold (3). The blue line indicates the desired threshold 
for the p value of the t-test (P < 0.05). Samples with a significant miRNA deregulation (dotted oval) were 
chosen at a fold difference 2: 3 and p < 0.05 . 
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Table 16 The fold difference and the p values for the expression of miR-625, miR-532, miR-618, 
miR-516-5p and miR-650 among HCC-post HCV positive patients using qRT-PCR. 
22 HCC 
23 HCC 
24 HCC 
25 HCC 
Highlighted cells indicate the patients who are showing either significant up-regulation or down-regulation of 
studied miRNAs 
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Figure 55 The fold difference for the expression of A) miR625 , miR-532 and miR-618 and 8) miR-516-
5p and miR-650 among HCC-post HCY positive patients using qRT-PCR. Fold difference was calculated 
using the equation 2-LlCt (miRNA) HCC / 2-LlCt (miRNA) Control. MiR-625, miR-532 and miR-618 were found to 
be significantly up-regulated in 18, 20, and 23 out of32 patients, respectively. Moreover, miR-516-5p and 
miR-650 were found to be significantly down-regulated in 16 and 23 out of 32 patients, respectively. 
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A B 
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Figure 56 Real-time PCR amplification of miR-625 and 5SrRNA among the HCC-post HCV positive 
patients. The 5SrRNA was used for normalization. A) PCR quantification curve. B) Melt curve. The 
experiment was carried out in duplicate to avoid the reading error of the PCR machine. - 5SrRNA, -
miR-625 . 
A - B 
Figure 57 Real-time PCR amplification of miR-532 and 5SrRNA among the HCC-post HCV positive 
patients. The 5SrRNA was used for normalization. A) PCR quantification curve. B) Melt curve. The 
experiment was carried out in duplicate to avoid the reading error of the PCR machine. - 5S rRNA, -
miR-532. 
A - B 
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Figure 58 Real-time PCR amplification of miR-618 and 5SrRNA among the HCC-post HCV positive 
patients. The 5SrRNA was used for normalization. A) PCR quantification curve. B) Melt curve. The 
experiment was carried out in duplicate to avoid the reading error of the PCR machine. - 5SrRNA, -
miR-618. 
157 
Moemen Abdalla HCC Biomarkers 
A B 
·100 1--0-<-'--_ ......... _ ................. __ ....... ____ ........................... _._ ........ _ 
~ ~ W U M M ~ ro n ~ • M W ~ M U ~ • ~ M 
Figure 59 Real-time PCR amplification of miR-516-5p, miR-650 and 5SrRNA among the HCC-post 
HCY positive patients. The 5SrRNA was used for normalization. A) PCR quantification curve. B) Melt 
curve. The experiment was carried out in duplicate to avoid the reading error of the PCR machine. - 5S 
rRNA, - miR-516-5p, - miR-650. 
A B 
Figure 60 Real-time PCR amplification of miR-516-5p, miR-650 and 5SrRNA among the control 
individuals. The 5SrRNA was used for normalization. A) PCR quantification curve. B) Melt curve. The 
experiment was carried out in duplicate to avoid the reading error of the PCR machine. - 5S rRNA, -
miR-516-5p, - miR-650 and - 5SrRNA (-RT). 
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Figure 61 Real-time PCR amplification of miR-625, miR-532, miR-618 and 5SrRNA among the control 
individuals. The 5SrRNA was used for normalization. A) PCR quantification curve. B) Melt curve. The 
experiment was carried out in duplicate to avoid the reading error of the PCR machine. - 5S rRNA, -
miR-625, - miR-532, - miR-618 and miR-532 (-RT). 
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qRT-PCR Screening of the Expression of miR-618 and miR-650 among High-Risk HCV 
Positive Patients 
Since the deregulation of expreSSIOn of miR-618 and miR-650 appeared to be a 
characteristic event among HCC patients, with 72% of HCC-post HCY positive patients 
exhibiting this deregulated pattern of expression, the expression levels of miR-618 and miR-650 
were examined among the 74 HCY positive patients using qRT-PCR in order to evaluate the 
potential of using these aberrant miRNA expression signatures as a HCC biomarker. MiR-618 
was significantly (three or more fold difference in expression levels and a p value of the student 
t-test lower than 0.05) up-regulated in 35 of the 74 HCY positive patients (Figure 62A), while, 
miR-650 was significantly down-regulated in 42 of the 74 HCY positive patients (Figure 62B). 
Figure 63 shows the relative expression levels of miR-618 and miR-650, expressed as the fold 
difference in expression levels relative to the control, among HCY positive patients. A typical 
quantitative Real-time PCR amplification of miR-618 in the HCC post HCY positive group is 
shown in Figure 64. 
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Figure 62 A Volcano Plot graphs the log2 for the fold difference in A) miR-618 and B) miR-650 
expression versus its p value from the t-test among Hev positive patients, The black line indicates a fold-
difference in gene expression of 1, The pink lines indicate the desired fold-change in gene expression 
threshold (3). The blue line indicates the desired threshold for the p value of the t-test (p < 0.05). Samples 
with a significant miRNA deregulation (dotted oval) were chosen at a fold change ~ 3 and p < 0,05 , 
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A 
B 
Figure 63 MiR-6l8 and miR-650 expression levels (Fold difference) among the HCY positive patients 
using qRT-PCR. A Histogram showing the fold difference in the expression of A) miR-6l8 and B) miR-
650 among the HCY positive patients. Fold difference was calculated using the equation 2-ilCt (miRNA) HCY 
/ 2-ilCt (miRNA) Control. MiR- 618 was found to be significantly up-regulated in 35 out of 74 patients, 
whereas miR-650 was found to be significantly down-regulated in 42 out of74 patients. 
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Figure 64 Real-time peR amplification of miR- 618 and miR-650 among the HeV positive patients. The 
5SrRNA was also amplified for normalization. A) peR quantification curve. B) Melt curve. The 
experiment was carried out in duplicate to avoid the reading error of the peR machine. - 5SrRNA, -
miR-618, - miR-650, 
B2, A4 and B4: 49-74. 
miR-650 (-RT) and - 5SrRNA (-RT). AI, Bl, A3 and B3: Samples 1-48. A2, 
Diagnostic Value ofmiR-618 and miR-650 for the Detection ofHCC among High-Risk 
Hev Infected Patients 
To evaluate the potential of using aberrant expreSSlOn of miR-618 and miR-650 for 
diagnostic purposes, the medical records, specifically AFP levels and CT scan results, of all 
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HCY positive patients were updated two years after initial sample collection. It should be noted 
that all HCY positive patients were diagnosed as being HCC-free (AFP level lower than 400 
ng/L and a negative CT scan) at the time of initial sample collection. The specificity, sensitivity 
and the diagnostic accuracy of miR-618 up-regulation and miR-650 down regulation (separately 
or in tandem) for diagnosing HCC were determined, based on the updated medical records of 
HCY patients. The following criteria were applied: patients with AFP levels of 400 ng/L or 
more, with a positive CT scan, and exhibiting significant deregulation of either miR-618 or miR-
650 expression, or deregulation of both, were considered true positives; patients whose AFP 
levels were 400 ng/L or more, with a positive CT scan, and not exhibiting significant 
deregulation of any of the miRNAs (either separately or in tandem) were considered false 
negatives; patients with AFP levels lower than 400 ng/L, with a negative CT scan, and exhibiting 
significant deregulation of miR-618 or miR-650 expression, or deregulation of both, were 
considered false positives; and finally, samples with AFP levels lower than 400 ng/L and not 
exhibiting significant deregulation of either miR-618 or miR-650 expression, or deregulation of 
both, were considered true negatives. 
By applying the abovementioned criteria (also in Table 17), the sensitivity and the 
specificity of miR-618 up-regulation for detecting HCC among HCY positive patients, based on 
AFP levels and CT scan results, were 64% and 68%, respectively with a 66% diagnostic 
accuracy. Whereas, the sensitivity and the specificity of miR-650 down-regulation for detecting 
HCC among HCY positive patients were 72% and 58%, respectively with a 65% diagnostic 
accuracy. Additionally, the sensitivity and the specificity of tandem deregulation ofmiR-618 and 
miR-650 expressions for detecting HCC were 58% and 75%, respectively with a diagnostic 
accuracy of 69%. There was no correlation between the relative expression of miR -618 or miR-
650 and AFP levels. 
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Table 17 Thefold difference, p values for the expression ofmiR-618, miR-650 as well as the 
AFP levels among the RCV positive patients using qRT-PCR (nn True Positive, • False Positive, 
II False Negative and 0 True Negative) 
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Table 17contd Thefold difference, p values for the expression ofmiR-618 as well as the AFP 
levels among the HCV positive patients using qRT-PCR (wt True Positive, _ False Positive, IIIIl 
False Negative and D True Negative) 
Sample 
HCV38 
HCV39 
HCV40 
HCV41 
HCV42 
HCV43 
HCV44 
HCV45 
HCV46 
HCV47 
HCV48 
HCV49 
HCV50 
HCV51 
HCV52 
HCV53 
HCV54 
HCV55 
HCV56 
HCV57 
HCV58 
HCV59 
HCV60 
HCV61 
HCV62 
HCV63 
HCV64 
HCV65 
HCV66 
HCV67 
HCV68 
HCV69 
HCV70 
HCV71 
HCV72 
HCV73 
HCV74 
Fold difference miR-618 
(HCV IControl) p Value 
165 
Fold difference miR-650 
(HCV IControl) PValue 
AFP 
546 
187 
365 
1279 
164 
51 
73 
126 
8 
846 
247 
452 
11 
24 
4 
156 
298 
165 
557 
67 
147 
324 
245 
846 
71 
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Discussion 
In the field of cancer research and detection, a biomarker is a substance or a process that 
is indicative of the incidence of cancer. A biomarker may be a macromolecule secreted either by 
the cancer itself or as a specific response of the body to the presence of cancer. Advances in 
molecular biology techniques have assisted in the detection of biomarkers from conventional 
sources, such as blood and body fluids, and from non- conventional sources, such as saliva and 
urine (Srinivas et aI., 2001). Macromolecules secreted by tumor tissue and not by non-tumor 
tissue, which are easily and cheaply detectable in serum or urine are ideal biomarkers because 
the cancer is detected specifically and non-invasively (Pepe et al., 2001). The goal of cancer 
screening is to diagnose tumors at an early stage of disease progression, when treatment is more 
likely to be successful. Furthermore, the screening tool must be suitably non-invasive and 
economical to allow widespread applicability (Pepe et al., 2001). 
Given the heterogeneity of the cancerous cells found in many cancer types, it is likely 
that no single biomarker will be able to provide enough sensitivity and specificity to be useful as 
an early detection screening assay. An alternative strategy is to develop a panel of biomarkers 
that can result in better diagnostic accuracy. When designing a panel of biomarkers, one factor 
that has to be taken into consideration is the diversity of biomarkers. Namely, the chosen 
biomarkers should reveal changes in different, independent tumorigenesis pathways because a 
panel of biomarkers that comes from the same or associated pathways is unlikely to be more 
reliable than individual use of these biomarkers, as factors that contribute to their deregulation 
are likely to be the same (Wagner et al., 2004). The problems associated with single based 
biomarkers are exemplified by the use of Prostate-specific antigen (PSA) as a tumor marker for 
prostate cancer. PSA has a relatively low specificity because its concentrations can be high in 
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both cancer and benign conditions (Perrotti, 2001). Moreover, a-fetoprotein levels, a marker for 
hepatocellular carcinoma (HCC) in patients with chronic liver disease, are normal in many 
patients with only small tumors (Izzo et at., 1999). The unreliability of these biomarkers has 
dictated the search for more specific molecular signatures. 
Hepatocellular carcinoma is the 6th most common neoplastic disease and the 3rd most 
common cause of cancer-related mortality worldwide (Parkin et ai., 2005). Approximately 
600,000 deaths per year, worldwide, are due to HCC (Parkin et al., 2005). Chronic infections 
with hepatitis B virus (HBV) and/or hepatitis C virus (HCV) are the major risk factors for 
developing HCC. Since an effective HBV vaccine is available, incidence of HBV-associated 
HCC is now significantly falling (Lee and ko, 1997). On the contrary, a similarly effective 
vaccine for the prevention of HCV infection is currently unavailable and approximately 130 
million HCV positive cases are found worldwide (Moradpour and Blum, 2005). Most HCV 
infected patients remain asymptomatic for years. The long latency between HCV infection and 
HCC development provides an important window period during which the infected individuals 
can be monitored for disease progression and can be treated by effective interventions (Steel et 
at., 2001). 
The major, potentially curative, form ofHCC therapy is still surgical resection; however, 
only 10% of HCC patients can be treated by this method after diagnosis of HCC. This is mainly 
due to the absence of reliable tools for early diagnosis of HCC. The most reliable method for a 
definite HCC diagnosis is liver biopsy; however, it is costly and usually associated with a risk of 
patient injury (He et ai., 2008). Moreover, the widely used serological tumor markers, such as a-
fetoprotein (AFP), lack the required specificity and sensitivity for the early detection of HCC 
(Johnson, 2001). HCC patients are usually diagnosed at late stages of disease progression and, 
hence, are not suited for either surgical interventions or other effective treatments (He et al., 
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2008). Therefore, identifying an effective biomarker(s) with high sensitivity and specificity for 
diagnosing HCC that is appropriate for large-scale clinical investigations would be highly 
beneficial. 
Urinary cancer biomarkers have been of great interest in the field of diagnostics 
throughout the 20th century and the early 21 sl century (Pisitkun et ai. , 2006). Urinary biomarkers 
offer a great opportunity for the development of novel, non-invasive assays for the diagnosis, 
monitoring and early detection of both renal and systemic diseases (Pisitkun et ai., 2006). 
Because urine is a filtrate of blood, it contains protein components similar to those found in the 
blood. Therefore, changes in the urinary proteome may be useful to detect not only kidney and 
urogenital tract disorders but also systemic disease (Barratt and Topham, 2007). Recent reports 
have identified urinary biomarkers that can predict acute pancreatitis (Comte et ai., 2006), early 
ovarian cancer (Chambers and Vanderhyden, 2006) and non-smaIl-cell lung cancer 
(Tantipaiboonwong et at., 2005). It is highly possible that urine will be used in the future to screen 
for a number of systemic disorders, the majority of which will have no or limited renal 
involvement (Barratt and Topham, 2007). 
Besides the presence of proteins and peptides in urine, circulating nucleic acids have also 
been detected in urine (Botezatu et ai., 2000). The content of DNA in plasma appears to be a sign 
of the amount of dead cells in the whole body and it also increases during harsh pathological 
processes, including cancers (Fournie et ai., 1993). Tumor-specific patterns were detected in 
DNA, isolated from urine of patients with tumors of different localization (Su et ai., 2004). The 
obvious advantage of urine sampling makes urine a useful source ofNA for the development of a 
non-invasive cancer assay. However, cell-free NA in urine has been, until now, poorly explored 
and its low concentration limits its use in diagnostics (Bryzgunova et ai. , 2006). 
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Therefore, in this study, urine was investigated as a source for identifying promising 
biomarkers for the early detection of HCC among high-risk HCV infected population. Before 
commencing with our biomarker discovery study, we developed a standardized protocol for the 
isolation and the purification of nucleic acids and proteins from the smallest urine volume using 
silicon carbide (SiC)-loaded spin columns. Our optimized protocol for the purification of total 
proteins from urine is faster and easier than other urinary protein purification methods (acetone 
precipitation and ultracentrifugation) (Thongboonkerd et ai., 2002). Most of the urinary proteins 
purification methods require large urine volume whereas our optimized method requires a urine 
input of not more than 2 mL. Moreover, our optimized protocol does not require any filtration or 
centrifugation steps before protein purification. In the presence of adequate protein preservatives 
(protease inhibitor cocktail and EDT A), urine can be stored for a long time at room temperature 
which facilitates the storage of the urine samples, in case of designing long-term studies. In 
addition to the optimized protein purification protocol, we have also developed a standardized 
protocol for the isolation of trans-renal nucleic acids. The quality of the isolated DNA was 
examined thoroughly by amplifying both the K-ras gene as well as the Y -chromosome gene. 
Furthermore, the protocol used for the isolation of the trans-renal DNA was optimized to be done 
from 1-2 mL of urine. 
Based on our optimized purification protocols, the identification of promising urinary 
HCC biomarker candidates were done through two approaches: a urinary proteomic-based HCC 
biomarker approach and a genomic-based HCC biomarker approach. The genomic-based HCC 
biomarker approach was further subdivided into Trans-Renal Nucleic Acid-based and miRNA-
based HCC biomarker approaches. 
169 
Moemen Abdalla HCC Biomarkers 
Proteomic-Based HCC Biomarker Approach 
Proteomic analysis ofliver tissues and sera of patients with Hee-post HeV infection has 
been used to identify new biomarkers that are able to predict Hee development at earlier stages, 
leading to more effective treatment (Yokoyama et ai., 2004 and Y oon et ai., 2004). In this 
approach, we used the shotgun "bottom-up" proteomic approach to identify promising biomarker 
candidates from the urinary proteins purified from the Hee-post Hev infected group and the 
Hev positive group. 
The mean concentrations of total urinary proteins purified from patients in the Hev 
positive group and the Hee-post Hev group were higher than that of the control group, with the 
difference in mean protein concentrations, relative to the control group, being more pronounced 
for patients in the Hee-post Hev group. This was expected due to the complexity of the cancer 
proteome which contains a variety of information that were gathered from almost all the 
biological activities that take place in cancer cells (Alaoui-Jamali and Xu, 2006). Additionally, 
varying concentrations of total urinary proteins were observed among patients that were part of 
the same groups and these were indicative of the variability of disease outcome. These variations 
were apparent when the total urinary proteins were separated on SDS-PAGE gels. However, the 
protein patterns of some samples that were acquired from patients in the Hee-post Hev positive 
group (1, 9, 18, 20, 21, 25, 26, 27 and 30) appeared similar to those acquired from patients in the 
Hev positive group (11, 12,23-25,33-38, 40-43,48,52-60 and 74). These similarities represent 
a possible common proteomic outcome for patients infected with Hev and patients who had 
developed Hee as a consequence of He v infection. 
Nine bands, commonly present in protein isolates of Hee-post Hev infected patients, 
but not among those of control individuals, were excised from the ID SDS-PAGE gel. Albumin 
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is the most abundant protein in serum, while Tamm-Horsfall protein (Uromodulin) is normally 
the most abundant soluble protein in urine (Wright et al., 2005 and Serafini-Cessi et al., 2003). 
Not surprisingly, both proteins were detected in the examined samples by the MALDI-TOF-MS 
analysis, which identified albumin in three different bands and Uromodulin in another band. The 
relative abundances of both Albumin and Uromodulin are thought to mask many other proteins 
that may be of potential use as biomarkers (Poon and Johnson, 2001 and Pisitkun et al., 2004). 
As expected, the abundance of these two proteins in the urine of HCC-post HCV infected 
patients hindered the detection of any new promising biomarker candidates. Depleting these 
abundant proteins from urine seemed like a possibility (McDonald and Yates, 2002), but 
unfortunately some of them function as carriers or transporters and their depletion may result in 
the loss of other, potentially important, proteins (Mehta et al., 2003). 
Another normal constituent of urinary proteins (Wakui et al., 1989), ' complex forming 
glycoprotein HC, was identified among the examined bands. Additionally, Alpha-I-acid 
glycoprotein (AGP), which is synthesized and secreted by hepatocytes, was also identified. AGP 
is considered a natural anti-inflammatory and immuno-modulatory agent (Fournier et al., 2000) 
and since all the patients participating in this study were infected with HCV, the presence of 
AGP in their urine was expected. During HCV infection many cytokines are over-produced, 
especially interferons (a, ~, and y) and interleukin-12 (Sun and Ran, 2004). This over-production 
is usually accompanied by a high necro-inflammatory activity in the liver of HCV infected 
patients (Sun and Ran, 2004), thus AGP production may act to reduce this necro-inflammatory 
response and to modulate the host immune response against HCV, which might be more 
destructive than protective. 
Immunoglobulin lambda light and Kappa chains were also among the identified proteins. 
Low levels of both immunoglobulins are normally present in the serum of healthy individuals, 
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with a ratio of 1 to 1.6, Kappa to Lambda (Abe et at. , 1998). They have also been detected in the 
urine of healthy individuals, albeit at lower levels than in serum (Abe et at., 1998). In accordance 
with the findings we obtained from our urinary protein analysis, their over-expression in HCC-
post HCV positive liver tissues has previously been reported by Kotaka et at. (2002) . 
Furthermore, the presence of Kappa/lambda (KIA) light chains in the urine of HCC-post HCV 
infected patients may be explained by their role in chromosome translocation and nucleotide 
repair, both of which may contribute to hepatocarcinogenesis (Kotaka et at., 2002). 
Since the aforementioned identified proteins were either a normal constituent of urine or 
were present as a consequence of HCV infection, they could not be used as potent and novel 
HCC biomarker candidates. The shotgun "bottom-up" proteomic approach was then applied to 
study the differential expression of proteins among the HCC-post HCV positive and the HCV 
positive patients relative to the control group. The gold standard 2D SDS-PAGE approach was 
not used for this purpose because it is labor-intensive, displays great variability and is very 
difficult to standardize, especially when analyzing large number of patients. In contrast, the 
shotgun strategy has a higher analytical sensitivity, higher sample loading capacity and offers the 
capacity for high-throughput protein identification (Feng et at. , 2006b). After subjecting the 
proteins pooled from each group to HPLC-MS/MS, 364 spectra were identified as follows: 122 
spectra from the pooled control group, 122 spectra from the pooled HCC post HCV positive 
group and 120 spectra from the pooled HCV positive group. 
A total of 24 proteins were identified when the spectra generated by the shotgun analysis 
were analyzed. Most of the proteins identified in the HCC-post HCV group and the HCV 
positive group were immunoglobulins. The presence of different immunoglobulin forms in the 
urine of HCC-post HCV group and the HCV positive group was indicative of an active immune 
response against the viral infection. One of the proteins identified in the HCV positive group was 
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Matrin 3. It is an RNA binding protein, reported to be one of the cellular proteins that interacts 
with the 3' UTR ofHCY and plays a role in HCY replication and HCY-associated pathogenesis 
(Harris et ai., 2006). More importantly, however, DJ-l, Chromatin Assembly Factor-l (p 150), 
Heat Shock Protein 60 and Stathmin 1/oncoprotein 18 were commonly identified in both the 
HCC-post HCY positive and the HCY positive group, but not in the control group. Stathmin 1, a 
major microtubule-depolymerizing protein, has been reported to be involved in cell cycle 
progression and cell motility. Stathmin 1 was found to be over-expressed in HCC patients and is 
associated with higher vascular invasion. Its over-expression has been considered to be an 
important prognostic factor for HCC, which may serve as a useful marker to predict early tumor 
recurrence (Yuan et al., 2006). Since the aim of this study was to discover novel biomarkers for 
the early detection of HCC, and not for prognosis, Stathmin 1 was excluded from further 
consideration as a suitable HCC biomarker candidate. 
As for DJ-l, it was firstly identified by Nagakubo et ai. (1997) as a novel oncogene that 
is expressed in different human tissues such as pancreas, kidney, muscle, liver, placenta and 
brain. Moreover, it was found to be over-expressed in the sera of 37% of newly diagnosed breast 
cancer patients, in primary lung tumors and in prostate cancer, indicating its association with 
cellular growth and transformation (Le Naour et ai., 2001; MacKeigan et al., 2003 and Grzmil et 
al., 2004). DJ-l functions as a pro-oncogenic protein especially when co-expressed with other 
oncogenes such as c-myc or c-ras. A recent study by Kim et al (2005b) reported that DJ-l might 
also act as a negative regulator of the tumor suppressor gene PTEN, which promotes apoptosis 
through the P13K-Akt pathway (Hammond, 2006). 
DJ-l over-expression provides a survival advantage to cancer cells by increasing the 
production of detoxification enzymes (Clements et al. , 2006). Persistent HCY infection is known 
to cause persistent endoplasmic reticulum stress, resulting in the accumulation of intra- and 
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extracellular DNA damaging factors that make the cell prone to mutagenesis. Additionally, 
transgenic mice expressing the HCY core protein showed an unusual production and 
accumulation of reactive oxygen species, which correlated with the progression of HCC 
development (Moriya et al. , 1998, 2001). HCY NS5A expression alters intracellular calcium 
levels, inducing oxidative stress and activating STAT-3 and NF-KB (Gong et al. , 2001 and Waris 
et al., 2002). DJ-l is, therefore, a pro-survival gene because it influences the expression of 
detoxification enzymes that offer protection against oxidative/endoplasmic reticulum stress 
(MacKeigan et al., 2003 and Taira et al., 2004). In light of its over-expression among HCY 
positive patients and its dual role as an oncogene and a pro-survival gene, DJ-l was our first 
HCC biomarker candidate. 
The second differentially expressed protein to be examined as a potential HCC biomarker 
candidate was the Chromatin Assembly Factor-l (CAF-l). CAF-l is a highly conserved protein 
complex that promotes nucleosome assembly (i.e. deposition of his tones H3 and H4, required for 
the progression of the S-phase of the cell cycle) on newly synthesized DNA (Ridgway and 
Almouzni, 2000 & Mello and Almouzni, 2001). Its chromatin assembly activity was associated 
with DNA repair in vitro during nucleotide excision repair (NER) (Gaillard et al., 1996) and 
repair of single strand breaks and gaps (Moggs et al., 2000). CAF-l has been found to be 
extremely down-regulated at both the RNA and protein levels upon cell cycle exit when cells 
enter the quiescent state. In cultured cells derived from breast tumors, CAF-l was found to be 
over-expressed, relative to cells from normal breast tissue. In another study that was conducted 
on clinical samples from breast lesions, a strong correlation was found between the expression of 
CAF-l and the routinely used proliferation marker Ki-67. CAF-l has been considered as a potent 
proliferation marker, since it can be used to distinguish between quiescent and proliferating cells 
(Polo et al. , 2004). In accordance with the previously mentioned correlation between CAF-l and 
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cellular proliferation, the nonnal, quiescent, hepatic stellate cells are known to proliferate when 
stimulated by liver injury and exposure to various cytokines. The activation of stellate cells is a 
key event in hepatic fibrosis (the accumulation of extracellular matrix in response to acute or 
chronic liver injury). Cirrhotic liver is the end-stage consequence of fibrosis that then develops 
into HCC (Farazi and DePinho, 2006). Thus, CAF-1 over-expression could be a promising HCC 
biomarker candidate. 
The third differentially expressed protein to be examined as a potential HCC biomarker 
candidate was the Heat Shock Protein 60 (HSP60) which belongs to the highly conserved HSP 
family. HSPs are produced in response to heat stress as well as many other fonns of stress, such 
as irradiation, hypoxia, toxic agents or infections (Lindquist and Craig, 1988). Most HSPs playa 
protective role and, hence, promote cell survival over apoptosis (Beere, 2004). Unlike other 
HSPs, HSP60 seems to have both pro-survival and pro-death functions. HSP60 was found to 
protect epithelial cells from stress-induced death by inhibiting caspase 3, which plays a central 
role in apoptosis (Zhang et at., 2004). HSP60 was found to be over-expressed in prostate cancer 
(Comford et at., 2000), colorectal cancer (Cappello et at., 2005) and cervical cancer (Castle et 
at., 2005) supporting its role as a pro-survival factor. Its anti-apoptotic effect may also be the 
result of its ability to modulate the expression of some members of the Bc1-2 family (Shan et at., 
2003). In contrast, HSP60 expression in oesophageal squamous cell carcinoma (Faried et at., 
2004) and ovarian cancer (Schneider et at., 1999) correlates positively with good prognosis. As 
an example of its role in pro-cell death functions, HSP60 was found to interact and accelerate the 
maturation of procaspase 3 in HeLa cells during apoptosis (Samali et at. , 1999). 
Based on the aforementioned evidence for the possible contribution of the selected 
candidates in the development and progression of cancer, the possibility of using DJ-1, CAF-1 
and HSP60 as HCC biomarkers among high-risk HCV infected patients was tested. They were 
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found to be over-expressed among the majority of the HCC-post HCY infected patients. The 
over-expression of these three candidate biomarkers appeared to be a characteristic event among 
HCC-post HCY infected patients. Moreover, their over-expression confirms their suggested 
contribution in the development of HCC among the HCY positive infected patients. The over-
expression of DJ-l confirms its roles as an oncogene and a down-regulator of PTEN expression, 
both of which aid the development of HCC (Hammond, 2006 and Fujiwara et ai., 2000). 
Furthermore, DJ-l over-expression, among HCC-post HCY infected patients, can also be 
attributed to its role in protection of cells against endoplasmic reticulum oxidative stress, which 
results from persistent HCY infection. As for CAF -1, its over-expression agrees with its role of 
stimulating the proliferation of quiescent cells (hepatic stellate cells) and its role in the 
development of fibrosis, cirrhosis and consequently HCC. In the case of HSP60, it was not 
studied before in the context of HCC-post HCY infection. The over-expression ofHSP60, which 
was found among HCC-post HCY infected patients, strongly suggests that HSP60 possesses a 
pro-survival function (Zhang et ai., 2004) rather than a pro-death function (Samali et ai., 1999). 
Examination of DJ-l, CAF-l and HSP60 expression levels among the HCY positive 
patients relative to the control group showed that they are significantly over-expressed in a 
number of patients, who were subsequently suspected as HCC patients. To validate the 
diagnostic value of the three candidate proteins for the detection of HCC in the high-risk HCY 
infected group, the medical records of the HCY infected patients, specifically AFP levels and CT 
scan results, were updated two years after initial sample collection. The three proteins showed 
great diversity in their ability to detect HCC among HCY positive patients. The most promising 
protein for early detection of HCC among HCY positive patients was CAF-l, which showed a 
specificity of 90%, a sensitivity of 66%, and an overall diagnostic accuracy of 78%. The positive 
predictive value (PPY) of CAF-l was 85% whereas the negative predictive value (NPY) was 
176 
Moemen Abdalla HCC Biomarkers 
74%. CAF-l over-expression correctly identified most of the true positive and the true negative 
patients, giving it a high HCC predictive value among high-risk HCY infected patients. This 
diagnostic value is a reflection of the role CAF-l plays in cellular proliferation, especially as a 
consequence of cancer development. 
According to its diagnostic value, DJ-l over-expression was the next best biomarker 
candidate, after CAF-l, for the early detection of HCC. Among HCY positive patients, DJ-l 
identified HCC with a specificity of 82%, a sensitivity of 58% and had an overall diagnostic 
value of 71 %. The PPY and the NPY of DJ-l were 75% and 67%, respectively. These values 
give DJ-l an acceptable diagnostic value for distinguishing HCC patients from normal 
individuals. Since DJ-l is not the only oncogene that contributes to the development ofHCC, as 
it might not be the only PTEN down-regulator, its diagnostic value was not as high as that of 
CAF-l, which is considered as a high proliferative factor. 
The diagnostic values of both CAF-l and DJ-l for predicting HCC in HCY infected 
patients were considered acceptable in comparison to the reported diagnostic value of the AFP 
(considered the gold standard, with a specificity and sensitivity of 75% and 68%, respectively). 
The specificity ofHSP60 was the lowest of the three candidates (42%), but its specificity was the 
highest (83%), resulting in a diagnostic value of 62%. The high sensitivity and low specificity of 
HSP60 over-expression was well reflected by its low PPY (58%) and its relatively higher NPY 
(73%). Taking all the values into consideration, HSP60 over-expression had major problems 
correctly identifying true negatives among HCY positive patients. An explanation for this trend 
is that HSP60 is over-expressed in infected hepatocytes as response to high oxidative and 
endoplasmic reticulum stress, which are caused by HCY viral proteins (HCY core and NS5A), 
therefore, it is a better indicator ofHCY than HCC. 
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In an attempt to increase the diagnostic value of the proposed HCC biomarker candidates, 
the diagnostic value for any combination of selected proteins was determined. The diagnostic 
value of the CAF-1 /HSP60 tandem was the highest among the evaluated combinations. The 
specificity and the sensitivity of CAF -lIHSP60 were 92% and 61 %, respectively, with an overall 
diagnostic value of 77%. CAF-1 /HSP60 was successful in identifying 88% of the true positive 
and 71 % of the true negative patients in the HCY positive group. The combination of all three 
candidates showed a very high specificity (95%) in detecting HCC, but also showed a very low 
sensitivity (31%), resulting in a diagnostic value of only 65%. The proteomic-based HCC 
biomarker approach identified two major biomarker candidates for the early detection of HCC 
among high-risk HCY infected populations. CAF-1 is the first proposed, single proteomic-based 
HCC biomarker, whereas CAF-1 /HSP60 tandem is the second proposed, multiple proteomic-
based HCC biomarker. Although the proposed proteomic-based HCC biomarkers showed a 
reasonable predictive value, their potential should be evaluated among a larger pool of samples 
and over a longer time interval. Moreover, since urine was used as a non-invasive sample source, 
it would be convenient to establish a non-invasive assay to be used for mass population 
screening. This should have a great impact on the early detection of HCC among HCY infected 
patients, and hence would reduce the high HCC mortality rates. 
Genomic-Based HCC Biomarker Approach 
Trans-Renal Nucleic Acids-Based BCC Biomarker Approach 
It has been observed that higher levels of DNA are found in the circulation of cancer 
patients relative to non-cancer patients (Stroun et ai., 1987 and Maebo, 1990). However, the 
patients who participated in these studies had already established cancer at the time they were 
tested; therefore, these studies could not determine the usefulness of the high circulating plasma 
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DNA levels as a biomarker for the early detection of cancer. Currently, no data are available for 
the direct use of the circulating nucleic acid levels as a preclinical diagnostic tool for the early 
detection of cancer, particularly for groups at a high-risk for developing HCC. 
The aim of this approach was to investigate the potential of using high levels of trans-
renal DNA for the early diagnosis of HCC in high risk groups. More specifically, the focus was 
placed on using the quantity of urinary apoptotic nucleic acids (low molecular weight DNA and 
RNA wrapped in apoptotic bodies) as an indicator ofHCC. As expected, the quantification ofthe 
urinary apoptotic nucleic acids (uaNA) revealed that, on average, samples acquired from HCC 
patients contained significantly higher concentrations of uaNA than those of the control group 
individuals. Furthermore, in samples acquired from HCY positive patients, the uaNA was also 
present in higher concentrations than in samples of the control group; however, this difference 
was less drastic in comparison to the observed difference between the HCC and control samples. 
The significantly high uaNA levels among HCC-post HCY patients were thought to have 
originated from a large number of liver cancer cells that underwent apoptosis. To explain further, 
the rate of apoptosis is relatively high at the beginning of cancer development due to the increase 
in the number of transformed cells, and even though the rate of apoptosis decreases at the later 
stages of cancer development, the absolute number of apoptotic cells remains to be high due to 
large tumor sizes (Tomasevic et ai., 1999 & Canman and Kastan, 1997). Therefore, this 
increased apoptotic activity is represented by both high circulating DNA levels and a large 
number of apoptotic bodies in the circulation, making their detection possible in urine of cancer 
patients (Botezatu et at., 2000). 
As the first line of defense against HCY infection, the innate immune response directly 
stimulates macrophages (Kupffer cells in the liver) and natural killer (NK) cells that cause the 
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death of infected cells. Furthennore, other mechanisms are known to be involved in the 
stimulation of apoptosis to eliminate the virus through the destruction of the infected liver cells. 
These mechanisms do not only kill the infected cells, but also kill the neighboring cells (Fischer 
et al., 2007). Therefore, the high uaNA levels among HCY positive patients may be attributed to 
the host immune response, while the high proliferative rate (i.e. cancer development) and the 
subsequent induction of apoptosis appear to be the most likely causes for the significant increase 
of the uaNA levels among HCC-post HCY patients. This, in part, explains the reasons for the 
observed high uaNA levels among both HCY infected and HCC positive groups. 
To prove that liver cells are the source of this observed uaNA, levels of miR-122 were 
examined in the urine of HCC-post HCY positive patients. There are a multitude of reasons that 
miR-122 was chosen for this purpose. Firstly, it is abundantly expressed in hepatocytes and 
constitutes approximately 70% of the total miRNA in the liver (Jopling et aI. , 2005). 
Furthennore, miR-122 was found to facilitate HCY replication as its suppression was followed 
by a significant decline in HCY replication rates (Jopling et al., 2005). Contrary to its specific 
localization in liver cells, miRNA-122 was abundantly present in the urine of HCC-post HCY 
positive patients, proving that the low molecular weight uaNA originated from liver cells that 
underwent apoptosis. 
Since uaNA levels of HCC-post HCY patients positively correlated to their AFP levels, 
the association between high uaNA levels and the development/progression ofHCC among HCY 
infected patients was examined. In particular, we investigated whether the appearance of 
epigenetic changes that contribute to the development of cancer correlated positively with uaNA 
levels. This association was explored based on the following reasoning: as the number of 
aberrant epigenetic changes increases, the cellular proliferation increases which, in tum, induces 
apoptosis, leading to high levels of DNA and apoptotic bodies in circulation and in the urine. 
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Specifically, the epigenetic silencing of known tumor suppressor genes was investigated with the 
purpose of correlating these aberrant events with the observed increase in uaNA levels of HCC 
patients. 
Aberrant hypermethylation of the CpG islands, in the promoter regIons of tumor-
suppressor genes (TSGs), is one of the epigenetic alterations that result in transcriptional 
silencing and genomic instability (Feinberg, 2004). CpG island hypermethylation is an important 
mechanism in carcinogenesis, as it is a multi-step process that has been characterized in the 
context of tumor progression (Feinberg et ai., 2006). Namely, as the number of epigenetic 
alterations in cancerous tissue increases, the histological changes worsen (Feinberg et ai., 2006). 
Moreover, the early appearance of these epigenetic changes represents a great opportunity to 
correlate them with the pathogenesis/outcome of cancer (Feinberg et ai., 2006). In 2007b, Zhang 
et ai. reported the potential of using the promoter methylation statuses ofthree ,TSGs (RASSF1A, 
p16 andp15) in DNA isolated from serum as a biomarker for the early detection ofHCC in high 
risk populations. 
Based on previously published reports, it appeared that the methylation of promoters of 
TSGs (involved in several signal transduction pathways) was a frequent event in HCC. The most 
frequent! y methylated TSGs were SOCS-l, GSTP 1, APC, E-cadherin, and p 15. When compared 
to non-tumor liver tissues, methylation of these five TSGs was specifically associated with HCC. 
Methylation of SOCS-l, GSTP1, and p 15 was also significant! y more frequent in H CC than in 
cirrhotic liver (Yang et ai., 2003). Other recent studies have also shown frequent methylation of 
SOCS-l, p15, and E-cadherin genes in Chinese and Japanese HCC (Wong et ai., 2000 and 
Yoshikawa et aI., 2001). It is likely that silencing of TSGs through promoter CpG island 
methylation plays an important role during hepatocarcinogenesis (Lee et ai., 2003b). Conversely, 
aberrant over-expression (hypomethylation) of the c-myc proto-oncogene, which has both 
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proliferative and apoptotic functions, has been reported for most human cancers (Patel et al. , 
2004). Accordingly, the aberrant methylation of eight different TSGs (SaCSl , ASCL, p16, p15, 
E-Cadherin, RASSFIA, GSTPI and APC) and the proto-oncogene c-myc was studied in the 
HCC-post HCV positive group (Table 18). 
Table 18 The relation between the tumor-suppressor genes/c-myc and Hepatocellular 
Carcinoma 
Genes selected to 
be studied 
ASCL (Apoptotic 
Speck protein-
Like) 
SOCS-1 
(suppressor of 
cytokine 
signaling) 
p15INK4B 
pl61NK4A 
RASSF1A 
Relation to Hepatocellular Carcinoma 
• ASCL was reported to be frequently methylated in HCC cell lines. 
In contrast, normal liver samples do not show any significant ASCL 
aberrant methylation (Kubo et al. , 2004). 
• Yoshikawa et al. (2001) reported an aberrant methylation of the 
CpG islands in the promoter region of the suppressor of cytokine 
signaling-l (SaCSl) gene in HCC cell lines. 
• Its methylation occurs at the hepatitis stage of disease progression, 
before the onset of HCC, and was found to correlate very well with 
liver fibrosis (Yoshida et al., 2004). 
• Aberrant methylation of CpG islands of p16 and p15 genes appears 
to be the major mechanism for their inactivation in primary HCC 
(Qin et al., 2004). 
• Silencing of p 16, which occurs through promoter hypermethylation, 
may be directly related to HCC development, since patients with 
either liver cirrhosis or hepatitis do not generally exhibit this 
aberrant suppression of p16 expression (Wong et al. , 1999). 
• The RASSFIA promoter was reported to be heavily 
hypermethylated in 80-90% of HCC tumors, indicating its 
importance in the progression of HCC (Zhang et al., 2002 and 
Zhong et al., 2003). 
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Table 18 contd. The reiation between the tumor-suppressor genes/c-myc and Hepatocelluiar 
Carcinoma 
Genes selected to 
be studied 
• 
Relation to Hepatocellular Carcinoma 
Frequent promoter methylation of GSTP 1 has been observed in the 
majority ofHCC in Chinese and Japanese populations (Tchou et aI., 
GSTP1 2000). 
APC 
(adenomatous 
polyposis coli) 
E-Cadherin 
C-myc 
• GSTP 1 methylation was significantly more frequently observed in 
HCC than in cirrhotic or normal liver (Yang et ai., 2005). 
• Methylation of APC was more frequently distinguished in HCV 
positive HCC than HCV/ HBV-negative HCC (Yang et ai., 2005). 
• E-Cadherin down-regulation in HCC occurs either by allelic deletion of 
the gene or by CpG island hypermethylation of its promoter (Kanai et 
ai., 2000 and Wei et ai., 2002). 
• Lee et ai., (2003b) have reported that E-Cadherin was methylated at a 
frequency of less than 7% in premalignant lesions, but in HCC the 
frequency of E-Cadherin methylation rose to 30%. 
• 
• 
• 
• 
Furthermore, E-Cadherin methylation has been reported to likely 
participate in the malignant transformation ofHCC (Lee et ai., 2003b). 
The c-myc proto-oncogene has been reported to be frequently over-
expressed (hypomethylated) in human cancers (Patel et ai., 2004). 
It has also has been shown to drive the quiescent cells into S phase in 
the absence of other mitogenic signals and regulate the expression of 
target genes involved in cell proliferation (Patel et ai., 2004). 
Moreover, c-myc can act as a potent inducer of apoptosis through p53-
dependent and independent mechanisms (Matsumura et ai., 2003 and 
Tanaka et ai., 2002). 
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The number of the hypermethylated TSGs positively correlated to both AFP levels and 
uaNA levels among the patients in the HCC-post HCV positive group. These correlations agree 
with all reports that linked the frequency of the epigenetic mutations with the progression of 
cancer (Feinberg et al., 2006). Furthermore, they demonstrated the relation between the uaNA 
levels and the progression ofHCC. As for the c-myc gene, it was hypomethylated in 81% of the 
cancer patients. Interestingly, all patients with uaNA levels of 70 ng/mL or more exhibited 
hypomethylation of the c-myc. Moreover, all patients with three or more hypermethylated TSGs 
exhibited uaNA levels of 70 ng/mL or more. Therefore, it appears that the hypomethylation of c-
myc, in tandem with the hypermethylation of TSGs, contributed to the high uaNA levels in HCC 
patients. This is possibly due to the increase in the apoptosis-inducing activity of the c-myc to 
offset the exponential cellular growth caused by the oncogenic role of c-myc and the aberrant 
methylation of TSGs. 
In consideration of the aforementioned trends and observations, a cutoff value of 70 ng 
uaNA/mL urine was selected to identify potential HCC patients among high-risk HCV infected 
patients. This cutoff value was determined consequent to the lowest uaNA level observed in the 
HCC-post HCV positive group. This was assessed using the aberrant methylation status of the 
eight TSGs and the c-myc oncogene among all the HCV infected patients. It should be noted that 
aberrant methylation of TSGs is not a characteristic event among either chronic HCV patients or 
healthy individuals (Lee et aI., 2003b). Based on this cutoff value, 77.5% of the suspected HCV 
infected patients were confirmed as truly HCC positive based on their updated AFP levels and 
CT scan results. 
In light of the trends observed for the HCC-post HCV group, we also looked for a 
positive correlation between uaNA levels and aberrant methylation of TSGs among all the 
patients in the HCV positive group. Of the 31 truly positive patients, 30 patients showed an 
aberrant hypermethylation of three TSGs or more and a hypomethylated c-myc. Only one 
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patient, #7, had only two hypennethylated TSGs and a nonnal c-myc methylation pattern. 
Moreover, the number of the hypennethylated TSGs positively correlated to the AFP levels of 
these HCV patients. These findings strongly confinn the relation between aberrant epigenetic 
events and the development/progression of HCC. The data generated from this study confinned 
that CpG island hypennethylation of known TSGs occurs in the premalignant stages, and have a 
propensity to build up during multi-step hepatocarcinogenesis. 
The PPV for correctly identifying HCC among chronic HCV patients was 77.5% with 
only 22.5% false positives. This result was based on the initial proposed cutoff value (~ 70 
ng/mL) for detecting HCC among high-risk HCV infected population. Interestingly, HCV 
patients who were confinned to be truly HCC positive had uaNA levels of 90ng/mL or more. 
The association of uaNA levels and HCC disease onset/progression was also confinned by the 
positive correlation between uaNA levels and the number of aberrantly hypennethylated TSGs. 
Furthennore, patients with a greater risk for developing HCC (uaNA ~70 ng/mL) mainly 
exhibited hypennethylation of p16, RASSFIA, SOCSI and GSTPI TSGs. These same patients 
also exhibited an aberrant methylation of their c-myc gene. All these factors appear to greatly 
influence exponential tumor growth and stimulate apoptosis, resulting in high uaNA levels. 
As for the patients with uaNA levels lower than 70 ng/mL, the number of 
hypennethylated TSGs did not correlate with either AFP levels or uaNA levels. Five HCV 
patients with uaNA levels lower than 70 ng/mL did test positive for HCC after their medical 
records were updated, representing the false negatives, but the NPV was still respectable at 85%. 
Furthennore, none of the healthy control individuals showed aberrant methylation patterns. This 
agrees with Lee et ai. (2003b) who reported the absence of any aberrant methylation events in 
either chronic HCV patients or in healthy individuals. The specificity and sensitivity of using 
uaNA levels of 70 ng/mL or more to diagnose HCC were 76% and 86%, respectively, with an 
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overall diagnostic value of 81 %. Considering all the attained data, uaNA levels could be a 
promising HCC predictor among high-risk HCY infected patients. 
In the past, urine research was focused mostly on urogenital diseases, whereas our data 
suggests that it can also be used to diagnose HCC. The current approach revealed that the uaNA 
levels of HCC-post HCY and HCY positive patients were significantly higher than those of the 
healthy control group individuals. Since both test groups shared the same risk factor for 
developing HCC, it was assumed that high uaNA levels could be a characteristic feature among 
HCC-post HCY patients. Finally, uaNA level of70 ng/mL or more is strongly recommended as a 
preclinical predictive biomarker for the early detection of HCC among high-risk HCY infected 
populations. Using high uaNA levels as a non-invasive HCC screening tool among high-risk 
HCY infected patients would significantly improve the outcome of these patients and hence 
reduce the HCC burden worldwide. 
MiRNA-based HCC Biomarker Approach 
MicroRNAs (MiRNAs) are negative gene regulators that have been shown to control 
many crucial biological processes, such as cellular proliferation, cellular differentiation and 
apoptosis. Not surprisingly, miRNAs playa critical role in the initiation and progression of 
human cancer (Cho, 2007). Recent evidence indicates that miRNAs can act as both tumor 
suppressors and oncogenes (or oncomirs) (Esquela-Kerscher and Slack, 2006). Half of the 
known miRNAs are localized inside or close to fragile sites, sites ofloss of heterozygosity and at 
familiar breakpoints associated with cancer (Calin et ai., 2006). Several recent studies reported 
that miRNA expression signatures may have a significant impact on the classification, diagnosis 
and prognosis of cancer (Yanaihara et ai., 2006 and Lu et ai., 2005). A comprehensive analysis 
of miRNA expression in different cancers showed a higher diagnostic and prognostic accuracy 
than expression profiling of 16,000 mRNAs (Lu et ai., 2005). 
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Understanding the pathogenesis of viral-associated HCC is important for developing 
effective means of prevention and treatment of this highly malignant form of cancer 
(Thorgeirsson and Grisham, 2002). Currently, the identification of a non-invasive biological 
biomarker that can be used to screen high-risk patients is highly needed to enhance HCC 
detection, resulting in earlier intervention and increasing the probability of successful treatment. 
Recent studies have already identified several miRNAs whose expression is deregulated in viral 
hepatitis infections and in HCC (Murakami et ai., 2006). Although important information was 
gathered about the hepatocarcinogenic effect of these deregulated miRNAs and the viral-host 
interactions that lead to the viral pathogenic effect, none of these studies evaluated the potential 
of using deregulated miRNA expression patterns to predict the development and progression of 
HCC among high-risk HCV infected patients. 
The aim of our biomarker discovery approach was to investigate the potential of using the 
deregulation ofmiRNA expression in HCC-post HCV infected patients for the early diagnosis of 
HCC in high risk groups. The analysis of miRNA expression profiles in pooled samples of both 
the HCC-post HCV positive group and the HCV infected group revealed differential expression 
patterns of several miRNAs relative to the control group. Only the miRNAs whose expression 
was commonly deregulated in both the HCC-post HCV group and the HCV positive group were 
explored as potential biomarkers, while those that were characteristically deregulated only in one 
group, but not the other, were not pursued further in this study. Although some of these miRNAs 
can not be used as HCC biomarkers, they are important for studying HCV pathogenicity, HCV-
host interaction, and the hepatocarcinogenic effect of miRNA. 
Importantly, ten miRNAs were found to be commonly deregulated in both the HCC-post 
HCV group and the HCV positive group. Of these ten deregulated miRNAs, five miRNAs were 
significantly down-regulated (miR-323, miR-449, miR-520d, miR-516-5p and miR-650), while 
the other five miRNAs were up-regulated (miR-335, miR-618, miR-625, miR-532, and miR-7), 
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relative to the control group. The common deregulation of these miRNAs represented possible 
HCC biomarker candidates. It was decided that three commonly down-regulated miRNAs (miR-
323, miR-449 and miR-520d) and two commonly up-regulated miRNAs (miR-335 and miR-7) 
would not be investigated as possible HCC biomarker candidates. This decision was based on 
their putative targets and a review of relevant literature. 
MiR-7 is thought to be an endocrine miRNA, highly expressed in the human pancreatic 
islets (Bravo-Egana et ai. , 2008). Since HCY is known to infect the pancreatic cells (Yan et ai., 
2000), the presence of miR-7 in both the HCC-post HCY positive group and the HCY positive 
group may have resulted from the destruction of pancreatic cells as part of the cellular immune 
response against HCY infection. As for miR-335, it reportedly inhibits tumor metastasis through 
regulating a set of genes whose expression is associated with a risk of distal metastasis, 
especially in breast cancer (Tavazoie et aI., 2008). Therefore, both miR-7 and miR-335 are not 
specific enough to be used as a HCC biomarker. 
Similarly to miR-7 and miR-335, the exclusion ofmiR-323 , miR-449 and miR-520d from 
this study was based on specificity factors . The transforming growth factor-a (TGF-a) is thought 
to be the putative target of miR-323. Growth factors are generally secreted by tumor cells in an 
autocrine fashion and are considered important factors in tumorigenesis (Bianco et aI., 2005). 
TGF-a has been reported to be over-expressed in various tumor tissues, and is likely to be 
associated with the occurrence of lymph nodes, liver metastases and short survival (De Jong et 
aI., 1998). TGF -a is also over-expressed in colorectal carcinoma and is associated with poor 
prognosis of this cancer (Liang et ai., 2007). It is likely that expression of miR-323 down-
regulates the expression of TGF-a; consequently, the down-regulation of miR-323 leads to the 
uncontrolled over-expression of TGF -a. 
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As for both miR-449 and miR-520d, their putative targets were previously reported in the 
proteomic-based biomarker approach section of the discussion. The putative target of miR-449 
is Stathmin 1, whereas Matrin 3 is the putative target of miR-520d. Theoretically, the down-
regulation of both these miRNAs results in the over-expression of their targets (i.e. Stathmin 3 
and Matrin 3) and the data generated from the proteomic-based approach suggests that this is in 
fact the case, as both putative targets were over-expressed in HCV and HCC patients. Since over-
expression of Stathmin 1 is already an important prognostic factor for HCC and, hence, not 
suitable for the purpose of early cancer detection, its putative regulator, miR-449, was excluded 
as a potential HCC biomarker (Yuan et ai., 2006). MiR-520d was excluded as well, primarily 
because the over-expression of its putative target, Matrin 3, plays an important role in HCV 
replication and HCV -associated pathogenesis, rather than being specifically related to 
carcinogenesis (Harris et ai. , 2006). 
Since the previously mentioned miRNAs or their putative targets seem to be not specific 
enough to be used as a HCC biomarker, therefore, we focused on five miRNAs (miR-516-5p, 
miR-650, miR-625, miR-532 and miR-618) as possible HCC biomarker candidates among high-
risk HCV patients. Based on the TargetScan and MiRanda databases, miR-516-5p, miR-650, 
miR-625, miR-532 and miR-618 were found to possibly target genes related to HCC 
development and progression. 
We reviewed the putative targets of the chosen miRNAs closely in order to explain the 
significance of the deregulation of their expression in the context of H CC. The putative target of 
miR-650 is TRAF4. TRAF4 is likely to play an important role in carcinogenesis as it was 
suggested that its over-expression could participate in and/or promote tumorigenesis (Camilleri-
Broet et ai., 2007). Accordingly, we hypothesized that its over-expression was a result of the 
down-regulation of its regulator, miR-650. MiR-650 is, therefore, a possible tumor-suppressor 
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gene and, thus, a potential candidate HCC biomarker among the high-risk HCY positive 
population. 
The putative target of miR-516-5p is Glypican 3 (GPC3). The serum level of GPC3 is 
significantly elevated in patients with HCC in comparison to healthy individuals or patients with 
non-malignant liver diseases (Nakatsura et al., 2003). It has already been suggested that GPC3 
could be used as a marker for HCC (Wright et al., 2007); therefore, the down-regulation of miR-
516-5p, which is a theoretical regulator of GPC3 expression, could also be a potential HCC 
biomarker among high-risk HCY positive patients. 
The putative target of the up-regulated miR-625 is methyl-CpG-binding domain 2 
(MBD2). MBD2 is one of five known MBD containing proteins (Berger and Bird, 2005) that 
specifically bind to any methylated gene and mediate its transcriptional repression (Hendrich and 
Bird, 1998). Given the epigenetic role of MBD proteins in regulating gene expression, they may 
also be involved in cancer development by affecting the expression of cancer-related genes 
(Schlegel et ai., 2002). MBD2 has been reported to bind specifically to methylated gene 
promoters and recruit histone deacetylases and chromatin re- modeling proteins. Consequently, 
the binding of these factors leads to the alteration of the chromatin structure that may be resistant 
to transcriptional machinery, causing repression of gene expression (Wade, 2001). In accordance 
with our data which showed that a large number of tumor-suppressor genes were methylated 
("silenced") among HCC-post HCY positive patients, the up-regulation of miRNA-625 may 
serve to reduce aberrant methylation events of TSGs by targeting the MBD2 protein and, thus, 
decrease the tumor growth rate. Therefore, miR-625 may have a tumor-suppressor role. 
The putative target of miR-532 is the DNA ligase I (LIG 1), which plays an important 
role in DNA replication. It has been reported that DNA ligase I is responsible for the majority of 
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DNA ligase activity in proliferating cells compared to non-dividing or resting cells (Lindahl and 
Branes, 1992 & J essberger et aI., 1997). In 2001, Sun et ai. reported the presence of high DNA 
ligase I activity in tumor tissues compared to normal tissues. This activity may improve the 
survival of tumor cells, especially in the presence of anti-cancer drugs, which directly or 
indirectly damage DNA. It was also postulated that DNA ligase I could be used as a unique 
target for the design of new anti-cancer agents (Sun et ai., 2002). Therefore, we assumed that the 
up-regulation of miR-532 is a natural anti-cancer response that can target and suppress DNA 
ligase lover-expression and, thus, can be used as a HCC biomarker candidate. 
As for miR-618, it was found to possibly target the Low-Density Lipoprotein Receptor-
Related Protein 12 (LPR12), which was firstly identified by Qing et ai. in 1999. LPR 12 was 
found to be expressed in normal tissues and was decreased in corresponding malignant tissues 
(Qing et ai., 1999). Several studies have demonstrated that LPR12 can act as a tumor suppressor 
gene as the tumor formation/growth tends to increase when LPR12 was down-regulated (Battle 
et aI., 2003). Since LPR 12 was found to be the putative target ofmiR-618, miR-618 is thought 
to function as an oncogene. The up-regulation ofmiR-618 could suppress LPR 12 expression and 
lead to the progression of HCC. Therefore, the up-regulation of mir-618 was evaluated as a 
possible HCC biomarker. 
Based on the above-mentioned correlations between the observed deregulated miRNAs 
and HCC progression and development, we decided to evaluate the deregulations of expression 
ofmiR-625, miR-532, miR-618, miR-516-5p and miR-650 as non-invasive biomarkers for the 
early diagnosis of HCC among high-risk HCV positive patients. Initially, we found that miR-
625, miR-532 and miR-618 were up-regulated in 56%, 62.5% and 72% of HCC-post HCV 
positive patients, respectively. In addition, miR-516-5P and miR-650 were found to be down-
regulated in 50% and 72% of HCC-post HCV positive patients, respectively. Interestingly, the 
191 
Moemen Abdalla HCC Biomarkers 
down-regulation ofmiR-516-5p among 50% of the HCC-post HCV positive patients agrees with 
the diagnostic value of its putative target, Glypican3, which can correctly identify HCC with a 
sensitivity of 50% (Wright et ai., 2007). Importantly, these results suggested that the 
deregulation of both miR-618 and miR-650 is a characteristic miRNA signature of HCC among 
HCV positive patients (72%). This is in accordance with their putative roles as regulators of 
genes involved in HCC progression and development. MiR-618 up-regulation suppresses the 
expression of the tumor-suppressor gene (LPR12) and miR-650 down-regulation leads to the 
over-expression of T ARF4. 
To evaluate the potential of using miR-618 and/or miR-650 as urinary miRNA-based 
biomarkers for the early detection of HCC among high-risk HCV positive patients, we studied 
their expression among HCV positive patients who were not diagnosed as HCC patients at the 
time of initial sample collection. The expression levels of miR-618 and miR-650 among HCV 
positive patients, relative to the control group, were evaluated using qRT-PCR. MiR-618 was 
significantly up-regulated in 48% of the HCV positive patients (~ 3 fold difference of expression 
and p value < 0.05), whereas miR-650 was significantly down-regulated in 57% of the HCV 
positive patients. The patients who were exhibiting either significant up-regulation ofmiR-618 or 
significant down-regulation ofmiR-650 were suspected as HCC patients. In order to evaluate the 
diagnostic value of the deregulation of these two miRNAs for identifying HCC among chronic 
HCV positive patients, the medical records of the HCV infected patients, specifically their AFP 
levels and CT scan results, were updated two years after initial sample collection. The updated 
records showed that AFP levels were elevated in 35 HCV infected patients, all of whom also 
tested positive for HCC by CT scans. Only one patient, #7, had a normal AFP level, but was 
diagnosed with HCC by CT scan. In total, 36 patients were identified as having developed 
cancer. 
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Of the 35 HCV positive patients who showed significant up-regulation of miR-618, 23 
were confinned as HCC positive based on the updated medical records. Furthennore, 26 of the 
42 HCV patients who showed significant down-regulation of miR-650 were con finned as HCC 
positive. The sensitivity and specificity of miR-618 for detecting HCC among HCV positive 
patients were 64% and 68%, respectively, with an overall diagnostic accuracy of 66%. The PPV 
of miR-618 for correctly identifying true HCC positive patients was 66% and the NPV for 
correctly identifying true negative HCC patients was 67%. Whereas, the sensitivity and 
specificity of miR-650 for detecting HCC among HCV positive patients were 72% and 58%, 
respectively, with an overall diagnostic accuracy of 65%. The PPV of miR-650 for correctly 
identifying true HCC positive patients was 62% and the NPV for correctly identifying true 
negative HCC patients was 69%. Additionally, the sensitivity and specificity for miR-618/ miR-
650 tandem were 58% and 75%, respectively, with an overall diagnostic accuracy of 69%. The 
PPV ofmiR-618/miR-650 for correctly identifying true HCC positive patients was 68% and the 
NPV for correctly identifying true negative HCC patients was 70%. 
Despite the poor predictive values of our findings, the sensitivity of miR-650 and the 
specificity of the mir-618/miR-650 combination were greatly improved compared to the AFP 
level-based detection method (sensitivity of 68% and specificity of 75%) (EI-Houseini et ai., 
2005). The proposed HCC miRNA signatures may be of great value for the early diagnosis of 
HCC, before the onset of the disease, among high-risk HCV infected patients. The significance 
of this approach is amplified by the sample source (urine) from which these miRNA signatures 
were extracted. The advantage of using urine as a sample source for studying diseases is that it 
offers a non-invasive approach for developing screening tools that can reduce worldwide 
mortality rates. 
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Conclusion and Significance 
This study proved that urine is a suitable sample source for the isolation and purification 
of liver-specific genomic and proteomic signatures. We have introduced a new methodology, 
using SiC-loaded Spin columns, for the purification of proteins and nucleic acids from a very 
low amount of urine. Moreover, the quality of such urinary macromolecules has proven to be 
suitable for many sensitive downstream applications. Following new trends in biomarker 
discovery, we have demonstrated many promising and novel biomarker candidates for the early 
detection ofHCC among high-risk HCV infected population. 
As promising single-based biomarker candidates, the relative over-expression (~3 folds 
relative to control group) of CAF-l was the best proteomic indicator of HCC. CAF-l correctly 
diagnosed HCC with a specificity of 90%, a sensitivity of 66%, and an overall diagnostic 
accuracy of 78%. High uaNA levels of 70 ng/mL or more were a good predictor of HCC and 
positively correlated to HCC development/progression. The specificity and the sensitivity of 
uaNA levels of 70ng/mL or more were 76% and 86%, respectively, with an overall diagnostic 
value of 81%. The pairing of the uaNA levels (~70 ng/mL) and the CAF-l over-expression 
produced a highly specific (100%) multiple-based HCC biomarker with an acceptable sensitivity 
of 64% and with a diagnostic accuracy of 82%. In comparison to the previous pairing, the uaNA 
levels (~70 ng/mL) together with HSP60 over-expression were less specific (89%) but highly 
sensitive (72%), resulting in a diagnostic accuracy of 64%. 
We were also the first to demonstrate the possibility of detecting the newly discovered 
RNA species, miRNA, from urine. Furthermore, the significance of detecting these urinary 
miRNAs was demonstrated when they showed a promising diagnostic accuracy for the early 
detection of HCC. Unfortunately, the miRNA-based approach did not reveal any better single-
based HCC biomarker candidates than the ones previously mentioned. However, the tandem 
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deregulation ofmiR-618 and miR-650 expression showed an acceptable HCC diagnostic value. 
The deregulation of both miR-618 and miR-650 expression correctly predicted HCC with a 
specificity of 75%, a sensitivity of 58% and an overall diagnostic accuracy of 69%. The down-
regulation of miR-650 along with either high uaNA content or HSP 60 over-expression resulted 
in a slightly less specific screening method when compared to the abovementioned pairing. The 
specificity of miR-650 combined with either high uaNA content or HSP 60 over-expression was 
82% and 79%, respectively, whereas, the sensitivity of these combinations were 64% and 58%, 
respectively. In general, the potential biomarkers identified in this study compare favorably with 
the diagnostic accuracy of the AFP levels test, which has a specificity of 75%, sensitivity of 68% 
and an overall diagnostic accuracy of70% (EI-Houseini et ai., 2005). 
Besides the diagnostic potential of the proposed urinary-based biomarkers, other urinary 
signatures offer valuable information for a better understanding of the HCY -host interaction and 
the hepatocarcinogenic process. Among these signatures, we were the first to demonstrate the 
characteristic over-expression of CAF -1, DJ -1 and HSP 60 in H CC patients, based on their 
relative abundance in the tested urine samples acquired from HCC patients. These characteristic 
events should be further validated on a larger scale, in order to understand their role during the 
hepatocarcinogenic events. In addition to the diagnostic potential of the miR-618 and miR-650, 
our data suggests that miR-618 is a potential "Oncomir", since it is up-regulated in HCC and 
whose putative target, based on sequence complementarity, is the Low density lipoprotein-
related protein 12. Moreover, miR-650 may function as a potential TSG, down-regulated in 
HCC, whose putative target, based on sequence complementarity, is the TNF receptor-associated 
factor 4. 
Based on our pioneer findings, many urinary-based assays can be developed for the 
purpose of screening high-risk HCY infected population for the early detection of HCC. In 
conclusion, this is the first study to prospectively examine urine as a sample source for the 
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discovery of new HCC biomarkers. Overall, this explorative study identified potential targets 
that merit further investigation for the development of diagnostically accurate biomarkers 
isolated from 1-2 mL urine samples that were acquired in a non-invasive manner. 
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Appendix A. Questionnaire for Sample Collection 
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Appendix B. Patient's Clinical Pathological Parameters 
Appendix Bl Clinical Pathological Parameters of HCC-post HCV positive 
Infected Patients 
+ve -ve +ve 1158 55 F -ve -ve -ve +ve 
3HCC +ve -ve +ve 60 M -ve -ve -ve +ve 
5HCC +ve -ve +ve 51 F -ve -ve -ve -ve 
7HCC +ve -ve +ve 2020 55 M -ve -ve -ve +ve 
.~iIIII 
9HCC +ve -ve 1798 55 F -ve -ve -ve -ve 
llHCC +ve -ve +ve 912 59 M -ve -ve -ve +ve 
13HCC +ve -ve +ve 1841 50 M -ve -ve -ve +ve 
IJTItU 
15HCC +ve -ve +ve 1250 44 M -ve -ve -ve +ve 
17HCC +ve -ve +ve 2236 45 F -ve -ve -ve -ve 
+ve -ve +ve 500 58 M -ve -ve -ve +ve 
+ve -ve +ve 1208 55 M -ve -ve -ve -ve 
23HCC +ve -ve +ve 1050 47 M -ve -ve -ve -ve 
~Ill'lII" W'v~\ii..'«b*"",x"- ' >::ill.' 
25HCC +ve -ve +ve 820 55 M -ve -ve -ve -ve 
BlSII 
+ve -ve +ve 320 53 M -ve -ve -ve -ve 
+ve -ve +ve 421 49 M -ve -ve -ve -ve 
31HCC +ve -ve +ve 1020 42 M -ve -ve -ve -ve 
E ... ;.;","',;,., - __ =o.x'_ 
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Appendix B2 Clinical Pathological Parameters of HCV positive Infected 
Patients 
3HCV +ve -ve -ve 95 48 M -ve -ve -ve -ve 
11HCV +ve -ve -ve 71 52 M -ve -ve -ve -ve 
hJl • • J~"" ~t ~i :, j if lI[J 
13HCV +ve -ve -ve 119 45 F -ve -ve -ve -ve 
15HCV +ve -ve -ve 264 41 M -ve -ve -ve +ve 
17HCV +ve -ve -ve 97 36 M -ve -ve -ve +ve 
IIlI)\7,;:· 
'0' ":<'>i" x><>,,,(>"W 
19HCV +ve -ve -ve 87 46 M -ve -ve -ve -ve 
21HCV +ve -ve -ve 384 35 F -ve -ve -ve -ve 
23HCV +ve -ve -ve 194 57 F -ve -ve -ve -ve 
-ve 
27HCV +ve -ve -ve 286 18 F -ve -ve -ve -ve 
+ve -ve -ve 246 48 M -ve -ve -ve +ve 
31HCV +ve -ve -ve 94 35 F -ve -ve -ve -ve 
+ve 
-ve -ve 291 50 F -ve -ve -ve +ve 
-ve -ve -ve -ve -ve 
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Appendix B2 contd. Clinical Pathological Parameters of HCV positive Infected 
Patients 
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Appendix C. PCR Amplification of the HCV 5'UTR 
Appendix Cl PCR Amplification of the HCV 5'UTR among HCC-post HCV 
Positive Infected Patients 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
M 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
M 31 32 -ve M 
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Appendix C2 peR Amplification of the HeV 5'UTR among HeV Positive 
Infected Patients 
2000 
1500 
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750 
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50 
M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
M 61 62 63 64 65 66 67 68 69 70 71 72 73 74 -ve 
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Appendix D. Activation/Wash Solution Preparation Scheme 
A scheme for the preparation of the preparation of the washing solution used in the purification 
of total proteins from urine 
pH 250 mM Basic solution (mL) Water (mL) 250 mM Acidic solution (mL) 
3 0.7 8.3 1 
3.5 0.9 8.1 1 
4 1.2 7.8 1 
4.5 1.4 7.6 1 
5 1.6 7.4 1 
5.5 1.8 7.2 1 
6 2 7 1 
6.5 2.2 6.8 1 
7 2.4 6.6 1 
7.5 2.5 6.5 1 
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Appendix E. Map of the Tumor-Suppressor Genes, c-myc and 
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Appendix F. Complete methylation digestion pattern of tumor-
suppressor genes and proto-oncogene c-myc 
Appendix Fl Complete methylation digestion pattern of tumor-suppressor 
genes and proto-oncogene c-myc among HCC-post HCV infected patients 
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Appendix FIA The methylation profile ofRASSFlA before and after digestion with DpnI among HCC-post HCV 
positive patients. U=Uncut, C=Cut. The size of the amplicon is 250 bp. M: Norgen PCR sizer marker. 
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Appendix FIB The methylation profile of ASCL before and after digestion with Dpnl among HCC-post HCY 
positive patients. U=Uncut, C=Cut. The size of the amplicon is 400 bp. M: Norgen FastRunner marker. 
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Appendix FIe The methylation profile ofp16 before and after digestion with Acil among HCC-post HCV positive 
patients. U=Uncut, C=Cut. The size of the amplicon is 763 bp. M: Norgen FastRunner marker. 
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Appendix FID The methylation profile ofpl5 before and after digestion with AciI among HCC-post HCV positive 
patients. U=Uncut, C=Cut. The size of the amplicon is 569 bp. M: Norgen FastRunner marker. 
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Appendix FIE The methylation profile of SOCSI before and after digestion with Ad! among HCC-post HCV 
positive patients. U=Uncut, C=Cut. The size of the amplicon is 346 bp. M: Norgen FastRunner marker. 
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Appendix FIF The methylation profile of E-Cadherin before and after digestion with Aci! among HCC-post HCV 
positive patients. U=Uncut, C=Cut. The size of the amplicon is 450 bp. M: Norgen FastRunner marker. 
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Appendix FIG The methylation profile of APC before and after digestion with DpnI among HCC-post HCV 
positive patients. U=Uncut, C=Cut. The size of the amplicon is 306 bp. M: Norgen FastRunner marker. 
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Appendix FIH The methylation profile of GSTP I before and after digestion with AciI among HCC-post HCV 
positive patients. U=Uncut, C=Cut. The size of the amplicon is 280 bp. M: Norgen FastRunner marker. 
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Appendix FlI The methylation profile of C-myc before and after digestion with AciI among HCC-post HCY 
positive patients U=Uncut, C=Cut. The size of the amplicon is 350 bp. M: Norgen FastRunner marker. 
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Appendix FlJ The amplification of GAPDH, as an internal control, before and after digestion with AciI among 
HCC-post HCY positive patients. U=Uncut, C=Cut. The size of the amplicon is 150 bp. M: Norgen FastRunner 
marker. 
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Appendix FIK The amplification of GAPDH as an internal control before and after digestion with DpnI among 
HCC-post HCV positive patients. U=Uncut, C=Cut. The size of the amplicon is 150 bp. M: Norgen FastRunner 
marker. 
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Appendix F2 Complete methylation digestion pattern of tumor-suppressor 
genes and proto-oncogene c-myc among HCV infected patients with high 
apoptotic NA levels 
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Appendix F2A The methylation profile of APC before and after digestion with AciI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 306 bp. M: Norgen FastRunner 
marker. 
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Appendix F2A The methylation profile of APC before and after digestion with AciI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 306 bp. M: Norgen FastRunner 
marker. 
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Appendix F2B The methylation profile of ASCL before and after digestion with DpnI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 400 bp. M: Norgen FastRunner 
marker. 
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Appendix F2B The methylation profile of APC before and after digestion with DpnI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 400 bp. M: Norgen FastRunner 
marker. 
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Appendix F2C The methylation profile of E-Cadherin before and after digestion with Aci! among HCV positive 
patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 450 bp. M: Norgen 
FastRunner marker. 
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Appendix F2C The methylation profile of E-Cadherin before and after digestion with Acil among HCV positive 
patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 450 bp. M: Norgen 
FastRunner marker. 
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Appendix F2D The methylation profile of GSTP 1 before and after digestion with AciI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 280 bp. M: Norgen FastRunner 
marker. 
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Appendix F2D The methylation profile of GSTP I before and after digestion with AciI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 280 bp. M: Norgen FastRunner 
marker. 
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Appendix F2E The methylation profile of pIS before and after digestion with Ad! among HCY positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 569 bp. M: Norgen FastRunner 
marker. 
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Appendix F2E The methylation profile of p 15 before and after digestion with Acil among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 569 bp. M: Norgen FastRunner 
marker. 
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Appendix F2F The methylation profile of p 16 before and after digestion with AciJ among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 763 bp. M: Norgen FastRunner 
marker. 
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Appendix F2F The methylation profile of p 16 before and after digestion with AciI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 763 bp. M: Norgen FastRunner 
marker. 
230 
Moemen Abdalla 
2000 
1500 
1000 
750 
500 
300 
150 
50 
2000 
1500 
1000 
750 
500 
300 
150 
50 
fg88 
1000 
750 
500 
300 
150 
50 
M u c 
M u c 
M u c 
u c u c 
10HCV 
U C 
23HCV 25HCV 
U C U C 
HCC Biomarkers 
u c u c u c u c 
14HCC 19HCC 20HCC 21 HCC 
U C U C U C U C 
26HCC 27HCC 28HCC 29HCC 
U C U C U C U C 
Appendix F2G The methylation profile of RASSFIA before and after digestion with DpnI among HCV positive 
patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 250 bp. M: Norgen 
FastRunner marker. 
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Appendix F2G The methylation profile of RASSFIA before and after digestion with DpnI among HCV positive 
patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 250 bp. M: Norgen 
FastRunner marker. 
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Appendix F2H The methylation profile of SOCS! before and after digestion with Acil among HCV positive 
patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 346 bp. M: Norgen 
FastRunner marker. 
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Appendix F2H The methylation profile of sacs 1 before and after digestion with Aci! among HCV positive 
patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 346 bp. M: Norgen 
FastRunner marker. 
234 
Moemen Abdalla 
2000 
1500 
1000 
750 
500 
300 
150 
50 
2000 
1500 
1000 
750 
500 
300 
150 
50 
?g88 
1000 
750 
500 
300 
150 
50 
M u c 
M u c 
u c u c 
10HCV 
u c U C 
HCC Biomarkers 
u c u c u c u c 
14HCC 19HCC 20HCC 21 HCC 
U C U C U C U C 
Appendix F2I The methylation profile of C-myc before and after digestion with DpnI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 350 bp. M: Norgen FastRunner 
marker. 
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Appendix F2I The methylation profile of C-myc before and after digestion with DpnI among HCV positive patients 
with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 350 bp. M: Norgen FastRunner 
marker. 
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Appendix F2J The methylation profile of GAPDH as an internal control before and after digestion with DpnI 
among HCV positive patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 150 bp. 
M: Norgen FastRunner marker. 
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Appendix F2J The methylation profile of GAPDH as an internal control before and after digestion with DpnI 
among HCV positive patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 150 bp. 
M: Norgen FastRunner marker. 
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Appendix F2K The methylation profile of GAPDH as an internal control before and after digestion with AciI 
among HCV positive patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 150 bp. 
M: Norgen FastRunner marker. 
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Appendix F2K The methylation profile of GAPDH as an internal control before and after digestion with AciJ 
among HCV positive patients with high apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 150 bp. 
M: Norgen FastRunner marker. 
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Appendix F3A The methylation profile of E-Cadherin before and after digestion with AciI among HCV positive 
patients with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 450 bp. M: Norgen FastRunner 
marker. 
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Appendix F3B The methylation profile of GSTP I before and after digestion with AciI among HCV positive patients 
with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 280 bp. M: Norgen FastRunner marker. 
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Appendix F3C The methylation profile of p 15 before and after digestion with Aci! among HCV positive patients 
with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 569 bp. M: Norgen FastRunner marker. 
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Appendix F3D The methylation profile of SOCS 1 before and after digestion with AciI among HCV positive 
patients with low apoptotic NA levels. U=Uncut, C=Cut. The size of the ampIicon is 346 bp. M: Norgen FastRunner 
marker. 
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Appendix F3E The methylation profile of pl6 before and after digestion with Acil among HCV positive patients 
with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 763 bp. M: Norgen FastRunner marker. 
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Appendix F3F The methylation profile of APC before and after digestion with DpnI among HeV positive patients 
with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 306 bp. M: Norgen FastRunner marker. 
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Appendix F3G The methylation profile of RASSFIA before and after digestion with DpnI among HCY positive 
patients with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 250 bp. M: Norgen FastRunner 
marker. 
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Appendix F3H The methylation profile of ASCL before and after digestion with DpnI among HCV positive 
patients with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 400 bp. M: Norgen FastRunner 
marker. 
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Appendix F31 The methylation profile of C-myc before and after digestion with DpnI among HCV positive patients 
with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 350 bp. M: Norgen FastRunner marker. 
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Appendix F3J The methylation profile of GAPDH as an internal control before and after digestion with DpnI 
among HCY positive patients with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 150 bp. 
M: Norgen FastRunner marker. 
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Figure F3K The methylation profile of GAPDH as an internal control before and after digestion with AciI among 
HCV positive patients with low apoptotic NA levels. U=Uncut, C=Cut. The size of the amplicon is 150 bp. M: 
Norgen FastRunner marker. 
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Appendix F4 Complete methylation digestion pattern of tumor-suppressor 
genes and proto-oncogene c-myc among Control group . 
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Appendix F4A The methylation profile ofRASSFlA before and after digestion with DpnI among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 250 bp. M: Norgen FastRunner marker. 
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Appendix F4B The methylation profile of ASCL before and after digestion with DpnI among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 400 bp. M: Norgen FastRunner marker. 
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Appendix F4C The methylation profile of APC before and after digestion with DpnI among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 306 bp. M: Norgen FastRunner marker. 
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Appendix F4D The methylation profile of SOCS! before and after digestion with AciI among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 346 bp. M: Norgen FastRunner marker. 
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Appendix F4E The methylation profile of pI6 before and after digestion with AciI among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 763 bp. M: Norgen FastRunner marker. 
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Appendix F4F The methylation profile of pI5 before and after digestion with AciI among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 569 bp. M: Norgen FastRunner marker. 
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Appendix F4G The methylation profile of GSTPI before and after digestion with AciJ among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 280 bp. M: Norgen FastRunner marker. 
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Appendix F4H The methylation profile of E-Cadherin before and after digestion with Ad! among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 450 bp. M: Norgen FastRunner marker. 
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Appendix F41 The methylation profile of C-myc before and after digestion with DpnI among Control patients. 
U=Uncut, C=Cut. The size of the amplicon is 350 bp. M: Norgen FastRunner marker. 
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Appendix F4J The methylation profile of GAPDH as an internal control before and after digestion with DpnI 
among Control patients. The size of the amplicon is 150 bp. M: Norgen FastRunner marker. 
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Appendix F4K The methylation profile of GAPDH as an internal control before and after digestion with Acii 
among Control patients. U=Uncut, C=Cut. The size of the amplicon is 150 bp. M: Norgen FastRunner marker. 
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